Development and evaluation of multiplex and high-throughput SNP analysis for the ABCA1 gene by Probst, Mario C. O.
  
Development and Evaluation of Multiplex 
and High-throughput SNP Analysis for the 
ABCA1 gene 
 
 
 
 
Dissertation zur Erlangung des Doktorgrades der 
Naturwissenschaften 
(Dr. rer. nat.) 
an der Fakultät für Chemie und Pharmazie 
der Universität Regensburg 
 
 
 
 
 
 
 
 
 
vorgelegt von 
Mario C.O. Probst 
Regensburg im März 2004 
  
 
Development and Evaluation of Multiplex 
and High-throughput SNP Analysis for the 
ABCA1 gene 
 
 
 
Doctoral Thesis 
by 
Mario C.O. Probst 
 I 
 
This work was performed at the Institute of Clinical Chemistry and Laboratory 
Medicine at the University of Regensburg between September 1999 and 
December 2003 under the supervision of Prof. Gerd Schmitz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date of colloquium: March 29, 2004 
 
Board of examiners: Chairperson: Prof. Hartmut Krienke 
 First expert: Prof. Otto S. Wolfbeis 
 Second expert: Prof. Gerd Schmitz 
 Third expert: Prof. Manfred Liefländer 
 II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The aim of science is not to open the door to infinite wisdom, but to set a limit to 
infinite error”. 
Berthold Brecht, “The Life of Galileo“ 
 
 
 III 
Acknowledgements 
Above all, I would like to thank Prof. Gerd Schmitz for providing the fascinating 
technological facilities at his institute. He also gave me the opportunity and 
support to visit various conferences and workshops and to participate in several 
interesting research projects. 
I gratefully acknowledge the support of the head of my working group, Prof. 
Charalampos Aslanidis. He was my teacher in molecular biology and he largely 
contributed to the completion of this thesis. I am also grateful for the fruitful 
cooperation with the former members of our working group: Harald Thumann, 
Hajnalka Andrikovics, Marek Bodzioch and Katarzyna Lapicka. 
I also acknowledge the support of Dr. Thomas Langmann and the members of 
his working group. 
For the excellent technical assistance and the good working conditions in our 
laboratory, I would like to thank Heidi Kölbl, Dagmar Richter, Ella Schlangstedt, 
Andrea Streinbrunner, Ewa Kowalewski and Sabine Witzmann. Especially 
Heidi’s assistance contributed in large parts to this thesis. 
I should not forget to thank our IT specialists Josef Mages and Markus Solleder. 
Josef’s programming skills were essential for the successful establishment of 
high-throughput analysis. 
Last but not least I would like to acknowledge the help of our engineers Alfons 
Gahr and Ruppert Lintl. No fancy machine works without professional 
maintenance. 
 IV 
Table of Contents 
1 Introduction ...........................................................................................................1 
2 Background ...........................................................................................................4 
2.1 The ABCA1 gene in HDL metabolism..............................................................4 
2.1.1 ABC transporters.........................................................................................4 
2.1.2 ABCA1 and Tangier Disease.......................................................................4 
2.1.3 ABCA1 plays a key role in cellular cholesterol and phospholipid efflux ......5 
2.1.4 ABCA1 defects ............................................................................................6 
2.1.5 Regulation of ABCA1 ..................................................................................7 
2.1.6 Important domains of ABCA1 and interacting proteins................................8 
2.2 Formats for SNP identification and analysis ..................................................9 
2.2.1 Hybridization techniques .............................................................................9 
2.2.2 Enzymatic methods ...................................................................................11 
2.3 Instrumentation for SNP analysis..................................................................16 
2.3.1 Capillary sequencer...................................................................................16 
2.3.2 Light Cycler ...............................................................................................18 
2.3.3 TaqMan .....................................................................................................21 
2.4 Bead-based multiplex analytical platforms ..................................................25 
2.4.1 Synthesis, dying and coating of beads......................................................26 
2.4.2 The Luminex Technology ..........................................................................27 
2.4.3 Assay formats in nucleic acid testing.........................................................28 
3 Materials and methods .......................................................................................32 
3.1 Patients ............................................................................................................32 
3.2 DNA isolation from EDTA blood ....................................................................34 
3.3 Study groups for polymorphism identification ............................................34 
3.4 Sequence of ABCA1........................................................................................35 
3.5 DNA sequencing of PCR products from ABCA1..........................................35 
3.6 Fluorescent fragment analysis of VNTR polymorphisms ...........................36 
3.7 Electrophoretic mobility shift assay (gel shift assay) .................................36 
3.8 Reporter gene assay with ABCA1 promoter.................................................37 
3.9 LightCycler SNP analysis ...............................................................................37 
3.10 TaqMan SNP analysis .....................................................................................38 
3.11 Microspheres...................................................................................................38 
3.12 Statistical data analysis..................................................................................38 
4 Objective ..............................................................................................................40 
5 Results .................................................................................................................40 
5.1 Screening for functional sequence variations and mutations in ABCA1 ..40 
5.1.1 Sequencing of ABCA1 promoter region and exon 1..................................41 
5.1.2 Sequencing of exons 49 and 50 of the ABCA1 gene ................................47 
5.1.3 Sequencing of the complete ABCA1 gene in individuals with aberrant 
HDL levels .................................................................................................47 
5.2 High-throughput genotyping of ABCA1 polymorphisms ............................50 
5.2.1 LightCycler SNP analysis ..........................................................................52 
5.2.2 TaqMan SNP analysis ...............................................................................53 
5.2.3 High-throughput workflow..........................................................................55 
 V 
5.2.4 Results of genotyping................................................................................58 
5.3 Development of a bead-based multiplex assay............................................62 
5.3.1 Design of primers ......................................................................................62 
5.3.2 Multiplex-PCR ...........................................................................................63 
5.3.3 Allelic discrimination ..................................................................................64 
5.3.4 Genotyping results using the multiplex bead assay ..................................67 
6 Discussion ...........................................................................................................70 
6.1 Screening for functional sequence variations and mutations in ABCA1 ..70 
6.2 High-throughput genotyping of ABCA1 polymorphisms ............................73 
6.3 Development of a bead-based multiplex assay............................................74 
6.4 Final remark.....................................................................................................75 
7 Appendix..............................................................................................................77 
8 Abbreviations, acronyms and symbols ............................................................91 
9 References...........................................................................................................95 
10 Summary............................................................................................................109 
11 Publications and Patents..................................................................................112 
12 Curriculum Vitae................................................................................................116 
13 Eidesstattliche Erklärung .................................................................................117 
 
1   Introduction 1 
 
1 Introduction 
The human genome consists of 3.2 billion base pairs. About 99.9% of human DNA 
sequences are the same across the population, the remaining 0.1% represent our 
genetic diversity which consists of evolutionarily stable sequence variations in the 
genome, that usually reflect past mutations. There are different types of genetic 
variations: base-substitutional polymorphisms, tandem repeat (microsatellite) poly-
morphisms and a few rare other classes like presence or absence of a region (e.g. 
rhesus factor gene RHD) or a mobile element (e.g. Alu element). About 90% of all 
human genetic variations are base-substitutional polymorphisms. These small genetic 
variations are called SNPs (Single Nucleotide Polymorphisms) and are very common in 
the human genome. Estimations range from one SNP per 100 to 2,000 nucleotides.[1, 
2] 
The sequence variations are the basis of differences between chromosomes or 
chromosomal regions and thus form the different alleles.[3-7] The prevalence of one 
allele within human beings depends on selection, population history and chance. By 
definition, the rarer allele should be more abundant than 1% in the general population 
otherwise the variation is referred to as a point mutation.[1, 3, 4, 8] 
In theory, a SNP could have four possible alleles, since there are four types of bases in 
DNA. However, most SNPs are bi-allelic (>99.9%) and they are not randomly 
distributed over the whole genome. SNPs with A/G substitutions (and reverse 
complement T/C) are most prevalent. Since the human genome contains only a few 
percent coding sequence, the vast majority of SNPs are likely to have little functional 
consequence. Extrapolations show, that of 106-7 SNPs, 105-6 are gene associated, 
which means, they are located in or in the near vicinity of genes (especially in introns 
and the promoter). Around 104-5 are found in the coding regions of genes (exons), of 
which 103-4 are suspected to result in a relevant phenotype.[7, 9, 10] 
SNPs do not cause disease, they can increase the susceptibility or resistance to 
develop a disease or determine the severity or progression of a disease. One good 
example for susceptibility to disease related to SNPs is the degenerative disorder 
Alzheimer’s disease. Two SNPs in the apolipoprotein E gene (apo E) have been 
associated with the age of onset of Alzheimer’s disease. These two variations cause 
amino acid exchanges at codons 112 and 158 and result in three possible alleles: E2 
(Cys-112, Cys-158), E3 (Cys-112, Arg-158) and E4 (Arg-112, Arg-158). The apo E4 
allele was significantly associated with the development of Alzheimer’s disease, 
whereas the E2 variant has a protective effect.[3, 4, 8, 11-13] 
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Furthermore, SNPs can alter the body’s response to therapeutic drugs. One example 
for variations that affect the response to therapeutic agents are SNPs in cytochrome 
P450 enzymes (CYPs). In humans, 49 different CYP isoforms have been identified so 
far, which play an important role in the oxidative part of drug metabolism. One isoform, 
CYP2D6, is responsible for the metabolism of about 25% of all drugs, including 
important agents like antiarrhythmics, ß-blockers and tricyclic antidepressants. More 
than 70 SNPs in CYP2D6 are known with some of them producing non-functional 
variants (e.g. CYP2D6*4 and CYP2D6*5), variants with decreased activity (e.g. 
CYP2D6*10), altered substrate specificity (e.g. CYP2D6*17) and increased activity 
(CYP2D5*2xN). An individual CYP-SNP-profile could increase the efficiency of medical 
treatment with therapeutic drugs and reduce or eliminate dose-dependent and dose-
independent adverse drug reactions.[6, 14] 
These two examples illustrate the motivation for the identification of functionally 
relevant sequence variations. But how can these SNPs be identified and 
characterized? 
Sequence variations are usually discovered by DNA sequencing and alignment of the 
sequences obtained of the different individuals and by comparison to database entries. 
The sequencing of individuals with different ethnical origins and certain phenotypes are 
more promising to display sequence variations, than randomly selected individuals. 
Mostly, candidate gene approaches are performed in SNP screening, since whole 
genome scans are too costly and laborious. Here, candidate genes are selected due to 
their function, their structure or their chromosomal location and sequencing of these 
genes or important regions of these genes (e.g. promoter and exons) is performed. 
After the discovery of a SNP, frequency determination and association studies in large 
cohorts are required to investigate the functional relevance of the polymorphism at a 
statistically reliable level. For a functionally relevant SNP, it has to be shown that one 
variant of the SNP is significantly more prevalent in one study population compared to 
another (e.g. patients with a certain disease compared to healthy controls). For this 
purpose, so-called high-throughput technologies are required to handle the huge 
amount of analyses. Although the expression “high-throughput” is used very frequently, 
a useful quantitative definition of this term is scarcely found. The reason for this might 
be, that technological abilities increase so quickly in this field. Also, different terms like 
“medium throughput” or “ultra-high-throughput” can be found in the literature, which are 
mostly used without proper reflection and are usually based on comparison between 
methods. Therefore, a suitable definition for “high-throughput analysis” would be the 
fast analysis of a large number of samples in an automated workflow, including the 
rapid availability of test results. 
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Usually, not a single, but a number of SNPs are identified to be associated with 
complex diseases or certain clinical parameters. Therefore, subsequent to the 
identification of relevant loci, a multiplexing technique, capable of the simultaneous 
determination of specific SNP profiles would be a great advantage for individual risk 
assessment or medical treatment.  
In the focus of this work is the ATP-binding cassette 1 transporter gene (ABCA1), 
which has recently been identified as a key player in reverse cholesterol transport. 
Mutations in ABCA1 are responsible for a rare form of genetic HDL deficiency known 
as Tangier disease (OMIM 600046), which is characterized by severely diminished 
plasma HDL-C levels and a predisposition to splenomegaly and frequently cardio-
vascular disease (CVD). Since the identification of the ABCA1 gene being responsible 
for Tangier disease, several causative mutations have been identified in affected 
individuals, either in homozygous or heterozygous state. These individuals had no 
detectable HDL and had CVD or hepatosplenomegaly. Interestingly, individuals that 
are heterozygous for one of the causative mutations have reduced HDL-levels (40-
45%) and display some lipid aberrations, thus being at risk for cardiovascular disease 
[15]. Therefore, it can be assumed that sequence variations in ABCA1 could influence 
HDL-C levels and development of HDL related diseases, such as arteriosclerosis or 
premature onset of coronary artery disease. Up to now, 13 sequence variations 
upstream to the translation initiation site in exon 2 have been reported and more than 
60 sequence variations have been found in the coding region of ABCA1. 
For the ABCA1 gene as a model, a screening approach for novel SNPs has been 
performed, a platform for high-throughput analysis has been established and a novel 
multiplexing technology has been developed. 
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2 Background 
2.1 The ABCA1 gene in HDL metabolism 
2.1.1 ABC transporters 
The ABCA1 gene belongs to the family of ATP-binding cassette (ABC) transporters. 
These proteins translocate or regulate the transport of specific molecules across the 
plasma membrane or intracellular membranes of the endoplasmatic reticulum, the 
peroxisome, and mitochondria.  
ABC transporters consist of two ATP-binding folds, also referred to as nucleotide 
binding domains (NBD), and two sets of typically six transmembrane domains (TMD). 
There are also half-size transporters, that contain only one NBD and one set of 
transmembrane domains, but these transporters usually form homo- or heterodimers to 
result in a functional transporter. The NBD contain three conserved motifs found in all 
ATP binding cassette transporters: walker A, walker B and signature (S). The 
signature, located between the two walker motifs, is characteristic for ABC transporters 
and is not found in other ATP binding proteins. One group of ABC transporters (e.g. 
ABCB1 (MDR1), ABCC1 (MRP1)) has strong ATPase activity; these proteins are direct 
transport pumps. Here, the energy provided by ATP hydrolysis is used for the 
translocation of molecules across membranes. The other group of ABC transporters 
(e.g. ABCA1, ABCC7 (CFTR), ABCC8 (SUR1)) shows very low ATPase activity. Here it 
seems more likely, that these proteins act as a transport facilitator rather than an active 
transporter. Conformational changes due to ATP binding could be linked to regulatory 
processes. The ABC superfamily, which consists of currently 48 known human ABC 
transporters, is divided into seven subfamilies (ABCA to ABCG) by phylogenetic 
analysis. One group, the ABCA subfamily contains 12 full-size transporters (ABCA1 to 
ABCA10, ABCA12 and ABCA13), of which ABCA1, which regulates efflux of 
cholesterol from cholesterol rich cells, is in the focus of this work. 
2.1.2 ABCA1 and Tangier Disease 
In 1965 Fredrickson et al.[16] discovered a familial high-density lipoprotein deficiency in 
two siblings living on Tangier Island in Chesapeake Bay (Virginia, USA), which was 
named “Tangier Disease”. This autosomal codominant disorder is characterized (in the 
homozygous state) by the absence of HDL cholesterol from plasma, hepato-
splenomegaly, peripheral neuropathy, and frequently premature coronary artery 
disease (CAD). In heterozygotes, HDL cholesterol levels are about half-normal. 
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Impaired cholesterol efflux from macrophages leads to the presence of foam cells 
throughout the body, which may explain the increased risk of coronary heart disease in 
several Tangier families. In 1999, the gene involved in this disease was identified.[17-
19] People with Tangier Disease were homozygous or compound heterozygous for 
mutations in the gene ABC1 (later dubbed ABCA1). Although ABCA1 has already been 
discovered in the murine system in the mid-1990s, only little was known about its 
biological function until 1999.[20] 
2.1.3 ABCA1 plays a key role in cellular cholesterol and phospholipid efflux 
Many epidemiological studies have shown a reciprocal relationship between 
arteriosclerotic coronary heart disease and HDL levels. The prevailing opinion is, that 
HDL plays a pivotal role in reverse cholesterol transport, a process that delivers excess 
cholesterol from macrophages within the arterial wall to the liver for disposal. This 
efflux prevents the accumulation of cellular cholesteryl esters and foam cell formation. 
The cholesterol is carried in HDL back to the liver, where it is converted into bile acids 
and secreted into bile. In this process, called reverse cholesterol transport, the ABCA1 
transporter plays a key role, since it facilitates the efflux of cholesterol and phospho-
lipids to lipid-poor apolipoproteins. In Fig. 2.1, the metabolism of HDL and HDL 
precursors is illustrated. In liver and intestine and during extra hepatic degradation of 
chylomicrons, apo AI rich discoidal preβHDL particles are formed. The apo AI induces 
ABCA1-mediated efflux of phospholipids and cholesterol of cholesterol rich cells, to 
generate phospholipid rich HDL precursor particles. These are converted to regular 
HDL by different reactions, such as phospholipid transfer protein (PLTP) mediated 
uptake of triglycerides (TG) and phospholipid (PL) from TG- and PL-rich particles, and 
by influence of lecithin:cholesterol acyltransferase (LCAT). A second mechanism 
involves aqueous diffusion of cholesterol from the plasma membrane to HDL3 particles 
along a concentration gradient continuously provided by LCAT that converts free 
cholesterol to cholesteryl ester (CE). Part of the mature HDL particles accumulate 
apo E and can then be uptaken by the liver via apo E- receptor. Alternatively, 
cholesteryl esters can be transferred from the HDL particles to apo B-100 rich 
lipoproteins via cholesteryl ester transfer protein (CETP). The formed apo B-100 rich 
LDL particles can then be uptaken by the liver via apo B-100 receptor. In addition, a 
selective uptake of cholesterol from CE-rich HDL particles mediated by scavenger 
receptor BI (SR-BI) has been proposed.[21, 22] 
In addition, at least two more, ABCA1-independent pathways for efflux of cellular 
cholesterol are known: A significant basal cholesterol and phospholipid efflux has been 
found in monocytes from Tangier patients, which have a defective ABCA1 protein 
product and hence, this pathway is independent of ABCA1. Here, other members of the 
ABC transporter family might be involved, such as MDR1 and ABCG1.[23, 24] 
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And it has been shown, that cholesterol can be oxidized to 27-hydroxycholesterol and 
3β-hydroxy-5-cholestenoic acid, of which at least 27-hydroxycholesterol can be 
secreted without a lipophilic acceptor.[25] 
 
 
 
Fig. 2.1  
Metabolism of HDL and HDL precursors [22]. ABCA1 facilitates efflux of cholesterol onto
apo AI rich discoidal preβHDL and HDL3, then transported to the liver for disposal. 
2.1.4 ABCA1 defects 
Disorders of HDL metabolism could result from mutations in genes along the metabolic 
pathway illustrated in Fig. 2.1, including apo AI, LCAT and ABCA1. Mutations in the 
ABCA1 gene have been identified as cause for high density lipoprotein (HDL) 
deficiency syndromes, including Tangier Disease. To clearly distinguish between 
Tangier Disease and other HDL deficiency syndromes, such as familial HDL deficiency 
syndrome, seems problematic. From a clinical point of view, typical Tangier Disease 
hallmarks include the recessive mode of inheritance, HDL deficiency, enlarged orange 
tonsils, hepatosplenomegaly, peripheral neuropathy and frequently premature onset of 
coronary heart disease. Familial HDL deficiency is diagnosed only on the basis of 
absence or reduced HDL levels. Since not all HDL deficient patients show typical signs 
of Tangier Disease, it has been proposed, that mutations in ABCA1 are diagnostic 
markers for incompletely expressed TD. However it could also be possible, that it 
depends on the type or location of the mutation in the ABCA1 gene, if a patient with a 
defective ABCA1 develops a typical symptom of TD such as splenomegaly or other 
HDL related diseases such as CAD. 
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The ABCA1 gene contains 50 exons and is located on chromosome 9 (9q31). Its open 
reading frame consists of 6,783 bp, coding a 2,261 amino acid protein product. The 
translation initiation site is located in exon 2. Since the identification of the ABCA1 gene 
being responsible for Tangier disease, several causative mutations have been 
identified in individuals with HDL deficiency, either in homozygous or heterozygous 
state. Individuals that are heterozygous for one of the causative mutations have 
reduced HDL-levels (40-45 %) and display some lipid aberrations, thus being at risk for 
cardiovascular disease.[15] 
Up to now, 19 sequence variations upstream to the translation initiation site in exon 2 
have been reported (see Tab. 7.2 and Fig. 7.2 of the appendix) and more than 60 
sequence variations have been found in the coding region of ABCA1 (see Tab. 7.1 and 
Fig. 7.1 of the appendix). HDL deficiency syndrome related to mutations in ABCA1 has 
been reported in 38 patients from 28 kindreds so far. Most patients show either 
splenomegaly or coronary artery disease. Occurrence of both symptoms in the same 
patient is quite rare (see Tab. 7.3 and Fig. 7.3 of the appendix). 
2.1.5 Regulation of ABCA1 
With the ABCA1 gene playing a pivotal role in facilitating cholesterol efflux, it is of 
interest to determine how the ABCA1 gene itself is regulated. A number of factors and 
compounds have been identified to control or influence the expression of ABCA1, since 
it was initially identified as a sterol sensitive gene. In the promoter of the gene, several 
transcriptional control elements have been characterized (Fig. 2.2). 
Tissue specific expression of ABCA1 is controlled by transcription factors Sp1 and Sp3, 
upstream stimulatory factor (USF) 1 and 2 and hepatic nuclear factor (HNF) 1α. Sp1, 
that binds to a GC-Box motif increases ABCA1 mRNA expression and enhances 
cellular cholesterol and phospholipid efflux, whereas Sp3 acts as a repressor and 
competes with Sp1 for binding at the –157 GnC motif. ABCA1 expression is regulated 
by cAMP and oxysterols that modulate binding of Sp1. It was shown that the conserved 
E-Box motif that binds USF 1/2 and HNF 1α has a silencing function, since 
mutagenesis of this motif increased ABCA1 expression.[26-35] 
Furthermore, oxysterols and retinoids (e.g. 9-cis-retinoic acid) stimulate ABCA1 
transcription through heterodimers of liver X receptor (LXR) and retinoic X receptor 
(RXR). The responsible control element was found to be an imperfect direct repeat of 
the nuclear receptor half-site TGACCT separated by four bases (DR4).[35-38] 
In addition, the Zink finger protein ZNF 202 that maps to a hypoalphalipoproteinemia 
locus (11q23) has been reported to repress basal and induced expression of the 
ABCA1 gene and various other genes involved in lipid metabolism. It has been shown, 
that the amino terminal SCAN domain and the juxtaposed krüppel-associated box 
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(KRAB) domain of ZNF202 are required for its repressional activity. The SCAN domain 
mediates selective oligomerization with itself and other SCAN domain containing 
proteins such as ZNF191 and SCAN domain protein (SDP) 1. There is evidence that 
the KRAB domain-mediated transcriptional repression results from interference with the 
TATA box-dependent basal transcription machinery possibly in conjunction with the co-
repressor KRAB associated protein (KAP) 1.[35, 39-44] 
Additional putative control elements like binding sites for sex-determining region Y 
gene product (SRY), sex determining region Y-box (Sox) 5, nuclear factor (NF) kappa 
B and others are found upstream of the ZNF202 binding site. These are of unknown 
importance and have not yet been investigated further. 
 
 
 
Fig. 2.2  
The ABCA1 core promoter region contains transcriptional control elements for binding of 
ZNF202, liver X receptor (LXR) and retinoic X receptor (RXR). Furthermore, binding-sites 
for transcription factors Sp1 and Sp3, upstream stimulatory factor (USF) 1/2 and hepatic 
nuclear factor (HNF) 1α have been found, that regulate tissue specific expression of 
ABCA1.[35] 
2.1.6 Important domains of ABCA1 and interacting proteins 
As all other ABC-transporters, ABCA1 contains nucleotide binding domains and 
transmembrane domains. These domains are of importance to maintain ABCA1 
function. Sequence variations in these regions should therefore be of increased 
significance, since they are very likely to affect ABCA1 function. Conversely, sequence 
variations that alter ABCA1 function could provide evidence for an important domain at 
this locus. 
Since ABCA1 is believed to be no active transporter, because it has no measurable 
ATPase activity, it might act as a regulatory channel-forming protein like SUR1 and 
CFTR. Therefore, in analogy to CFTR, ABCA1 could bind SNARE proteins at its N-
terminus to regulate the vesicular transport and the targeting of ABCA1 to the plasma 
membrane. Although, there is a strong conservation of several amino acid stretches in 
the N-terminal part of all ABCA transporters, which could indicate an essential function 
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of theses peptides, there is still no evidence to confirm this. However, like CFTR, 
ABCA1 contains a PDZ binding domain at its C-terminus and it has been shown, that 
this part of the protein interacts with β2-syntrophin.[45, 46] 
In addition, a 23 aa long sequence rich in proline, glutamic acid, serine and threonine 
(PEST-sequence) has been found in the ABCA1 gene at codons 1284 – 1306 (coded 
in exons 27 and 28). It has been shown, that this sequence modulates the degradation 
of ABCA1 by calpain proteases.[47] 
Furthermore the cell division cycle 42 (Cdc42) small GTP binding protein that controls 
cell polarity, cytoskeletal remodeling and vesicle transport was found associated with 
ABCA1 function and filopodia formation, but the mechanism and the domains involved 
in Cdc42 interaction with the ABCA1 pathway are not identified so far.[46, 48, 49] 
2.2 Formats for SNP identification and analysis 
In order to investigate the effects of SNPs in the ABCA1 gene, a suitable method has 
to be selected for the detection of these sequence variations. Today, numerous formats 
of wetware exist for preparation of allele distinguishable products. The various 
procedures can roughly be divided into hybridization techniques and enzymatic 
methods. This paragraph gives a brief overview of enabling techniques for SNP 
discrimination. For the development of high-throughput and multiplexing technology, an 
optimal wetware has to be selected. 
2.2.1 Hybridization techniques 
Hybridization techniques like the competitive hybridization (Fig. 2.3 A) usually involve 
the binding of complementary oligonucleotide sequences to the locus carrying the SNP 
query position. A problem with the detection of SNPs using complementary oligo-
nucleotides is the similarity of their sequences. A difference of only one nucleotide will 
result in significant cross talk. Therefore, usually appropriate buffers, temperature 
adjustment or multiple washing steps are required to increase stringency. An 
alternative would be the use of specially modified oligonucleotides like the use of minor 
grove binders (especially used in TaqMan SNP analysis, see 2.3.3), which significantly 
increase the melting temperature of oligonucleotides. Hence, shorter oligonucleotides 
can be used, resulting in a higher match/mismatch ratio and so producing a more 
stringent annealing. In competitive hybridization, usually the unbound oligonucleotide 
or the decline of free oligonucleotide is detected by solid-phase binding (chip or bead-
based technologies). For the detection, the oligonucleotide has to be labeled with 
fluorescent dyes or other appropriate tags.[50] 
Another application is the use of melting curves with a single hybridization probe (Fig. 
2.3 B). The probe binds at low temperatures to the desired position, whether there is a 
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mismatch or not. When steadily increasing the temperature of the reaction mixture, a 
miss-matched probe will melt off earlier than a probe bound with perfect match. Hence, 
the different alleles can be distinguished by their different melting points. The 
measurement of the melting curve can be done by a FRET (fluorescence resonance 
energy transfer) technique. An anchor probe, carrying a fluorescent donor dye and 
melting off significantly higher than the hybridization probe, is bound adjacent to the 
hybridization probe that carries a suitable fluorescent acceptor dye. As long as both 
probes are bound to the template DNA, FRET occurs, resulting in quenching of the 
fluorescence of the donor dye and emission of the acceptor dye. Continuously 
monitoring the fluorescence of the acceptor dye during the melting process will show a 
decline of the emission signal when the hybridization probe starts to melt off. The first 
negative derivative of the recorded fluorescence- temperature function will represent 
the melting point (50% dissociation) as peak. This format of wetware is especially used 
in LightCycler SNP analysis (see 2.3.2).[51] 
Sophisticated hybridization probes like molecular beacons (Fig. 2.3 C) increase 
stringency of allelic discrimination. A molecular beacon is an oligonucleotide with the 
relevant sequence for hybridization and a self-complementary sequence at its 3’- and 
5’-end, unrelated to the target sequence. For this reason, the unbound oligonucleotide 
forms a so-called hairpin or stem-loop structure, with the complementary target 
sequence in the loop and the self-complementary sequence in the stem. During 
hybridization, the probe will only form a hybrid with the target molecule, if the probe-
target hybrid is more stable than the self-complementary stem structure. This not only 
increases stringency, a hybridization event to the target sequence can easily be 
monitored by applying a FRET technique. The 3’- and the 5’-end of the molecular 
beacon are both labeled, one end with a fluorescent moiety, the other one with an 
appropriate quenching moiety. When the oligonucleotide forms a hairpin structure, 
quencher and fluorophore are in close proximity and FRET takes place (the rate of 
energy transfer in FRET is indirect proportional to the sixth power of the distance 
between donor and acceptor). Upon hybridization, both arms of the probe gain a 
significant distance of each other and FRET can no longer occur, this causes the 
fluorescent moiety to emit light.[50, 52] 
Scorpions are so-called self-priming probes. These are hybridization probes with a 
hairpin structure (like molecular beacons), which are attached via a spacer to a PCR 
primer. The spacer is necessary to cease elongation of the complementary strand 
during PCR beyond that point, to make sure that the hair-pin-part of the generated 
amplicon remains single-stranded. After denaturation of the double-stranded PCR 
product, the scorpion binds to the SNP query position if the detection sequence 
harbored in the loop part is exactly complementary to the target sequence (Fig. 2.3 D). 
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Like molecular beacons, stringency of hybridization is increased by the self-
complementary parts of the probe and an appropriate fluorophore and quencher at 
both ends of the stem part can be used to monitor the hybridization event.[53] 
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Fig. 2.3  
Schematic representation of hybridization techniques for SNP discrimination. 
 
2.2.2 Enzymatic methods 
In PCR-RFLP (restriction fragment length polymorphism), subsequent to amplification 
of a relevant region by PCR, enzyme digestion is performed. Sequence recognizing 
restriction enzymes are used, that cut DNA only, if a specific sequence is found in it 
(Fig. 2.4 A). After enzyme digestion, the generated fragments are detected by agarose 
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gel electrophoresis. With a huge number of available enzymes, a large number of 
single nucleotide polymorphisms can be analyzed.[50, 54] 
The Primer Extension reaction (Fig. 2.4 B) is a very common technique, used in 
multiple applications. Here, subsequent to PCR, only one primer is used that binds to 
the generated amplicon. This technique is often used in DNA sequencing. The relevant 
segment of DNA is amplified by PCR, then a primer (preferably one primer of the 
previous PCR) is extended by DNA polymerase. For this reaction, a mixture of 
unlabeled deoxynucleotide triphosphates (dNTPs) and labeled dideoxynucleotide 
triphosphates (ddNTPs) is used. The ddNTPs lack a hydroxyl group at the 3’-position, 
thus subsequent to incorporation, primer extension will terminate. Since the 
polymerase used cannot distinguish between dNTP and ddNTP, all possible lengths of 
fragments will be generated, each terminated with a ddNTP. By using a different label 
for each type of ddNTP, the reaction can be carried out in one approach; by using only 
one or two different labeled chain-terminators, up to four reactions have to be 
performed in parallel. An alternative to using labeled ddNTPs is the use of a labeled 
primer for extension. Then, four reactions have to be carried out in parallel, each with a 
different (unlabelled) ddNTP. The generated fragments are subjected to gel or capillary 
electrophoresis, aligning them by their size. Since the fragments carry a known base at 
their 3’-end (identified by the label), the targeted sequence can simply be assembled. 
In pyrosequencing, only one type of dNTP is added at a time. If the nucleotide is 
incorporated, pyrophosphate (PPi) is released, which can be detected by a multi-
enzyme system producing luminescent light. Pyrosequencing can be used for 
sequencing of shorter fragments as well as for the detection of SNPs. In the latter case, 
the primer for extension is placed as close as possible to the SNP query position.[50] 
The use of primers that bind upstream the SNP query position, with their 3’-end exactly 
one nucleotide before the SNP allow the extension of only one nucleotide, 
complementary to the SNP query position. This primer extension method is also called 
minisequencing. Here solely ddNTPs are used, to guarantee the elongation of the 
primer by a single base. The identification of the incorporated nucleotide can be 
determined by different (fluorescent) tags or by the presence or absence of a tag; this 
method is also known as template-directed dye-terminator incorporation (TDI) assay. 
Genetic Bit analysis is a method applying colorimetric detection of incorporated 
ddNTPs. Using MALDI-TOF mass spectrometry, the identity of the incorporated 
polymorphic nucleotide is detected at an m/z value specific to the added ddNTP. 
Fluorescence Polarization allows distinguishing between incorporated and non-
incorporated fluorescently labeled nucleotides.[50] 
In allele specific PCR, one of the used primers has a polymorphic base at or very close 
to its 3’ end. The formation or the rate of formation of a PCR product then depends on 
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the allele present in the template DNA since only a so-called allele specific 
oligonucleotide (ASO) with a matched 3’-residue will function as primer. Usually, one 
reaction is run for each allele. The successful formation of PCR product can be 
detected by gel electrophoresis (amplification refractory mutation system, ARMS) or by 
real time PCR (kinetic PCR) using intercalating dyes such as Ethidium bromide or 
SYBR Green.[50] 
Allele specific primer extension (ASPE, Fig. 2.4 C), combines primer extension and 
allele specific PCR. Primers carry the polymorphic base at their 3’-residue and are only 
extended, when they match the SNP query position. Compared to minisequencing, no 
differently labeled ddNTPs are needed. Only one labeled dNTP (usually dCTP) is used 
in this reaction, which is incorporated multiple times upon extension, hence signal 
intensity is increased. This reaction has been used in solid phase technologies, with 
ASOs, carrying a 5’ dangling end used for immobilization of the generated product to 
the complementary sequence bound to solid support.[55] 
In the oligonucleotide ligation assay (OLA, Fig. 2.4 D), two adjacent hybridized 
oligonucleotides are enzymatically ligated to each other using DNA ligase. This 
reaction only takes place, when the nucleotides next to the ligation position are fully 
complementary. By this means, one of the used oligonucleotide must carry the allelic 
base at the very 5’- or 3’-end. The 3’-end is even more discriminatory than the 5’-end, 
but both procedures work well. This method has been used in chip technology and 
bead-based analysis platforms, using one fluorescently labeled reporter oligonucleotide 
that can be ligated to another oligonucleotide, carrying a 5’-dangling end, which can 
bind to the chip or bead (zip code). By attaching a FRET donor dye to one 
oligonucleotide and an appropriate acceptor dye to the adjacent oligonucleotide, a 
homogeneous assay can be established, which is carried out on a real time PCR 
machine. This method is also referred to as dye-labeled oligonucleotide ligation (DOL) 
assay.[50] 
OLA has also been used in combination with rolling circle amplification (RCA, also 
called rolling circle replication RCR). Here, circularizing oligonucleotide probes 
(padlock probes) are used that anneal with their 5’ and 3’ end to the target SNP 
forming an open circle. With the polymorphic base usually located at the 3’ end of the 
open circle probe, ring closure by oligonucleotide ligation does only occur upon perfect 
complement of the hybridizing ends of the probe. After ring closure, a primer extension 
reaction is performed, using a primer that binds to the oligonucleotide probe and a 
polymerase with strand displacement activity. If the probe has been circularized, a long 
single-stranded DNA containing multiple tandem repeats complementary to the original 
circle sequence is formed. A large number of labeled dNTPs can be incorporated 
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during RCR, resulting in a powerful signal amplification. This allows SNP discrimination 
directly from genomic DNA, no amplification step is required in advance. [54, 56-60] 
The 5‘-exonuclease assay (Fig. 2.4 E), also called TaqMan assay, is performed using 
two detection probes, each recognizing a specific allele. For allelic discrimination, the 
oligonucleotides are usually modified with a minor-groove binder (MGB) at the 3’-end. 
The MGB increases the melting temperature of the probe thus allowing a more 
stringent annealing. During PCR, a probe with a perfect match will be cut into pieces by 
the 5’-3’ exonuclease activity of the Taq polymerase, while a mismatched probe will be 
displaced. For detection, each probe is labeled with a fluorophore on the 5’ end and an 
appropriate quencher attached to a MGB on the 3’ end. The NFQ quenches the 
fluorescence of the fluorophore as long as both are attached to the same oligo-
nucleotide. Degradation of the probe by the 5’-3’-exonuclease activity releases the 
fluorophore from the vicinity of the quencher, thus it will emit light upon excitation. So 
after PCR, simply the end-point fluorescence intensity needs to be measured.[50] 
In the invader assay (Fig. 2.4 F), a flap endonuclease (FEN) is used for allelic 
discrimination of SNPs. This DNA repair enzyme recognizes and cleaves a redundant 
5’-portion (flap) of the downstream segment, when two overlapping DNA segments are 
bound to the complementary sequence. In the assay, two probes are used, an invader 
oligonucleotide hybridizing with the targeted complementary polymorphic base at the 
3’-end and a signal oligonucleotide hybridizing downstream to the SNP and 
overlapping the invader oligonucleotide. The 5’-flap of the signal probe is usually not 
complementary to the target sequence and will be cleaved off by FEN, if the last base 
of the invader oligonucleotide does match the polymorphic base. Otherwise, a structure 
is formed that cannot be recognized by FEN and the signal probe will not be cleaved. 
Invader assays have been shown to function without a previous PCR and linear 
amplification of the cleaved product works without temperature cycling. In a so-called 
invader squared assay, the cleaved off flap of a primary signal probe serves as invader 
oligonucleotide in a secondary invader reaction. This two-step reaction squares the 
amount of amplification of the cleaved product. The invader assay has been shown to 
function with MALDI-TOF, but fluorescent-based techniques, like FRET, should also 
work.[50, 54, 61, 62] 
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Fig. 2.4  
Schematic representation of enzymatic techniques for SNP discrimination. 
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2.3 Instrumentation for SNP analysis 
Various platforms for detection of discriminated SNP products exist. Most novel 
platforms are fluorescent based, since fluorescence is a very sensitive and versatile 
technique. In this chapter only platforms that have been used for discovery, 
development and evaluation of SNP analysis for the ABCA1 gene will be described: 
capillary sequencer, LightCycler and TaqMan. Other well established platforms at this 
time are fluorescence polarization, pyrosequencing, and MALDI-TOF, however these 
platforms will not be discussed here. 
2.3.1 Capillary sequencer 
DNA sequencing is an essential technique for the identification of novel sequence 
variations, including SNPs and for the detection of multiple sequence variations in 
highly polymorphic regions. Although genotyping of single SNPs can be performed by 
DNA sequencing, it is usually not done if alternative, more cost-effective techniques are 
available. With the ABI Prism 3100 sequencer, the most commonly used method for 
DNA sequencing is applied, the Sanger dideoxy sequencing. Here, chain-terminating 
dideoxy nucleotide triphosphates are used in the sequencing reaction. The ddNTPs 
carry a fluorescent tag, which identifies the incorporated nucleotide by the wavelength 
of the emitted light. Usually, fluorescein dyes like FAM, JOE, ROX, etc. were used 
before they recently have been replaced by BigDyes. BigDyes are intra-molecular 
FRET dyes (energy transfer-dyes), which consist of a derivative of a 5-carboxy-
dichlororhodamine acceptor dye and a 5- or 6-carboxyisomer of 4’-aminomethyl-
fluorescein as donor dye. A rigid linker (4-aminomethylbenzoic acid) is used to 
separate both residues. The BigDye is connected via a proparagyl ethoxyamino linker 
to the dideoxy nucleotide triphosphate. Fig. 2.5 shows the structure of the ddTTP-
BigDye terminator as an example.[63] 
Since dNTPs or ddNTPs are incorporated by the DNA polymerase all possible lengths 
of DNA fragments are produced. In capillary electrophoresis, the generated fragments 
travel though a capillary filled with a polymer, where they are separated by their size. In 
the optical window of the capillary, near the anode, the fragments traveling by, are 
excited by a 488 nm Argon laser. The emitted fluorescence of the Big Dye terminators 
is detected by means of a CCD camera. A set of dye terminators is required, capable 
of being excited at 488 nm and showing sufficient spectral separation of emission light 
(Fig. 2.6).[64] 
With the ABI Prism 3100 capillary sequencer, 16 samples can be processed in 
approximately one hour. 
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Fig. 2.5  
Structure of BigDye-ddTTP. The intra-molecular FRET dye consist of a 5-carboxy-
dichlororhodamine acceptor dye and a 6-carboxyisomer of 4’-aminomethylfluorescein 
as donor dye which are connected via the rigid linker 4-aminomethylbenzoic acid. The 
BigDye is bound via a proparagyl ethoxyamino linker to the dideoxy nucleotide 
triphosphate.[63] 
 
 
 
Fig. 2.6  
Normalized emission spectra of BigDye terminator dyes (excitation: 488 nm).[64] 
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2.3.2 Light Cycler 
The LightCycler (Roche Diagnostics, Basel, Switzerland) is a microvolume multisample 
fluorimeter with rapid temperature control. The outstanding speed of the thermal cycler 
(30 temperature cycles in 15-20 minutes) is achieved by forced air heating using a 
chamber fan. Small size samples (10-20 µl) are processed in thin glass capillaries that 
allow rapid heat transfer due to a high surface to volume ratio. The capillaries are made 
of clear borosilicate glass, which is ideal for fluorescence analysis, due to its optical 
properties. Furthermore, a capillary conducts emitted light to its tip in a way, which is 
comparable to fiber optics, producing an intense fluorescent signal at the tip. The 
cylindrical sample holder (carousel) carries up to 32 capillaries, which are positioned to 
the detection spot by a stepper motor quickly rotating the carousel. Fast fluorescence 
optics were adopted from flow cytometry. The light beam, originating from a blue light 
diode (480 nm), is focused on the capillary tip from below. The emitted fluorescent light 
is detected from the capillary tip by means of three photodiodes with appropriate filters 
(F1: 530 nm, F2: 640 nm and F3: 710 nm).[65, 66] 
Due to patent situation and for historical reasons, SNP detection using the LightCycler 
technology is usually based on hybridization probes applying fluorescence resonance 
energy transfer (FRET). Other techniques like hydrolysis probes, molecular beacons 
and others can also be performed when using appropriate fluorescent tags, but they 
are less well established. As a donor dye for FRET, Fluorescein can be used, emitting 
in the F1 channel. LightCycler Red 640 and LightCycler Red 705 are appropriate 
acceptor dyes for Fluorescein, emitting in channel F2 and F3, respectively (Fig. 2.7). 
 
 
 
 
Fig. 2.7  
Excitation and emission spectra of LightCycler dye set. As a donor dye for FRET, 
Fluorescein is used, emitting in the F1 channel (530 nm). LightCycler Red 640 and 
LightCycler Red 705 are appropriate acceptor dyes for Fluorescein, emitting in channel 
F2 (640 nm) and F3 (710 nm), respectively. 
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Other FRET dyes that match the integrated filter set can also be used. One example is 
Fluorescein together with Cy5 and Cy5.5 instead of LightCycler Red 640 and 
LightCycler Red 705, respectively. 
For SNP analysis with the LightCycler, the DNA fragment of interest (harboring the 
SNP) is amplified using standard PCR primers under optimized conditions. Two 
sequence-specific oligonucleotide probes are used for the detection of the amplicon. 
The detection or sensor probe hybridizes to the SNP query position (marked with a 
black dot in Fig. 2.8) and carries a FRET acceptor dye (LightCycler Red 640 or 
LightCycler Red 705) at its 5’ end. The anchor probe is coupled with a FITC derivative 
of Fluorescein at its 3’-end and binds upstream of the detection probe, leaving a gap of 
1-5 nucleotides between the two probes. To prevent the sensor probe from extension 
by Taq polymerase, it must be phosphorylated at the 3’ position. The anchor probe 
carries a fluorophore at its 3’-end and though cannot be extended. Only if hybridized to 
the amplicon, the two probes are in such close proximity, that FRET can occur and 
hence emission light can be detected in channel F2 or F3, respectively. Although the 
probe set can be used to monitor the emergence of PCR product during the annealing 
steps, which is of relevance when expression levels of mRNAs or copies of genomes 
are analyzed, its intended purpose is the allelic discrimination during melting curve 
analysis subsequent to the last PCR cycle. The reaction mixture is first denatured at 
95°C and cooled to below 45°C, then the temperature in the thermal chamber is slowly 
raised (0.1-0.2°C/sec) and fluorescence is continuously monitored. The melting curve 
analysis allows the determination of the melting point of the probe-target hybrid. The 
detection probe spans the polymorphic site, if there is a mismatch or not. But a 
mismatch will destabilize the hybrid and the probe melts off at a lower temperature than 
with a perfect match. Fig. 2.9 illustrates this principle. The melting curve is plotted as 
temperature against fluorescence intensity (FI). At the melting point of the probe-target 
hybrid, per definition, 50% of the probe is annealed to the target. This is represented by 
the turning point of the melting curve. For better visualization, the first negative 
derivative of the melting curve (dFI/dT) is calculated, which shows a maximum at the 
melting point. The determination of the melting point allows the assignment of the 
corresponding genotype and assessment whether the proband is homozygous or 
heterozygous (Fig. 2.9) 
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Fig. 2.8  
The principle of FRET probes. The detection or sensor probe hybridizes to the SNP query 
position (marked with a black dot) and carries FRET acceptor dye F2 at its 5’ end. The 
anchor probe is coupled with donor dye F1 at its 3’-end and binds upstream of the 
detection probe, leaving a gap of 1-5 nucleotides between the two probes. To prevent the 
sensor probe from extension by Taq polymerase, it is phosphorylated at the 3’ position. 
Only if hybridized to the amplicon, the two probes are in such close proximity, that FRET 
can occur and hence emission light of F2 can be detected. 
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Fig. 2.9  
The melting curve analysis allows the determination of the melting point of the probe-
target hybrid. A mismatch will destabilize the hybrid and the probe melts off at a lower 
temperature than with a perfect match. The melting curve is plotted as temperature 
against fluorescence intensity (FI). The first negative derivative of the melting curve 
(dFI/dT) is calculated, which shows a maximum at the melting point. The determination 
of the melting point allows the assignment of the corresponding genotype and 
assessment whether the proband is homozygous or heterozygous. 
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2.3.3 TaqMan 
Although the name “TaqMan” refers to the 5’ nuclease assay (see 2.2.2) and is a 
registered Trademark of Roche Molecular Systems, it is often used – colloquial 
speaking – for analysis platforms from Applied Biosystems (Foster City, CA, USA) of 
type “ABI Prism Sequence Detection System”, which are commonly used with the 5’ 
nuclease assay. Among several different types of sequence detection systems, the ABI 
Prism 7900HT is especially designed for high-throughput analysis and was used for 
this work. 
The 7900HT is a standard peltier-based thermal cycling system with a fluorescence 
excitation and detection unit. An Argon 488 nm laser is used as excitation source. The 
emission is detected by a CCD camera between 500 and 660 nm continuously, with a 
resolution of 5 nm, this allows multi-color applications. The movable dual-axis optical 
head of the system moves quickly over the 384-well microtiter-plate in the thermal 
cycler. The microtiter-plate is sealed with an optical cover slide and covered with a 
heated lid with a hole over each well. From above, the optical head pipes laser light 
into the samples and collects emission light simultaneously of 8 wells using fiber optics. 
After the data have been recorded, a virtual filter is set by the software to isolate the 
correct wavelength for the used fluorescent dye. The system has to be calibrated in 
advance, by recording the emission spectrum of each fluorescent dye to be used. 
Usually dyes from Applied Biosystems, especially the aforementioned fluorescein dyes 
are used (Fig. 2.10). The PCR master mix must contain an amount of ROX dye for 
normalization of all other fluorescence signals. 
 
 
 
Fig. 2.10  
Recorded (normalized) emission spectra of pure dyes between 500 and 660 nm. The 
spectrograph records one data point every 5 nm. 
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The TaqMan 7900HT is equipped with an integrated bar code scanner and a custom 
Zymark Twister, that can hold up to 84 microtiter plates, is used as an automatic plate 
loader for continuous plate loading without user intervention. In this configuration, the 
TaqMan can measure 26 microtiter-plates per hour, which corresponds to around 
10,000 samples, if additional external thermal cyclers are used. The outstanding speed 
can be explained by the fact, that for the analysis of SNPs it is not necessary to 
continuously monitor fluorescence. Measurement of end-point fluorescence 
(subsequent to PCR) is sufficient and hence, the PCR reaction can be carried out in 
standard thermocyclers, without fluorescence unit. 
As described previously (see 2.2.2), the 5’ nuclease assay involves a probe with a 
fluorophore attached to its 5’ end, and a suitable quencher at the 3’ moiety. During 
PCR, a mismatched probe is displaced, while a perfect-matched probe will be 
degraded by the 5’-3’ exonuclease activity of Taq polymerase, releasing the 
fluorophore from the quencher and hence producing fluorescent light (Fig. 2.11). 
One probe for each allele is required. Usually, the two fluorescent dyes VIC and FAM 
are used as fluorophores for the TaqMan probes, together with a non-fluorogenic 
quencher connected to a minor groove binder molecule. The chemical structure of VIC, 
the non-fluorogenic quencher and the minor groove binder are a trade secret of Applied 
Biosystems. The minor groove binder is necessary to obtain a good discrimination of 
matched and mismatched probes. A minor groove binder (MGB) is a crescent shaped 
molecule, binding into the minor groove of double-stranded DNA and hence increasing 
stability of the duplex-structure. As an example, the MGB CDPI3, a dihydropyrroloindole 
tripeptide is illustrated in Fig. 2.12, which can be attached to the 3’-residue of 
oligonucleotides and then binds into the minor groove of the formed double-helix 
structure and hence increases its stability (Fig. 2.13). A 12-mer oligonucleotide then 
has the same melting temperature (Tm) of 65°C as an unmodified 27-mer. The 12-mer 
probe had a 20°C difference in Tm between matched and mismatched duplex, which is 
very advantageous for single nucleotide discrimination. The use of short MGB probes 
compared to standard oligonucleotide probes provides hence an increased specificity 
due to a higher mismatch-to-match-ratio and an increased sensitivity due to more 
efficient quenching caused by a lower separation distance between fluorophore and 
quencher.[67-69] 
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Fig. 2.11  
The TaqMan assay involves a probe with a fluorophore attached to its 5’ end, and a 
suitable quencher at the 3’ moiety. During PCR, a mismatched probe is displaced, while 
a perfect-matched probe will be degraded by the 5’-3’ exonuclease activity of Taq 
polymerase, releasing the fluorophore from the quencher and hence producing 
fluorescent light. 
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Fig. 2.12  
Chemical structure of minor groove binder CDPI3 (tri-peptide of N-3-carbamoyl-1,2-
dihydo-3H-pyrrolo[3,2-e]indole-7-carboxylate) with a phosphate linker.[67] 
 
 
 
 
 
Fig. 2.13  
Left: Connoly surface representation of calculated structure of a double-stranded 
oligonucleotide decamer with attached (red) CDPI3.[69] Right: Schematic illustration of 
the double helix structure, showing minor and major groove. 
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2.4 Bead-based multiplex analytical platforms 
In genomics, test platforms which allow to characterize a single biological sample 
regarding multiple analytes simultaneously have recently been broadly introduced in 
the format of high density DNA arrays, which mainly serve sequence verification, gene 
expression monitoring and detection of sequence variations. 
An important disadvantage of arrays is the low flexibility in the selection of combi-
nations of analytes on pre-manufactured chips. These chips typically cover a large 
number of parameters to suit different individual needs and hence find a ready market. 
This allows mass production and makes these chips affordable. But reducing the 
number of parameters to necessary analytes only can also cut analytical costs. Here, 
bead-based assays provide a promising and cost-effective alternative, since distinct 
bead species can be mixed individually to target multiple analytes in a single sample 
and then analyzed simultaneously. This saves reagent costs and reduces sample 
volumes. Less sophisticated instrumentation and hence lower investment costs for 
bead-based platforms are another important fact. 
The first diagnostic application of beads was the latex agglutination test (LAT). It was 
invented in 1956 by SINGER and PLOTZ [70, 71], who introduced a rheumatoid factor 
agglutination test. With LATs, antibodies and high-molecular-weight antigens can be 
detected. Due to the fact that antibodies are not monovalent, high aggregates of 
antigen-coated beads and free antibody or antibody-coated beads and free antigen 
form, causing the highly disperse suspension of beads to form clumps. Since its 
invention, the LAT grew more and more popular since it required no sophisticated 
instrumentation, was rapid and required no extensively trained personnel. Very soon 
these beads were used as carriers for ELISA or FLISA and also introduced in flow 
cytometry. 
In order to be used in flow cytometry, beads have to be homogeneous microspheres or 
microparticles, which are used as carriers for biomolecules in tests or assays. Beads 
made of polystyrene and other synthetic polymers are also referred to as "latex" 
particles, since they can be regarded as a dispersion of synthetic polymer. They are 
available in sizes ranging from 0.4 µm to about 200 µm. Like cells, beads are analyzed 
by flow cytometry, when the particles pass one by one through a light beam. Forward 
and side scatter of the light is measured and fluorescent dyes attached to the beads 
can be excited and their emission can be detected. Several hundreds of single beads 
are measured, giving a mean signal with high precision. A very important property to 
discriminate single beads from aggregates and debris is that they all have the same 
light scattering properties. This can only be achieved by using so-called uniform latex 
particles, having the same shape and size. 
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2.4.1 Synthesis, dying and coating of beads 
The polymerization of emulsions of styrene for instance results in the creation of 
microspheres in multiple sizes. For the synthesis of particles with the same size, 
sophisticated methods like swollen emulsion polymerization or seed emulsion 
polymerization have been developed.[72] Swollen emulsion polymerization involves the 
use of an emulsifying agent like potassium laureate or sodium dodecyl sulfate, which 
form micelles of identical size in water. Styrene is added, which travels into the 
lipophilic interior of the micelles and is polymerized upon addition of a free radical 
initiation reagent. This method allows the production of particles up to 3 µm in 
diameter. To obtain larger particles, adding styrene to an aqueous suspension of 
microspheres can swell small particles. This process is called seed emulsion 
polymerization.[73] 
In flow cytometry fluorescence intensity and spectral diversity are used to distinguish 
between several species. Hence, particles could be impregnated with fluorophore to 
generate spectrally distinct populations. Most beads are made of polystyrene or are at 
least copolymers of polystyrene; there are also silica beads, superparamagnetic beads 
with a magnetite core and beads made of polymethylmethacrylate and several other 
materials, but polystyrene gives beads the property of swelling in organic solvent, 
which is an important condition for dying the particles. Upon the addition of lipophilic 
solvent to an aqueous suspension of polystyrene beads, the lipophilic particles begin to 
swell by taking up the organic solvent. Lipophilic dyes dissolved in the organic solvent 
will by this way be transported into the interior of the particles. Azeotropic distillation or 
multiple washing steps will remove the organic solvent, causing the particles to shrink 
to their original size and trapping the dye in the interior of the bead. 
In order to carry out assays with beads, they have to be “sensitized” by attaching 
biological ligands to their surface. This process is called coating and can be done either 
by passive adsorption or covalent coupling. Passive adsorption is due to hydrophobic 
attractions between the polymeric surface and hydrophobic parts of the ligand. 
Although passive adsorption is a very simple technique, it does not guarantee binding 
of the ligand in its most biologically active orientation (antibodies should be bound with 
the Fc portion to the polymeric surface). Large excess of ligand might be required or 
lack of sensitivity can be the consequence. As a remedy, surface modified beads have 
been developed, carrying chemical groups like carboxylic acid, amines, hydroxyl 
groups and others, which can be used for covalent coupling of biomolecules. 
Carboxylic groups on the bead surface for instance can be converted into a reactive 
NHS-ester, which readily reacts with amino groups from antibodies or amino modified 
oligonucleotides. Covalent coupling provides a more precise control of the coating 
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level, allows to work with lower coating concentrations of biomolecules, binds more 
protein compared to adsorption and the coated beads are thermally more stable.[74] 
Covalent coupling also allows the use of spacers between bead and attached 
biomolecule to improve sensitivity. An alternative to covalent coupling is the use of 
commercially available Nickel beads, which readily bind His-tagged biomolecules and 
biotinylated ligands can easily be bound to streptavidin-coated beads. 
2.4.2 The Luminex Technology 
The Luminex Lab Map Technology (Luminex, Austin, TX, USA) utilizes beads dyed 
with different amounts of fluorescent dye. Currently 100 different species of beads are 
available, which are impregnated with a distinct blend of two fluorescent dyes (Fig. 
2.14). It is planned to use a third dye in the near future, resulting in 1,000 spectrally dis-
tinct species of beads. Luminex beads are available in a carboxylated format and with 
streptavidin coating. So-called universal array beads, which carry a unique zip-code for 
hybridization of nucleic acids have recently been introduced (FlexMAP Beads). 
 
 
Fig. 2.14  
Suspension array of 100 species of spectrally distinct color-coded microspheres. Beads 
are impregnated with a blend of two fluorescent dyes. 
A conventional flow cytometer with three fluorescence channels, measures two dyes 
that specify the bead population and a reporter dye that specifies hybridization events. 
By using more sophisticated flow cytometers with additional fluorescent channels (e.g. 
FACSCalibur, BD Biosciences, San Diego, CA, USA), it would be possible to use more 
dyes for color-coding of beads or more colors for the test reaction. However, flow 
cytometers are expensive and their capabilities exceed what is required for bead-based 
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analysis. With the Luminex100 (Luminex, Austin, TX, USA) a low-cost flow cytometer 
(LX 100) is available that is specifically adapted to the measurement of color-coded 
beads and has only the size of a desktop PC. The instrument uses solid phase lasers 
and avalanche photo diodes replace photomultipliers for light scatter (635 nm) and two 
emission channels (645-669 nm and >712 nm). The excitation wavelength for the 
reporter dye has been increased to 532 nm to reduce Rayleigh stray light and to match 
the excitation of phycoerythrin, which is detected by a photomultiplier (Fig. 2.15) For 
the analysis of large numbers of samples, a Luminex HTS brings high-throughput 
capabilities.[75-77] 
 
 
 
Fig. 2.15  
Schematic of Luminex optics. The instrument uses solid phase lasers for excitation and 
avalanche photo diodes (APDs) replace photomultipliers for light scatter (635 nm) and 
two emission channels (645-669 nm and >712 nm). Reporter emission is detected at 
532 nm by means of a photomultiplier (PMT). 
2.4.3 Assay formats in nucleic acid testing 
2.4.3.1 Direct hybridization 
Several formats of wetware were adapted to bead-based nucleic acid testing. The 
simplest method is the direct hybridization of labeled nucleic acids to beads carrying a 
sequence specific oligonucleotide. 
An assay for gene expression analysis using color-coded microspheres was developed 
using this technique. In this ‘Beads Array for the Detection of Gene Expression’ 
(BADGE), labeled cRNA was generated which was hybridized to a set of 20 bead 
populations carrying specific capture sequences of 25 base pairs for 20 Arabidopsis 
genes. The obtained expression profiles were similar to those obtained by Affymetrix 
GeneChip Analysis.[78] 
In addition to expression profiling, sequence specific hybridization of labeled PCR 
product to microspheres has been performed. A sensitive multiplexed bead assay for 
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the detection of three viral nucleic acids (HIV, HSV and HCV) was developed. Here, 
labeled primers were used in amplification of the relevant viral nucleic acids, which 
were hybridized to sequence specific oligonucleotides bound to the beads.[79] 
A third test applying the format of direct hybridization was a screening test for 
mutations in the CFTR gene, which can cause cystic fibrosis. A set of 10 bead 
population, each carrying a sequence specific oligonucleotide for 10 common mu-
tations, and 10 bead populations, each carrying the corresponding wild-type sequence, 
were used. The relevant DNA segments were amplified by PCR using labeled primers 
prior to hybridization to the beads.[80] 
2.4.3.2 Competitive hybridization 
Since hybridization of longer PCR products to microspheres results in significant cross-
talk and decreased sensitivity, a different assay format, the competitive hybridization, 
was applied. With this technique, allele specific, fluorescently labeled oligonucleotides 
(reporter oligonucleotides) are hybridized to the target amplicon. Afterwards, micro-
spheres coated with oligonucleotides complementary to the reporter oligonucleotides 
are added and capture the remaining non-hybridized oligonucleotides. A decrease of 
fluorescence intensity compared to the negative control (inhibition of fluorescence) will 
report a positive test result. This assay format was used for example for a multiplexed 
hybridization assay to perform HLA-DQA1 tissue typing of PCR-amplified human 
genomic DNA.[81] 
2.4.3.3 Zip code techniques 
The simultaneous and efficient hybridization of oligonucleotides with different lengths 
and GC-contents is still a problem, even when using special hybridization buffers. In 
addition, the allelic discrimination of single nucleotide polymorphisms by hybridization 
is problematic due to the similarity of the sequences. To this end, the idea of using so-
called zip codes was brought to light. Here, probes for allelic discrimination carry a 5’-
dangling end with an artificial unique DNA sequence for hybridization to beads 
subsequent to allelic discrimination. This zip-codes are designed with identical length 
and GC content and limited cross-talk in simultaneous hybridization to their 
complementary sequence bound to the bead. An additional advantage is, that the 
development of novel assays does no longer require production of differently coated 
beads. With this assay format, three different techniques have been evaluated: the 
oligo ligation assay (OLA), minisequencing (also called: single base primer extension, 
SBCE) and the allele specific primer extension (ASPE). 
In the OLA, two adjacent hybridized oligonucleotides are enzymatically ligated to each 
other using DNA ligase. This reaction only takes place, when the nucleotides next to 
the ligation position are fully complementary. The first (capture) oligonucleotide is 
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designed to hybridize to the target amplicon with its 3’ base complementary to the 
polymorphic base. It also carries a 5’-dangling end with the zip code. The second 
(reporter) oligonucleotide hybridizes to the target sequence just adjacent to the 3’ end 
of the capture probe and carries a fluorescent tag at its 3’ end. If the capture probe 
matches exactly the SNP query position, the probes are ligated to each other, bringing 
a fluorescent tag to the capture oligonucleotide, which is detected by flow cytometry 
subsequent to hybridization to the bead populations. Two detection probes with 
different zip-codes are required to cover each of the two possible alleles. This method 
has been successfully applied in the analysis of 9 SNP markers located near the apo E 
locus on chromosome 19.[82] 
In OLA, one additional, labeled reporter oligonucleotide is required for each variation. 
In minisequencing, only one primer for each allele is necessary, which is extended by 
one single labeled nucleotide terminator. The SBCE primer, carrying a zip-code at its 
5’-dangling end, hybridizes to the target amplicon with its 3’-end one base upstream of 
the SNP query position. The primer is elongated by DNA polymerase using labeled 
dideoxynucleotide triphosphates (lacking a 3’ hydroxyl group), so that only a single 
base – complementary to the polymorphic base being analyzed – is incorporated. The 
disadvantage of the SBCE format is, that up to four different label are required in 
multiplexing assays to cover each ddNTP and hence a sophisticated flow cytometer 
with six fluorescence channels would be necessary. The alternative is to use a 
separate reaction for each type of terminator nucleotide. Then, the analysis can be 
performed on a standard flow cytometer, but up to four different reactions are required 
in a multiplex assay to cover all possible nucleotides. This method has been 
successfully performed with 55 randomly selected SNPs near the apo E locus.[83] 
In allele specific primer extension only one reaction is required for genotyping. Here, 
like in OLA, one oligonucleotide is designed for each allele to hybridize to the target 
amplicon with its 3’ base complementary to the polymorphic base and a 5’-dangling 
end with a unique zip code. Standard deoxynucleotides are used, with one type of 
them (e.g. dCTP) being labeled. A DNA polymerase lacking 3’-5’ exonuclease activity 
is used to elongate primers with a perfect match at their 3’ end. During elongation, 
dependent on the sequence several labels are incorporated which increases sensitivity 
compared to formats incorporating only one label (like OLA or SBCE). After the 
genotyping reaction, the zip-coded primers are hybridized to color-coded beads (Fig. 
2.16). Only one fluorescent channel is required for detection of each possible genotype 
and no labeled oligonucleotides are required, which are expensive. This format seems 
to be the most suited and cost-efficient method for bead-based nucleic acid testing of 
SNPs and mutations. For evaluation, 20 random selected SNPs have successfully 
been analyzed in 633 probands applying this method.[84] 
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Fig. 2.16  
Principle of the ASPE reaction. One oligonucleotide is designed for each allele to 
hybridize to the target amplicon carrying a 5’-dangling end with a unique zip code. Only 
primers with a perfect match at their 3’ end are elongated by DNA polymerase 
incorporating several labeled dNTPs. After the genotyping reaction, the zip-coded 
primers are hybridized to color-coded beads. 
A set of 100 color-coded beads carrying unique zip codes (FlexMAP Beads) is 
available as platform for the development of bead-based nucleic acid tests (Luminex, 
Austin, Texas). Several commercially available kits (Tm Bioscience, Toronto, Canada) 
have been developed with this platform, applying the ASPE format, including multiplex 
tests for screening of sequence variations in genes relevant for blood coagulation 
(Factor V, Prothrombin, MTHFR), drug metabolism (CYP450-2D6) and cystic fibrosis 
(CFTR).[85, 86] 
2.4.3.4 Benefits of bead-based technology 
At this time, bead-based nucleic acid testing might not be able to compete with high-
density DNA arrays in gene expression profiling and with the determination of more 
precise expression levels using homogeneous real time PCR methods. However, it has 
been shown, that bead-based assays produce accurate results in low density gene 
expression profiling and sequence detection. In terms of the analysis of sequence 
variations, especially genotyping of single nucleotide polymorphisms and point-
mutations, bead-based technology provides a real alternative to conventional methods 
due to its flexibility and high multiplexing capability. The individual combination and the 
simultaneous determination of complete parameter profiles might be more cost-efficient 
than conventional single analysis methods and so could find their way into laboratory 
diagnostics. Flow cytometry is a robust and automatable platform for bead-based 
testing. A large set of commercially available zip code beads (Luminex FlexMAP 
beads) provides an ideal condition for the development of new bead-based nucleic acid 
tests. With allele-specific primer extension, an optimal wetware has been established, 
allowing high specificity, increased sensitivity and thus requiring a less sophisticated 
platform at the same time. 
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3 Materials and methods 
3.1 Patients 
Patient A (individual II-1 from pedigree A, see Fig. 3.1) is a 40-year old woman with 
HDL levels of 125-145 mg/dl with fluctuations of 20-30 mg/dl resulting from the use of 
contraceptives and during menstrual cycle. She had spontaneous abortions due to 
trophoblast dysplasia and a family history of thrombosis and congestive heart failure. 
Lipid parameters prior to lipid lowering therapy are shown in Fig. 3.1. As can be seen in 
pedigree A, her sister (II-2) and her mother (I-2) had also elevated cholesterol but HDL 
was normal. 
One 50-year old female (patient B) had very low HDL (2 mg/dl) and apo A-I (<4 mg/dl) 
levels. She suffered from polyneuropathy, xanthelasmas in both eyes and gingiva 
hyperplasia. She underwent tonsillectomy, but showed no signs of coronary artery 
disease or splenomegaly. 
Another patient (C) with very low HDL (4 mg/dl) and apo A-I levels was a 61-year old 
male with abdominal aorta aneurysm and arcus lipoides who had suffered myocardial 
infarction at the age of 57. 
Patient D (individual II-2 of pedigree D) is a third patient with analphalipoproteinemia 
(HDL 2 mg/dl, apo A-I 5 mg/dl) originating from England. As can bee seen from 
pedigree D (Fig. 3.1), his sister and his father also had reduced HDL and apo A-I 
levels, but the lipid status of the mother seemed normal. 
Pedigree E (Fig. 3.1) consists of four members originating from the Middle East (Iran) 
with a low-HDL-syndrome associated with cardiac hypertrophy and myopathy and a co-
segregation of glucose-6-P-dehydrogenase (G6PD) deficiency. At the time of diag-
nosis, the father, a 60-year old man presented with normal plasma lipids under lipid-
lowering treatment and a disturbed glucose tolerance. Xanthelasms had been known 
since the age of 24. There is a family history of myocardial infarction and vascular dis-
ease. Hypertrophic cardiomyopathy has been diagnosed about 6 years ago and arryth-
mias are existent since the age of 30 years. Dystonia and myopathy of the right arm 
and hand were also reported since puberty. The 53-year old mother (I-2) had reduced 
lipid parameters. She is homozygous for the Mediterranean (Ser188Phe) variant of 
Favism (G6PD deficiency). The index patient (patient E, individual II-1), her 19-year old 
daughter (II-2) had significant myopathy of the eyelids (ptosis), clinical signs of favism 
and low HDL-levels (30 mg/dl). Her 30-year old daughter (II-1) had low HDL levels (27 
mg/dl) as well. The Mediterranean (Ser188Phe) mutation was detected in the 
heterozygous form in both siblings, whereas the father has a wild-type G6PD genotype. 
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Fig. 3.1  
Pedigree A shows a patient with extremely high HDL (cholesterol levels prior to statin 
therapy). Pedigree D illustrates a family with a known Tangier mutation ∆(TC). Pedigree 
E shows a family with low cholesterol levels and co-segregation of Mediterranean form 
of G6PD deficiency.  
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3.2 DNA isolation from EDTA blood 
Genomic DNA was extracted from whole blood EDTA samples using QIAamp Blood 
DNA Midi Kit (Qiagen, Hilden, Germany) or MagNa Pure LC DNA Isolation Kit using 
the MagNa Pure LC extraction robot (Roche Molecular Biochemicals, Mannheim, 
Germany). Extraction yielded up to 260 µl of DNA with a maximum concentration of 
180 ng/µl. For single samples, the quality of the DNA was checked by agarose gel and 
the concentration was determined by absorption measurement. DNA was normalized 
to a concentration of 10 ng/µl. For large numbers of DNA samples for archivation, a 
BIOMEK FX pipeting robot was used (Beckman Coulter, Fullerton, CA, USA). The DNA 
was pipeted into microtiter plates, the concentration was determined using PicoGreen 
Assay (Molecular Probes, Eugene, OR, USA) and the DNA was normalized to a con-
centration of 10 ng/µl. Normalization was carried out using BFX-Normalization Software 
and Biomek FX pipeting robot (Beckman Coulter, Fullerton, CA, USA). 
3.3 Study groups for polymorphism identification 
The German cohorts consisted of 476 healthy blood-donors from the University 
Hospital Regensburg (DON) as control group, as well as 614 patients with coronary 
artery disease (CAD). In addition, 508 German octogenarians (OCT) partly from the 
Berlin Aging Study (436 individuals) and partly recruited by our laboratory (72 
individuals) were available. From a large cohort of patients with type 2 diabetes mellitus 
(TTDM), collected in 30 dialysis centers in South Germany, 384 individuals were 
randomly selected. 
Also, a group of individuals with high HDL (High-HDL) and a group with low HDL (Low-
HDL) values were constituted. Individuals of these groups were patients of the 
University Hospital, as well as selected participants of the RESPECT study (Risk 
Evaluation and Stroke Prevention in the Elderly), which were individuals between 65 
and 80 years with high or low HDL levels prior to statin therapy. Additional samples 
with high HDL were collected in Austria and some individuals with low HDL were from 
the Netherlands. Of all available probands, the samples with the highest and lowest 
HDL values were selected. In this study, high HDL was defined as above 100 mg/dl 
and low HDL as below 50 mg/dl. 
The Hungarian cohorts consisted of 105 healthy blood donors (DON_H), 153 patients 
with coronary artery disease (CAD_H) and 246 patients who had suffered from stroke 
(STROKE_H). 
The Italian cohorts were constituted from 191 healthy blood donors (DON_I) as the 
reference group and 130 centenarians of age 100 and older (CENT). 
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3.4 Sequence of ABCA1 
The sequences used for analysis and numbering of ABCA1 sequence variations were 
obtained from GeneBank (www.ncbi.nlm.nih.gov). The genomic DNA sequence was 
derived from accession number AF275948, mRNA and codon assignment was 
according to NM005502 (mRNA). ABCA1 promoter sequence and numberings relative 
to transcription start point is derived from Langmann et al.[34] 
3.5 DNA sequencing of PCR products from ABCA1 
DNA sequencing was performed with an ABI Prism 3100 Genetic Analyzer with Big 
Dye Terminator technology (ABI, Foster City, CA, USA). PCR products from ABCA1 
were generated with the set of primers listed in Tab. 7.4 of the appendix (see page 89), 
which were purchased from MWG (Ebersberg, Germany) in HPSF grade purity. For the 
screening approach, the promoter region including exon 1 was sequenced in a larger 
set of individuals using promoter primer ABCA1-pro2-f and the reverse primer from 
exon 1 (ABCA1-ex1-r). Here, a longer capillary was used in the sequencer for 
improved read-out of increased fragment lengths. 
In selected individuals, the complete ABCA1 gene (except introns) was analyzed. Here, 
the promoter was sequenced using primer pairs ABCA1-pro1-f/r, ABCA1-pro2-f/r and 
ABCA1-pro3-f/r. The sequence of all 50 exons was analyzed using primer pairs 
ABCA1-ex1-f/r to ABCA1-ex50-f/r. 
CoreKit (Qiagen, Hilden, Germany) was used for all PCR reactions. The reaction 
mixture contained 1x PCR-Buffer, 1x Q-Solution, 200 µM each dNTP, 0.4 µM each 
Primer, 0.05 U/µl Taq polymerase and approximately 0.5 ng/µl genomic DNA. The 
reaction mixture with a final volume of usually 50 µl was processed in a PE 9600 
GeneAmp PCR System thermal cycler (ABI, Foster City, CA, USA) with 5 min of initial 
denaturation, followed by 40 cycles of 45 sec at 95°C, 30 sec at 60°C and 30 sec at 
60°C. Final extension was performed for 10 min at 72°C. After PCR, the obtained 
product was purified using QIAquick spin columns (Qiagen, Hilden, Germany) and 
agarose gel electrophoresis was performed. 
The cycle sequencing reaction was performed using BigDye Terminator Kit 1.1 (ABI, 
Foster City, CA, USA). The final volume of 20 µl contained 4 µl of BigDye Terminator 
Mix RR-2500, 4 µl of 5x sequencing buffer, 3.2 pmol (3.2 µl of 1 pmol/µl) of either 
forward or reverse primer, and 1 to 8.8 µl of purified PCR-product, depending on 
concentration of PCR product as roughly determined by agarose gel electrophoresis. 
The final product was purified using Centrisep spin columns (ABI, Foster City, CA, 
USA), vacuum-dried, dissolved in 20 µl of Hi-Di formamide (ABI, Foster City, CA, USA), 
and processed in the ABI 3100 Genetic Analyzer. 
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Sequence analysis was done using Sequencher software (GeneCodes, Ann Arbor, MI, 
USA) by comparing the patient derived sequences to a reference sequence from the 
database. Trimmed sequences were aligned to each other or to the wild-type 
sequence. All electronically reported sequence variations and heterozygosities were 
checked individually in the original electropherogram. 
3.6 Fluorescent fragment analysis of VNTR polymorphisms 
PCR was carried out with appropriate primer pairs (ABCA1-pro3-f/r and ABCA1-pro4-
f/r), of which one primer was labeled with 6-FAM at its 5’-end. The same concentrations 
and conditions for PCR as presented in 3.4 were used. The PCR product was diluted 
with water (1:7), then 3 µl of it were pooled with 1 µl of ROX-labeled size standard 
Genscan-500 (ABI, Foster City, CA, USA) and supplemented with 20 µl of Hi-Di 
formamide. The mixture was analyzed on an ABI Prism 3100 Genetic Analyzer with 
Gene Scan software. 
3.7 Electrophoretic mobility shift assay (gel shift assay) 
HeLa cells were harvested by centrifugation, washed once with ice-cold PBS, and 
washed twice with wash buffer composed of 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 
10 mM KCl, 0.5 mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF). After resuspension in 1 ml ice-cold wash buffer, cells were centrifuged 1 min 
at full speed in a microfuge. Hypotonic buffer containing 0.1% Nonidet P-40 was added 
to lyse the cell pellet. After 5 min incubation on ice, nuclei were pelleted in a microfuge 
for 15 min at 4°C. Nuclei were resuspended in lysis buffer containing 20 mM HEPES, 
pH 7.9, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 
10% v/v glycerol, and incubated at 4°C for 15 min with gentle vortexing. Subsequently, 
the nuclear debris was pelleted by centrifugation at 4°C for 15 min and the supernatant 
was diluted 1:6 with storage buffer composed of 20 mM HEPES, pH 7.9, 0.05 M KCl, 
0.2 mM EDTA, 0.5 mMDTT, 0.5 mM PMSF, and 20% v/v glycerol. The extracts were 
aliquoted and stored at -70°C. [87] 
An equivalent of 40,000 cpm of double-stranded [32P] end-labeled oligonucleotide 
probe containing either double stranded oligonucleotide -210F-wt (5’-TCC ACC CCC 
ACC CCA CCC CAC CCA CCT CCC CCC-3’) or -210R-mut (5’-TCC ACC CCC ACC 
CCA CCC ACC TCC CCC C-3’) was incubated with 10 µg of nuclear extract from the 
HeLa cells in a buffer containing 50 mM HEPES/HCl, pH 7.9, 6 mM MgCl2, 50 mM 
dithiothreitol, 100 µg/ml bovine serum albumin, 0.01% Nonidet P-40, and 2 µg of 
poly(dI-dC) (Amersham Biosciences, Freiburg, Germany) at room temperature for 
20 min. In competition experiments, nuclear extracts were pre-incubated with a 100-
fold molar excess of competitor for 10 min prior to the addition of the radiolabeled 
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probe. DNA-protein complexes were resolved on a native 8% polyacrylamide gel and 
audioradiographed with Kodak BioMax MR films at 80°C. 
3.8 Reporter gene assay with ABCA1 promoter 
Genomic DNA served as a template for the amplification of a 600 (595) bp-fragment of 
the promoter sequence including the VNTR-ZNF-polymorphism. Forward primer -381F 
with NheI restriction site (5‘-GGG GCT AGC CAA ATT CCA CTG GTG CCC TTG-3‘) 
and reverse primer +214R with BglII restriction site (5‘-GGG AGA TCT TTT CCA CCT 
TTG TGT TTG CGT CTC) were used in PCR with Taq PCR Core Kit (Qiagen, Hilden, 
Germany) and standard protocol. The reporter constructs from two individuals each 
homozygous for one form of the VNTR-polymorphism (595 bp, 600 bp), as verified by 
fragment analysis, were cloned by ligation of PCR fragments into the BglII and NheI 
restriction sites of the pGL3-basic vector. A promoterless pGL3-basic vector served as 
negative control, while the pGL3-control vector, which contains the SV40 early 
promoter, was used as positive control. RAW264.7 cells were transiently transfected 
with Fugene reagent (Roche Molecular Biochemicals, Mannheim Germany) as 
described by the manufacturer. Two µg of the respective reporter gene constructs were 
co-transfected with 1 µg of the pSV  β-galactosidase vector in order to normalize 
differences in transfection efficiency. Cells were harvested 24 hours after transfection 
and lysed in reporter lysis buffer (Promega, Madison, WI, USA). Luciferase assay 
reagent containing Luciferyl-CoA was added after centrifugation. Luciferase activity 
was determined in a LUMAT LB9501 (Berthold). The β-galactosidase enzyme assay 
(Promega) was used for the determination of β-galactosidase activity. Each experiment 
was repeated three times with two distinct plasmid preparations and measurements 
were done in triplicate. The experiment was repeated with co-transfection of up to 4 µg 
of ZNF202m1 vector containing nucleotide positions 8-1960 (GeneBank accession 
number AF027219) cloned into pcDNA3.1/V5/His-Topo plasmid (Invitrogen Carlsbad, 
CA, USA).[87] 
3.9 LightCycler SNP analysis 
Hybridization probes were purchased from TIB MOLBIOL (Berlin, Germany), which 
were labeled with fluorescent dyes FITC and LC Red 640 or LC Red 705, respectively. 
Primers with HPSF quality were obtained from MWG (Ebersberg, Germany). The 
standard reaction mixture (20 µl) contained 1x LightCycler DNA Master Hybridization 
Probes (Roche Molecular Biochemicals, Mannheim, Germany), 4 mM MgCl2, 0.5 µM 
each primer and 0.2 µM each probe when using LC Red 640 or 0.4 µM when using 
LC Red 705, respectively. In the amplification step, for each assay, 40 cycles of 94°C 
(0 sec), 57°C (10 sec) and 72°C (15 sec), were performed. 
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3.10 TaqMan SNP analysis 
Assays based on the hydrolysis probes from TaqMan were usually run as 5 µl 
reactions on a ABI Prism 7900 HT instrument in 384-well plates. The probes specific 
for the individual SNP were labeled either with VIC- or FAM-fluorophore and with a 
non-fluorogenic quencher (NFQ) and a minor groove binder (MGB) for better allelic 
discrimination. PCRs were cycled in 384-well microtiter plates in the TaqMan (ABI 
Prism 7900 HT) or externally in conventional block thermocyclers MWG Primus (MWG, 
Ebersberg, Germany). Endpoint fluorescent data acquisition was achieved using the 
TaqMan instrument. All assays were adapted to the standard protocol: 0.2 µM each 
probe and 0.9 µM each primer in 1x Universal PCR Master Mix. All reagents were from 
ABI (Foster City, CA, USA). The program for thermal cycling was identical for all 
assays (40 cycles of 15 sec at 95°C and 60 sec at 60°C in the amplification step). 
3.11 Microspheres 
FlexMAP microspheres were purchased from Luminex Corp. (Austin, TX, USA). These 
carboxyl modified beads were 5.5 µm in diameter and were color-coded with two 
fluorescent dyes. Beads were coated with unique isothermal “anti-tag” sequences (zip 
codes). The “tag” sequences (complementary “anti-tag” sequences) are presented in 
Tab. 3.1. Oligonucleotides that should be hybridized to FlexMAP beads must carry 
these taq sequences at their 5’ end. The microspheres were stored in TRIS-EDTA 
buffer (10 mM TRIS, 1 mM EDTA) at a concentration of 2.5x105 microspheres per ml. 
Bead-based assays were analyzed on Luminex LX100 analyzer with XY platform and 
IS software. 
3.12 Statistical data analysis 
Pearson’s χ² test was performed to check for differences in distribution of wild-type, 
homozygous and heterozygous individuals in cohorts compared to the control group 
(healthy blood donors). Differences were considered significant, when p(χ²) was 0.05 
or below. 
Observed allelic frequencies were also checked for Hardy-Weinberg equilibrium by 
Fisher’s exact test. A frequency distribution is considered to be significantly different 
from Hardy-Weinberg, when pHWE is 0.05 or below. 
For matched pair data, McNemar test was performed instead of normal χ² test. 
To indicate the level of statistical significance, values are marked with a single asterisk 
(*) for p≤0.05, a double asterisk (**) for p≤0.01, and a triple asterisk (***) for p≤0.001. 
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 No Zip Code Sequence No Zip Code Sequence  
 01 CTT TAA TCT CAA TCA ATA CAA ATC 51 TCA TTT CAA TCA ATC ATC AAC AAT  
 02 CTT TAT CAA TAC ATA CTA CAA TCA 52 TCA ATC ATC TTT ATA CTT CAC AAT  
 03 TAC ACT TTA TCA AAT CTT ACA ATC 53 TAA TTA TAC ATC TCA TCT TCT ACA  
 04 TAC ATT ACC AAT AAT CTT CAA ATC 54 CTT TTT CAA TCA CTT TCA ATT CAT  
 05 CAA TTC AAA TCA CAA TAA TCA ATC 55 TAT ATA CAC TTC TCA ATA ACT AAC  
 06 TCA ACA ATC TTT TAC AAT CAA ATC 56 CAA TTT ACT CAT ATA CAT CAC TTT  
 07 CAA TTC ATT TAC CAA TTT ACC AAT 57 CAA TAT CAT CAT CTT TAT CAT TAC  
 08 AAT CCT TTT ACA TTC ATT ACT TAC 58 CTA CTA ATT CAT TAA CAT TAC TAC  
 09 TAA TCT TCT ATA TCA ACA TCT TAC 59 TCA TCA ATC AAT CTT TTT CAC TTT  
 10 ATC ATA CAT ACA TAC AAA TCT ACA 60 AAT CTA CAA ATC CAA TAA TCT CAT  
 11 TAC AAA TCA TCA ATC ACT TTA ATC 61 AAT CTT ACC AAT TCA TAA TCT TCA  
 12 TAC ACT TTC TTT CTT TCT TTC TTT 62 TCA ATC ATA ATC TCA TAA TCC AAT  
 13 CAA TAA ACT ATA CTT CTT CAC TAA 63 CTA CTT CAT ATA CTT TAT ACT ACA  
 14 CTA CTA TAC ATC TTA CTA TAC TTT 64 CTA CAT ATT CAA ATT ACT ACT TAC  
 15 ATA CTT CAT TCA TTC ATC AAT TCA 65 CTT TTC ATC AAT AAT CTT ACC TTT  
 16 AAT CAA TCT TCA TTC AAA TCA TCA 66 TAA CAT TAC AAC TAT ACT ATC TAC  
 17 CTT TAA TCC TTT ATC ACT TTA TCA 67 TCA TTT ACT CAA CAA TTA CAA ATC  
 18 TCA AAA TCT CAA ATA CTC AAA TCA 68 TCA TAA TCT CAA CAA TCT TTC TTT  
 19 TCA ATC AAT TAC TTA CTC AAA TAC 69 CTA TAA ACA TAT TAC ATT CAC ATC  
 20 CTT TTA CAA TAC TTC AAT ACA ATC 70 ATA CCA ATA ATC CAA TTC ATA TCA  
 21 AAT CCT TTC TTT AAT CTC AAA TCA 71 ATC ATT ACA ATC CAA TCA ATT CAT  
 22 AAT CCT TTT TAC TCA ATT CAA TCA 72 TCA TTT ACC TTT AAT CCA ATA ATC  
 23 TTC AAT CAT TCA AAT CTC AAC TTT 73 ATC AAA TCT CAT CAA TTC AAC AAT  
 24 TCA ATT ACC TTT TCA ATA CAA TAC 74 TAC ACA TCT TAC AAA CTA ATT TCA  
 25 CTT TTC AAT TAC TTC AAA TCT TCA 75 AAT CAT ACC TTT CAA TCT TTT ACA  
 26 TTA CTC AAA ATC TAC ACT TTT TCA 76 AAT CTA ACA AAC TCA TCT AAA TAC  
 27 CTT TTC AAA TCA TAT CTC AAC TTT 77 CAA TTA ACT ACA TAC AAT ACA TAC  
 28 CTA CAA ACA AAC AAA CAT TAT CAA 78 CTA TCT ATC TAA CTA TCT ATA TCA  
 29 AAT CTT ACT ACA AAT CCT TTC TTT 79 TTC ATA ACT ACA ATA CAT CAT CAT  
 30 TTA CCT TTA TAC CTT TCT TTT TAC 80 CTA ACT AAC AAT AAT CTA ACT AAC  
 31 TTC ACT TTT CAA TCA ACT TTA ATC 81 CTT TAA TCT ACA CTT TCT AAC AAT  
 32 ATT ATT CAC TTC AAA CTA ATC TAC 82 TAC ATA CAC TAA TAA CAT ACT CAT  
 33 TCA ATT ACT TCA CTT TAA TCC TTT 83 ATA CAA TCT AAC TTC ACT ATT ACA  
 34 TCA TTC ATA TAC ATA CCA ATT CAT 84 TCA ACT AAC TAA TCA TCT ATC AAT  
 35 CAA TTT CAT CAT TCA TTC ATT TCA 85 ATA CTA CAT CAT AAT CAA ACA TCA  
 36 CAA TTC ATT TCA TTC ACA ATC AAT 86 CTA ATT ACT AAC ATC ACT AAC AAT  
 37 CTT TTC ATC TTT TCA TCT TTC AAT 87 AAA CTA ACA TCA ATA CTT ACA TCA  
 38 TCA ATC ATT ACA CTT TTC AAC AAT 88 TTA CTT CAC TTT CTA TTT ACA ATC  
 39 TAC ACA ATC TTT TCA TTA CAT CAT 89 TAT ACT ATC AAC TCA ACA ACA TAT  
 40 CTT TCT ACA TTA TTC ACA ACA TTA 90 CTA AAT ACT TCA CAA TTC ATC TAA  
 41 TTA CTA CAC AAT ATA CTC ATC AAT 91 TTC ATA ACA TCA ATC ATA ACT TAC  
 42 CTA TCT TCA TAT TTC ACT ATA AAC 92 CTA TTA CAC TTT AAA CAT CAA TAC  
 43 CTT TCA ATT ACA ATA CTC ATT ACA 93 CTT TCT ATT CAT CTA AAT ACA AAC  
 44 TCA TTT ACC AAT CTT TCT TTA TAC 94 CTT TCT ATC TTT CTA CTC AAT AAT  
 45 TCA TTT CAC AAT TCA ATT ACT CAA 95 TAC ACT TTA AAC TTA CTA CAC TAA  
 46 TAC ATC AAC AAT TCA TTC AAT ACA 96 ATA CTA ACT CAA CTA ACT TTA AAC  
 47 CTT CTC ATT AAC TTA CTT CAT AAT 97 AAT CTC ATA ATC TAC ATA CAC TAT  
 48 AAA CAA ACT TCA CAT CTC AAT AAT 98 AAT CAT ACT CAA CTA ATC ATT CAA  
 49 TCA TCA ATC TTT CAA TTT ACT TAC 99 AAT CTA CAC TAA CAA TTT CAT AAC  
 50 CAA TAT ACC AAT ATC ATC ATT TAC 100 CTA TCT TTA AAC TAC AAA TCT AAC  
      
Tab. 3.1  
Zip code sequences to be appended to ASPE primer at 5’ end. The complementary
sequence (“Anti-Tag” sequence) is attached to the correponding region of FlexMAP
Bead.[88] 
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4 Objective 
SNPs build the essence of our genetic diversity. Therefore, the identification of relevant 
markers and the efficient analysis of these small sequence variations in our genome 
are of major importance for effective medical treatment and preventive medicine. 
ABCA1 has recently been identified as the main regulator for plasma HDL cholesterol, 
which has a protective effect in the development of arteriosclerosis and related 
diseases (such as coronary heart disease), sequence variations in this gene could be 
responsible for altered levels of HDL cholesterol and hence predisposition to the 
development of these diseases. 
The aim of this work is to screen for novel sequence variations of relevance in the 
ABCA1 gene and to develop assays for variations of potential interest for diagnostic 
and epidemiological studies. Existing formats and instrumentation for their use in SNP 
genotyping will be compared and evaluated. A high-throughput laboratory for the 
efficient analysis of huge numbers of samples should be set up and tested for 
genotyping of several large cohorts using the newly developed assays. Finally, a 
multiplex assay system for a novel bead-based platform for the simultaneous 
determination of genotypes will be set up and evaluated. 
5 Results 
5.1 Screening for functional sequence variations and mutations in ABCA1 
In order to identify new sequence variations of potential relevance, a knowledge-based 
approach was pursued by analyzing (1) the promoter region and exon 1, (2) selective 
regions of ABCA1 (exons 49 and 50) in a large number of individuals and (3) the 
complete ABCA1 gene in a few individuals with abnormal HDL-levels for the following 
reasons: 
(1) Sequence variations in promoters are good candidates to be responsible for altered 
regulation of gene expression. The prevalence of such polymorphisms may be different 
in various study populations. The first exon of ABCA1 is non-coding and its sequence 
may also contribute to the regulation of ABCA1 gene expression. In order to find 
sequence variations, this region was sequenced of 248 individuals from four study 
groups: 63 healthy octogenarians, 62 healthy blood donors, 62 individuals with low 
HDL and 62 individuals with high HDL. Healthy blood donors are regarded as a 
representative cross-section of the population, so this cohort should display the normal 
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distribution of genotypes in the population. However, these mostly quite young people 
still could develop diseases and aberrant lipid levels if they harbor genotypes that 
predispose such a development. In contrast, very old people with healthy phenotype 
should have “good genes” and sequence variations should accumulate which have 
protective effects to develop diseases such as cardiovascular disease as well as 
normal or good HDL levels. If sequence variations encountered during screening are 
related to HDL levels, a different distribution of genotypes should be found in the 
cohorts with low and high HDL. Since ABCA1 is involved in cholesterol efflux, changes 
in ABCA1-expression should have impact on perturbations in lipoprotein profiles and 
affect disease predisposition. The promoter region of ABCA1 is under investigation and 
contains binding sites for several transcription factors, one of them being ZNF202. 
Sequence variations near or at such a binding site might well influence the expression 
of ABCA1 and be of diagnostic or therapeutical value. 
(2) It has been shown that the C-terminal amino acids of ABCA1, which are part of the 
cytoplasmatic terminal tail, interact with various proteins and thus participate and 
manipulate intracellular processes resulting in aberrant phenotypes [45]. Therefore 
exons 49 and 50 of the ABCA1 gene have been analyzed, which code for 127 amino 
acids (amino acids 2,135-2,261). In order to find relevant polymorphisms in those 
region, both exons in the individuals from the four study groups described above. 
(3) Because patients with severely diminished HDL-levels usually have mutations in the 
ABCA1 gene, it seems conceivable that individuals with extremely aberrant HDL-levels 
(very high or very low) will display sequence variations in ABCA1 that are not present 
or are less frequent in healthy controls. So far, 21 different homozygous or compound-
heterozygous mutations in ABCA1 have been reported in 31 patients with analpha-
lipoproteinemia (Tangier Disease). By identifying new mutations and correlating the 
location of the mutations with the patients‘ epicrisis, it might be possible to elucidate 
important domains in the transporter. 
5.1.1 Sequencing of ABCA1 promoter region and exon 1 
In order to identify novel polymorphisms that may have effects on the expression of 
ABCA1, sequencing of ABCA1 promoter and (non-coding) exon 1 of many individuals 
has been performed. In this screening, along with 3 known SNPs (C1176G, G1355C 
and C1487G [89, 90]), 3 novel SNPs compared to database entry AF275948 have 
been identified (G1047C, C1152T and C1440T). In addition, a VNTR polymorphism, 
designated VNTR-ZNF, was found in the screening approach (see below). Frequencies 
of all encountered SNPs are presented in Tab. 5.1 and reflect the frequencies as have 
been identified in the sequenced individuals, which are homozygous for one form of 
VNTR-ZNF. Due to scrambling of the DNA sequence in a few VNTR-heterozygous 
individuals, proper genotyping of these samples was not possible without cloning of 
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PCR products. Therefore, the presented frequencies may not reflect frequencies in the 
general population and Hardy-Weinberg equilibrium cannot be applied. 
The statistical data analysis (Tab. 5.1) revealed, that the G1047C (G-395C) exchange 
was significantly more frequent in the Low-HDL cohort (18% homozygotes and 55% 
heterozygotes) compared to the High-HDL cohort (27% homozygotes and 24% 
heterozygotes). The exchange C1152T (C-290T) was found at a significantly higher 
prevalence in Low-HDL (5% homozygotes, 25% heterozygotes) than in DON (5% 
homozygotes, 10% heterozygotes) or octogenarians (10% homozygotes, 5% 
heterozygotes). The C1440T (C-7T) exchange was found significantly increased in 
Low-HDL (9% homozygotes, 45% heterozygotes) compared to DON (10% 
homozygotes, 18% heterozygotes) and octogenarians (14% homozygotes and 10% 
heterozygotes). The known polymorphisms C1176G and G1355C were found 
signifycantly decreased in High-HDL compared to DON and Low-HDL. 
Two additional polymorphisms in simple repeat motifs were found (VNTR poly-
morphisms). In the repeat motif GTTTTT GTTT GTTT GTTTT GTTT GTTT (Pos. 674-
700), along with the wild-type sequence, two variations ∆(GTTT) and ∆(GTTTTGTTT) 
were identified. This polymorphism was designated “VNTR-SRY”, since it is located at 
a putative SRY binding site. Since the SRY gene is located on the Y-chromosome, this 
polymorphism was investigated further in male probands of DON, High- and Low-HDL 
cohorts. Another variation, ∆(ACCCC), was found in the simple repeat motif ACCCCC 
ACCCC ACCCC ACCC ACC (Pos. 1,216-1,238), which is located at a putative 
ZNF202 binding site, therefore the polymorphism was designated “VNTR-ZNF”. Since 
ZNF202 is known to down-regulate ABCA1-expression, further functional investigation 
of the VNTR-ZNF was performed. All encountered sequence variations are illustrated 
in Fig. 5.1. 
Further functional testing of the VNTR-ZNF polymorphism was performed. Allele 
frequency data in various study groups should help to elucidate a possible role in 
specific phenotypes. A 380-bp fragment of the promoter containing the VNTR-ZNF 
polymorphism using forward primer CCC TAA GAC ACC TGC TGT ACC C (ABCA1-
pro3-f) with 5’-FAM modification and reverse primer CTG AGA ACC GGC TCT GTT 
GGT (ABCA1-pro3-r) was generated. Separation of PCR products was done by 
capillary electrophoresis (fragment analysis) on 119 individuals: 53 healthy blood 
donors, 39 probands with hyperalpha- and 27 probands with hypoalphalipoproteinemia. 
Results are presented in Tab. 5.2 and show an increased prevalence of the wild-type 
sequence in patients with high HDL-C-levels. The non-deleted form of the VNTR is 
more frequent in the individuals with high-HDL (70.4%) compared to the reference 
group (DON) and the low-HDL group (54.4% and 57.2%, respectively), however the 
difference is not significant. 
5   Results 43 
 
 
 
 
 
      
       
  DON OCT Low-HDL High-HDL Total 
number of individuals 62 56 63 51 232 
Promoter       
G1047C* het 45% 27% 55% 24% 38% 
(G-395C) hom 21% 25% 18% 27% 23% 
     p=0.003**   
C1152T* het 10% 5% 25% 14% 13% 
(C-290T) hom 5% 10% 5% 4% 6% 
   p=0.001***    
   p=0.010**     
C1176G[89] het 26% 17% 41% 6% 23% 
(C-266G) hom 21% 25% 18% 27% 23% 
     p=0.000***   
    p=0.019*   
VNTR-ZNF 
∆1222-6* (Ins-220) hom 5% 8% 7% 4% 6% 
G1355C[90] het 22% 31% 35% 6% 24% 
(G-92C) hom 17% 9% 7% 8% 10% 
    p=0.002**   
   p=0.001***   
  p=0.001***   
C1440T* het 18% 10% 45% 25% 23% 
(C-7T) hom 10% 14% 9% 16% 12% 
   p=0.000***    
   p=0.001***    
Exon 1       
C1487G[90] het 1% 6% 11% 12% 7% 
(C+41G) hom 3% 1% 0% 0% 1% 
       
Tab. 5.1  
Prevalences (in %) of heterozygous and homozygous polymorphisms in ABCA1 
promoter and exon 1. Novel sequence variations are marked with an asterisk. The 
remaining percentage represents wild-type individuals. p-values are given for significant 
differences in distribution of genotypes only. Numberings are based on accession 
number AF275948, numberings in parentheses refer to the position relative to 
transcription start point.[34] OCT, octogenarians; DON, healthy blood donors. 
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       SRY 
 601 GTCCTGTGTT TTTATCACAG GGAGGCTGAT CAATATAATG AAATTAAAAG GGGGCTGGTC -773 
      Sox-5                         SRY 
 661 CATATTGTTC TGTGTTTTTG TTTGTTTGTT TTGTTTGTTT CTTTTTTTGT TTTTGTGGCC -713 
                               ▪▪▪ ▪▪▪▪▪▪ 
 721 TCCTTCCTCT CAATTTATGA AGAGAAGCAG TAAGATGTTC CTCTCGGGTC CTCTGAGGGA -662 
                     NF-kappa B 
 781 CCTGGGGAGC TCAGGCTGGG AATCTCCAAG GCAGTAGGTC GCCTATCAAA AATCAAAGTC -602 
             MZF1     SRY                                      MZF1 
 841 CAGGTTTGTG GGGGGA AAAC AAAAGCAGCC CATTACCCAG AGGACTGTCC GCCTTCCCCT -542 
    MZF1         SRY      Evi-1 
 901 CACCCCAGCC TAGGCCTTTG AAAGGAAACA AA AGACAAGA CAAAATGATT GGCGTCCTGA -482 
                                                             SRY 
 961 GGGAGATTCA GCCTAGAGCT CTCTCTCCCC CAATCCCTCC CTCCGGCTGA GGAAACTAAC -422 
                              C                                     
1021 AAAGGAAAAA AAAATTGCGG AAAGCAGGAT TTAGAGGAAG CAAATTCCAC TGGTGCCCTT -362 
                              ▲ 1081 GGCTGCCGGG AACGTGGACT AGAGAGTCTG CGGCGCAGCC CCGAGCCCAG CGCTTCCCGC -302 
              T                         C 
1141 GCGTCTTAGG CCGGCGGGCC CGGGCGGGGG AAGGGGACGC AGACCGCGGA CCCTAAGACA -242 
              ▲        ZNF202/SRE-like [89]   MZF1 
1201 CCTGCTGTAC CCTCCACCCC CACCCCACCC CACCCACC TC CCCCCAACTC CCTAGATGTG -187 
                         ♦♦♦♦♦     Sp1/3             E-Box 
1261 TCGTGGGCGG CTGAACGTCG CCCGTTTAAG GGGCGGGCCC CGGCTCCACG TGCTTTCTGC -127 
                                       C    Sp1 
1321 TGAGTGACTG AACTACATAA ACAGAGGCCG GGAAGGGGGC GGGGAGGAGG GAGAGCACAG -67 
       DR4        DR4                 [90]      TATA-Box          T 
1381 GCTTTGACCG ATAGTAACCT CTGCGCTCGG TGCAGCCGAA TCTATAAAAG GAACTAGTCC -7 
        ↓                                           G             ▲ 
1441 CGGCAAAAAC CCCGTAATTG CGAGCGAGAG TGAGTGGGGC CGGGACCCGC AGAGCCGAGC +54 
                                                      [90]              
1501 CGACCCTTCT CTCCCGGGCT GCGGCAGGGC AGGGCGGGGA GCTCCGCGCA CCAACAGAGC +114 
                                                                   1561 CGGTTCTCAG GGCGCTTTGC TCCTTGTTTT TTCCCCGGTT CTGTTTTCTC CCCTTCTCCG +174 
                                                                   1621 GAAGGCTTGT CAAGGGGTAG GAGAAAGAGA CGCAAACACA AAAGTGGAAA ACAGGTAAGA +234 
    
▲ novel single nucleotide polymorphisms (G1047C, C1152T and C1440T) 
♦ part of VNTR-ZNF polymorphism; nucleotides do not contribute to numberings on right-hand side 
▪ part of VNTR-SRY polymorphism; nucleotides do not contribute to numberings on right-hand side 
 
Fig. 5.1  
ABCA1 promoter sequence and polymorphisms therein. Numberings on the left refer to 
accession number AF278948, numberings on the right reflect the distances relative to the 
transcription start point according to Langmann et al.[34]. 
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  DON High-HDL Low-HDL Total  
 Individuals 46 27 21 94  
 HDL-C 66±14 121±14 40±9 76±33  
 wt 54.3% 70.4% 57.2% 59.6%  
 het 41.3% 18.6% 33.3% 33.0%  
 ∆1,222-6 4.4% 11.1% 9.5% 7.4%  
 p(χ²) – 0.103 0.637 –  
       
Tab. 5.2  
Frequencies of VNTR-ZNF in various study groups and mean HDL levels. p-values are 
calculated compared to DON. An increased prevalence of wild-type homozygotes was 
found in patients with high HDL-C-levels, however the differences are not significant. 
 
 
 
An in vitro gel shift assay with two labeled double stranded oligonucleotides, derived 
from the “wild-type” and “mutant” (shorter) form of the VNTR, was performed. As can 
be seen in Fig. 5.2, the shorter form of the VNTR polymorphisms (∆1,222-1,226) was 
bound more efficiently by transcription factors of the nuclear extracts from HeLa cells. 
Lane 1 and 2 show the free probe of mutant (1) and wild-type (2) oligonucleotide. Lane 
3 and 4 contain mutant (3) and wild-type (4) oligonucleotide incubated with 5 µg of 
nuclear extract. Competition with 100-fold excess of unlabeled wild-type oligonucleo-
tide reversed the binding while reversal was not as efficient with the mutant oligo-
nucleotide (data not shown). 
In a reporter gene assay, performed in RAW264.7 cells, using the two forms of the 
VNTR polymorphism as part of the ABCA1 promoter and luciferase gene, a significant 
difference with and without co-transfection with ZNF202 vector could not be detect 
(data not shown). 
Frequencies of the VNTR-SRY polymorphism were determined by fragment analysis in 
males only, since the SRY gene is located on the Y-chromosome. A 246 bp fragment 
of the promoter region containing the VNTR polymorphism at a SRY binding site 
(VNTR-SRY) was amplified using forward primer 5’-GGA GGT CTG GAG TGG CTA 
CAT-3’ (ABCA1-pro4-f) and labeled reverse primer 5’-FAM-AGA GGA CCC GAG AGG 
AAC AT (ABCA1-pro4-r). No significant differences in prevalence were found in the 
three study groups. Therefore the VNTR-SRY polymorphism was not characterized 
further. The data are presented in Tab. 5.3. 
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Fig. 5.2  
Electromobility shift assay. Lane 1, free probe of mutant (∆1222-1226) oligonucleotide; 
lane 2, free probe of wild-type oligonucleotide; lane 3, mutant oligonucleotide incubated 
with 5 µg nuclear extract; lane 4, wild-type oligonucleotide incubated with 5 µg nuclear 
extract. 
       
  DON High-HDL Low-HDL Total  
 Individuals 50 33 44 221  
 HDL-C 57±12 93±16 35±7 59±25  
 Homozygotes:  
 wt 2.0% 12.1% 6.8% 6.3%  
 ∆(GTTT) 8.0% 3.0% 2.3% 4.7%  
 ∆(GTTTTGTTT) 18.0% 21.2% 29.5% 22.8%  
 Heterozygotes:  
 wt / ∆(GTTT) 12.0% 15.2% 11.4% 12.6%  
 wt / ∆(GTTTTGTTT) 24.0% 15.2% 15.9% 18.9%  
 ∆(GTTT) / ∆(GTTTTGTTT) 34.0% 33.3% 34.1% 33.9%  
 Allele frequencies:  
 wt 20.0% 27.3% 20.5% 22.0%  
 ∆(GTTT) 32.0% 27.3% 25.0% 28.3%  
 ∆(GTTTTGTTT) 47.0% 45.5% 54.5% 49.2%  
 p(χ²) – 0.541 0.516 –  
       
Tab. 5.3  
Frequencies of VNTR-SRY in various study groups and mean HDL levels (males only). p-
values are calculated compared to DON. No significant differences were detected. 
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5.1.2 Sequencing of exons 49 and 50 of the ABCA1 gene 
Since the C-terminal amino acids of ABCA1, which are part of the cytoplasmatic 
terminal tail, interact with various proteins and thus participate and manipulate 
intracellular processes [45], sequence variations in this region could be of major 
importance. Therefore, exons 49 and 50 of the ABCA1 gene have been sequenced, 
which code for 127 amino acids (amino acids 2,135-2,261) in the individuals from the 
four study groups described above. Sequencing of 63 healthy octogenarians, 62 
healthy blood donors, 62 individuals with low HDL and 62 individuals with high HDL 
revealed only one sequence variation, resulting in amino acid exchange P2150L 
(C143444T) which has been reported earlier by Clee et al.[15] One individual (healthy 
octogenarian) was found to be heterozygous for this sequence variation. 
5.1.3 Sequencing of the complete ABCA1 gene in individuals with aberrant HDL 
levels 
Individuals with extremely aberrant HDL-levels (very high or very low) are expected to 
display sequence variations in ABCA1 that are not present or are less frequent in 
healthy controls. Therefore, the complete coding region and the promoter of several 
individuals has been sequenced. 
In patient A (individual II-1 in pedigree A, Fig. 3.1) a G102555A (V771M) polymorphism 
in a homozygous state was identified. No further sequence variations of potential 
interest were found. Sequencing of additional genes possibly leading to high HDL did 
not reveal any mutation that might account for the high HDL in this individual (CETP, 
SR-BI, LDL receptor). The V771M polymorphism was analyzed in the DON cohort. It 
was found that 451 (94.4%) out of 478 successfully genotyped individuals were wild-
types, only 27 (5.6%) were heterozygous V/M771 and no homozygous M771 individual 
was found. 
Sequencing of the complete ABCA1 gene of the 50-year old female with 2 mg/dl HDL 
(patient B) showed that she was heterozygous for A107009G (N935S), a known 
Tangier mutation [17], and also heterozygous for the novel mutation T103822A, which 
results in the amino acid exchange W840R. The DON cohort was genotyped for this 
variation and no R840 variation was found in 570 successfully determined individuals. 
In the 61-year old male (patient C) the novel mutation G98481T was identified in a 
heterozygous state, which results in amino acid exchange W590L. A mutation in the 
same codon (W590S) has already been described in a previous analyzed Tangier 
patient in our laboratory.[17] The patient was also heterozygous for two known 
polymorphisms (R219K and I883M), but no second mutation could be identified so far. 
The L590 allele was not detected in 570 individuals of the DON cohort. 
Sequencing of the complete ABCA1 gene in the proband of pedigree D (Fig. 3.1) 
revealed, that the patient is heterozygous for a two base-pair deletion (∆TC) in exon 23 
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affecting position 1 and 2 in codon 1,114, leading to a premature stop codon, following 
out-of-frame translation, in codon 1145. This mutation was found in the original kindred 
with HDL deficiency from Tangier Island.[91] In addition, patient D was heterozygous 
for a novel sequence variation in exon 22, which results in the amino acid exchange 
arginine to cysteine at codon 1,068 (R1068C). Three other known sequence variations 
have been found (heterozygous R219K, heterozygous E1172D and homozygous 
R1587K). Sequencing of exons 22 and 23 in the other family members revealed that 
the father and the sister were heterozygous for the Tangier mutation. This concurs with 
the reduced HDL and apo A-I levels in those individuals. The mother was found 
heterozygous for amino acid exchange R1068C (see pedigree D, Fig. 3.1). 
Because of the low-HDL-syndrome, which was obvious in both daughters of pedigree E 
(Fig. 3.1), the complete ABCA1 gene was sequenced in individual II-2 (patient E). 
Several sequence variations were identified, with two of them located within exon 49 
(F2163S) and exon 50 (V2244I) near the COOH terminus of ABCA1. Analysis of the 
rest of the family focusing on the identified polymorphisms revealed that the mother is 
heterozygous for F2163S and the father is heterozygous for V2244I. Both variations 
are present in heterozygous form also in her sister and may account for their low HDL-
cholesterol. This is supported by the fact that one of the enzymes that was identified in 
the yeast two hybrid system to interact with the COOH-terminus of ABCA1 is part of the 
succinate dehydrogenase complex (iron sulfur complex), which is known to be involved 
in the pathogenesis of hypertrophic cardiomyopathy [45]. The S2163 allele was not 
found in 544 successfully genotyped individuals of the DON group, the I2244 variation 
could not be detected in 473 successfully determined donors. 
Tab. 5.4 summarizes the sequence variations or mutations that have been identified 
within the coding region of the ABCA1 gene leading to amino acid changes and their 
origin within the individuals analyzed. Fig. 5.3 shows the location of these variations in 
the ABCA1 protein product. For observed single nucleotide variations in the coding 
region, affecting amino acid sequence, assays based on hydrolysis probe technology 
(TaqMan) were established to clarify if these variations are polymorphisms or point 
mutations. With one exception (V771M), none of these SNPs was found in more than 
500 individuals of the DON cohort. Therefore, it can be concluded, that V771M 
represents a SNP, while all other variations are (point-) mutations. The primers and 
probes that have been developed for TaqMan analysis are presented in Tab. 5.5, 
which can be used with the same conditions specified in 3.10. The development of 
TaqMan assays and their processing in high-throughput workflow will be described in 
more detail in the next section. 
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Fig. 5.3  
Location of sequence variations in the coding region of ABCA1. The amino acid position 
and structure is according to Tanaka et al.[92] Black dots indicate mutations in the 
Tangier patients or relevant sequence variations. 
 
   
  
 
Exon Amino acid Nucleotide Pos. DNA AF275948 
Pos. mRNA 
NM005502 phenotype of patient 
14 W590L TGG→TCG 98,481 2,082 HDL deficiency (C) 
16 V771M GTG→ATG 102,555 2,624 increased HDL (A) 
17 W840R TGG→AGG 103,822 2,831 HDL deficiency (B) 
22 R1068C CGC→TGC 109,904 3,515 HDL deficiency (D) 
49 F2163S TTT→TCT 143,483 6,801 
50 V2244I GTT→ATT 144,665 7,043 
low HDL and G6PD 
deficiency (E) 
Tab. 5.4 Sequence variations found in ABCA1 and phenotypes of patients. 
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W590L 
TM-W590L-f 
TM-W590L-r 
5‘-AGC TGA CCC CTT TGA GGA CAT-3‘ 
5‘-CTC CAC CAC ATC CTG CAA GTA G-3‘ 
(G2082C) TM-W590-vic 
TM-L590-fam 
5‘-VIC-CCC CCC AGA CGT A-MGB-NFQ-3‘ 
5‘-FAM-CCC CCG AGA CGT A-MGB-NFQ-3‘ 
 
V771M 
TM-V771M-f 
TM-V771M-r 
5‘-GGC ATC ATC TAC TTC ACG CTG TA-3‘ 
5‘-CAG AGG TAC TCA CAG CGA AGA TCT T-3‘ 
(G2624A) TM-V771-vic 
TM-M771-fam 
5‘-FAM-TGT GAA GCC CAC GTA G-MGB-NFQ-3‘ 
5‘-VIC-TGA AGC CCA TGT AGT C-MGB-NFQ-3‘ 
 
W840R 
TM-W840R-f 
TM-W840R-r 
5‘-GCT GTT TGA CAC CTT CCT CTA TGG-3‘ 
5‘-TGT ACC TGG AAA GAC AGC CTC AA-3‘ 
(T2831A) TM-W840-vic 
TM-R840-fam 
5‘-VIC-TGT ACC AGG TCA TCA C-MGB-NFQ-3‘ 
5‘-FAM-TGT ACC TGG TCA TCA C-MGB-NFQ-3‘ 
 
P2150L 
TM-P2150L-f 
TM-P2150L-r 
5‘-TTC AGG TTT GGA GAT GGT TAT ACA ATA G-3‘ 
5‘-GAA ATG CAA GTC CAA AGA AAT CCT-3‘ 
(C6762T) TM-P2150-vic 
TM-L2150-fam 
5‘-VIC-CAA CCC GGA CCT GA-MGB-NFQ-3‘ 
5‘-FAM-CAA CCT GGA CCT GAA-MGB-NFQ-3‘ 
 
F2163S 
TM-F2163S-f 
TM-F2163S-r 
5‘-AAG CCT GTC CAG GAT TTC TTT G-3‘ 
5‘-CAT GTT CCG GTG TTT CTC TTT TAG-3‘ 
(T6801C) TM-F2163-vic 
TM-S2163-fam 
5‘-VIC-CCA GGA AAT GCA AGT C-MGB-NFQ-3‘ 
5‘-FAM-CAG GAG ATG CAA GTC-MGB-NFQ-3‘ 
 
V2244I 
TM-V2244I-f 
TM-V2244I-r 
5‘-ATG ATG ACC ACT TAA AAG ACC TCT CA-3‘ 
5‘-GCT TTC TTT CAC TTT CTC ATC CTG TAG-3‘ 
(G7043A) TM-V2244-vic 
TM-I2244-fam 
5‘-VIC-TGG ACG TTG CAG TTC-MGB-NFQ-3‘ 
5‘-FAM-AGT AGT GGA CAT TGC-MGB-NFQ-3‘ 
   
Tab. 5.5  
Primers and probes for TaqMan analysis of novel polymorphisms in the coding region 
of ABCA1. 
 
5.2 High-throughput genotyping of ABCA1 polymorphisms 
In this part, a concept for high-throughput analysis of single nucleotide polymorphisms 
has been established using TaqMan technology integrated in a roboting platform. Since 
the previously analyzed promoter region contains numerous polymorphisms, partly in 
close proximity to each other, this region was not chosen for the development of 
assays, to avoid difficult primer design and laborious troubleshooting of assays. The 
main focus of this part was the establishment of the high-throughput technology. 
Therefore, four interesting polymorphisms in the coding region of the ABCA1 gene 
have been selected, which affect amino acid sequence: R219K, I883M, V771M and 
E1172D (the location of these polymorphisms is presented in Fig. 5.4). The R219K 
polymorphism has been associated with reduced severity of arteriosclerosis, fewer 
coronary events, decreased triglycerides and a trend to increased HDL in men with 
coronary heart disease.[93, 94] The M771 variant is suspected to be involved in the 
cause of increased HDL levels in one subject (see 5.1.3), but no association has been 
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shown so far. The M883 allele is associated with significantly higher plasma HDL 
cholesterol in Canadian Inuit and Japanese.[95, 96] The D1172-allele has been found 
significantly increased in CHD end points.[97] Several cohorts were subject to 
genotyping with the new established workflow. Before the high-throughput concept 
could be achieved, genotyping was carried out using LightCycler melting curve 
analysis. Data obtained from this method will also be included in the association study, 
since both methods are reliable and firmly established. In addition, since experience 
has been gained with both methods, LightCycler and TaqMan, a direct comparison and 
evaluation can be performed. 
 
 
 
Fig. 5.4  
Structure of the ABCA1 protein product and location of four selected polymorphisms 
therein. 
 
The selected cohorts constituted for analysis were healthy people older than 80 years 
(OCT), patients with premature onset of coronary artery disease (CAD), stroke 
(STROKE) and others. The distribution of genotypes in these groups can be compared 
to a cohort of healthy blood donors (DON). If the polymorphisms investigated, have an 
effect on HDL levels or other related lipid parameters, an unequal distribution of 
genotypes should be observed in the different cohorts. E.g., if one allele had a positive 
effect on lipid parameters or a protective effect in aging, it should be more abundant in 
very old people. Since HDL has a protective effect on the development of 
arteriosclerosis and HDL levels are influenced by a certain polymorphism, a different 
distribution of genotypes could be observed in cohorts with related diseases, such as 
the cohort of patients with coronary artery disease or stroke. A group of patients with 
diabetes mellitus type 2 (TTDM) was also analyzed, since low HDL cholesterol and 
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apolipoprotein AI levels are often found in association with other cardiovascular risk 
factors, including the type 2 diabetes mellitus.[98] 
In addition a large set of samples from Hungary (_H) and Italy (_I) were available. It 
might also be possible to find an unequal distribution of genotypes in populations with 
different ethnical origin. 
5.2.1 LightCycler SNP analysis 
Primers and hybridization probes for SNPs in ABCA1 for LightCycler melting curve 
analysis were designed manually or using primer3 software [99]. With 3 LightCycler 
instruments, running up to 10 times per day for genotyping of large cohorts, 960 
samples could be processed per day. Genotypes were obtained applying the melting 
curve analysis inherent of the LightCycler technology. Genotyping had to be done 
manually by checking each melting curve plot manually and recording the data into 
Excel spreadsheets. The designed primers and probes were used with standard 
LightCycler protocols (see 3.9). Primers and probes are given in Tab. 5.6, typical 
metling curve plots for each assay are presented in Fig. 5.5. 
 
 
   
   
 
R219K 
LC-R219K-f 
LC-R219K-r 
5‘-TTT TGC AAG GCT ACC AGT TAC A-3‘ 
5‘-CAG GAT TGG CTT CAG GAT GT-3‘ 
(G969A) LC-R219-det 
LC-R219-anc 
5‘-LCRed705-GCC TAC CAA GGG AGA AAC TG-(P)-3‘ 
5‘-CTT GGT GAC CAA GAA GTT TCT GAG CTT TG-FITC-3‘ 
 
V771M 
LC-V771M-f 
LC-V771M-r 
5'- TAC AAG TGA GTG CTT GGG ATT -3' 
5'- CCC ATT GGA AAA GAC AAT CAT C -3' 
(G2624A) LC-V771-det 
LC-V771-anc 
5‘-LCRed640-GCA GGA CTA CGT GGG CTT C-(P)-3‘ 
5‘-CTG-TAC CTG CCC TAC TGC CTG TGT GTG GCA-FITC-3‘ 
 
I883M 
LC-I883M-f 
LC-I883M-r 
5‘-AGG CCC TGG TAT TTT CCT TG-3‘ 
5‘-CCC TGG AGT GGT TTC ACA GT-3‘ 
(A2962G) LC-I883-det 
LC-I883-anc 
5‘-LCRed640-CTT TCT GAT ATT CTC TTC TGG-(P)-3‘ 
5‘-TTA AAG AAA GAG CAG GAG GTC AAC AGC ACT-FITC-3‘ 
 
E1172D 
LC-E1172D-f 
LC-E1172D-r 
GGA CAG TGT TTC TCA GAG CAG 
5‘AGC AGC AAA CCT TGA GTC AG 
(G3829C) LC-E1172-det 
LC-E1172-anc 
5‘-LCRed640-CGT GTC ACT CTC ATG GTC G-(P)-3‘ 
5‘-AGA AAC CCC AGA GTC CTT ACC GAT GGT C-FITC-3‘ 
   
Tab. 5.6  
Primers and hybridization probes for LightCycler 
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R219K V771M 
  
  
I883M E1172D 
  
  
Fig. 5.5  
Typical melting curve analysis plots for LightCycler assays R219K, V771M, I883M and 
E1172D. 
 
5.2.2 TaqMan SNP analysis 
TaqMan assays were run as 5 µl reactions on an ABI Prism 7900 HT instrument in 
384-well plates. The probes specific for the individual sequence were labeled either 
with VIC or FAM-fluorophore at their 5’-end and with a non-fluorogenic quencher (NFQ) 
and a minor groove binder (MGB) for better allelic discrimination at the 3’-end. In the 
high-throughput phase the PCRs were cycled externally in 384-well microtiter plates on 
up to six conventional block thermocyclers (MWG, Ebersberg, Germany) and endpoint 
fluorescent data acquisition was achieved on the ABI Prism 7900 HT. Results were 
gated manually by the operator. The TaqMan was integrated in the high-throughput 
workflow as described later. Primers and hydrolysis probes were designed manually, 
using primer3 software [99], Primer Express (ABI, Foster City, CA, USA) or ABI’s 
Assay-by-Design service. Primers and probes were used with the standard ABI 
protocol for TaqMan SNP analysis (see 3.10). Typical discrimination plots for the 
developed assays are presented in Fig. 5.6, primers and probes are listed in Tab. 5.7. 
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Fig. 5.6  
Typical discrimination plots for TaqMan assays R219K, V771M, I883M and E1172D. 
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R219K 
TM-R219K-f 
TM-R219K-r 
5‘-TGA CCA AGA AGT TTC TGA GCT TTG T-3‘ 
5‘-TGT CCA TGT TGG AAC GAA GTA CTC-3‘ 
 
 (G969A) TM-R219-vic 
TM-K219-fam 
5‘-VIC-ACC AAG GGA GAA AC-MGB-NFQ-3‘ 
5‘-FAM-ACC AAA GGA GAA ACT-MGB-NFQ-3‘ 
 
  
V771M 
TM-V771M-f 
TM-V771M-r 
5‘- GGC ATC ATC TAC TTC ACG CTG TA-3‘ 
5‘- CAG AGG TAC TCA CAG CGA AGA TCT T-3‘ 
 
 (G2624A) TM-V771-vic 
TM-M771-fam 
5‘-FAM-TGT GAA GCC CAC GTA G-MGB-NFQ-3‘ 
5‘-VIC-TGA AGC CCA TGT AGT C-MGB-NFQ-3‘ 
 
  
I883M 
TM-I883M-f 
TM-I883M-r 
5‘-AGA GCC ACC CTG GTT CCA A-3‘ 
5‘-AAA GAA AGA GCA GGA GGT CAA CAG-3‘ 
 
 (A2962G) TM-I883-vic 
TM-M883-fam 
5‘-VIC-CTT ACT TTC TGA TAT TCT-MGB-NFQ-3‘ 
5‘-FAM-CTT TCT GAC ATT CTC-MGB-NFQ-3‘ 
 
  
E1172D 
TM-E1172D-f 
TM-E1172D-r 
5‘-GGA CAG TGT TTC TCA GAG CAG TTC T-3‘ 
5‘-CCC AGA GTC CTT ACC GAT GGT-3‘ 
 
 (G3829C) TM-E1172-vic 
TM-E1172-fam 
5‘-VIC-CGA CCA TGA GAG TGA-MGB-NFQ-3‘ 
5‘-FAM-CCA TGA CAG TGA CAC G-MGB-NFQ-3‘ 
 
     
Tab. 5.7  
Primers and hydrolysis probes for TaqMan. 
 
 
 
5.2.3 High-throughput workflow 
For the fast analysis of a large number of samples the main tasks outlined in Tab. 5.8 
have to be performed in an automated workflow. Subsequent to DNA isolation of a 
multitude of EDTA blood samples, DNA concentrations have to be determined and 
DNAs need to be normalized to a standardized concentration for archivation in 
appropriate large volume storage plates. After archivation of all DNAs, the samples of 
interest for a study project are chosen and an appropriate amount of the selected 
DNAs is withdrawn from the archive (hit picking) and stored in working plates. For 
efficient and reliable processing of a large number of samples, a pipeting robot is 
required. Normalization, archivation and hit picking are performed by means of a robot 
as well as the pipeting of SNP discrimination reactions. All samples and microtiter 
plates have to be barcoded for the fast manual or automated identification of samples 
and plates and for the recording of performed work steps. Automated data processing 
and sample tracking during the whole workflow guarantees ready availability of test 
results subsequent to assignment of genotypes to the obtained test results 
(genotyping). 
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1. Isolation of DNA 
2. Determination of concentration and normalization 
3. Archivation 
4. Hit picking 
5. Pipeting of SNP reaction 
6. Genotyping 
 
Tab. 5.8  
High-throughput workflow process. 
 
 
 
The pipeting robot Biomek FX (Beckman Coulter, Fullerton, CA, USA), equipped with 
an 8-channel pipettor and a 96-channel pipettor, was used for this work. The 8-channel 
pipettor, with independent volume control of each channel, is ideal for transferring in-
dividual samples into the 96-well format (archivation), for individual dilution of samples 
(normalization) and for picking single samples out of a microtiter plate (hit picking). The 
96-channel pipettor is best suited for transferring material from one whole plate into 
another (e.g. adding DNA to the reaction plate). In addition, the Biomek FX contains a 
barcode reader and a stacker carousel that can hold additional 40 plates or tip boxes to 
be used with the robot, which both are essential for a high-throughput workflow. 
For normalization and archivation, barcoded DNA samples were transferred to deep-
well-microtiter-plates using the pipeting robot. Up to five identical plates were 
generated with 50 µl of original DNA eluate each. The position of DNA samples in the 
microtiter-plates were stored together with their barcodes in a SYBASE database. To 
determine the concentration of DNA, a PicoGreen assay (Molecular Probes, Eugene, 
OR, USA) was performed. One microliter of DNA was transferred to PicoGreen assay 
reagent with the 96-channel pipettor. Using Fluostar BMG-Reader, connected to 
Biomek FX software, DNA concentration was determined. Then BFX normalization 
software provided from Beckman Coulter calculated the amount of water to be added 
to each well, to dilute DNA samples to a uniform concentration of 10 ng/µl in the deep 
well plates. BFX normalization software generated a working list for Biomek FX 
Pipeting Robot and dilution was carried out automatically. The normalized DNA Bank 
was stored at -80°C. 
Cohorts were constituted by hit picking from probands sharing similar clinical 
phenotypes such as premature coronary artery disease or diabetes mellitus, or 
aberrant lipid profiles. With custom made storage management program, all necessary 
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barcoded plates of the DNA-bank were acquired and transferred to the Biomek FX 
Stacker Carrousel. DNA of the relevant probands was picked from the normalized 
DNA-bank automatically using Biomek FX Hit Picking Wizard. Usually, 96-well (round-
bottom) working plates were generated that contained up to 200 µl of DNA each at a 
concentration of 5 ng/µl. 
Assays were carried out in a total volume of 5 µl. With Biomek FX, using 96-
multichannel pipettor, 4 µl of master mix, containing probes and primers, was 
transferred to each well of a 384-well-reaction plate. Then DNA from four 96-well 
round-bottom working plates was added (1 µl each). Reaction plates were sealed with 
a heat sealer (Abgene, Epsom, UK) and cycled on MWG Primus multiblock thermo-
cyclers (MWG, Ebersberg, Germany). Endpoint fluorescence measurement was 
carried out on TaqMan 7900HT using Zymark Twister for automated plate loading. 
High-throughput SNP genotyping requires sophisticated software infrastructure. Using 
SYBASE database (Sybase, Dublin, CA, USA) and custom made C++ programs 
(Borland Software Corporation, Scotts Valley, CA, USA), sample tracking, hit picking, 
DNA storage management and automated result generation were achieved. In Fig. 5.7, 
data handling in the high-throughput workflow is schematically illustrated. Patients and 
DNA samples (more than one sample can belong to a single patient) are fed into the 
database. Numbers and barcodes are assigned for patient and sample automatically 
and linked to each other. The barcoded DNA samples are transferred to storage plates 
and the barcode of the storage plate, the assignment of the well position and the 
archived amount of samples is stored. For hit picking, the relevant storage plates are 
selected from the database. The amount of DNA withdrawn is subtracted from the 
storage plate entry, the barcode and the assignment of the well positions are fed into 
the database. The database also contains all relevant assay information, like name and 
assignment of fluorescent signal and genotype. Then, for TaqMan analysis, only 
barcodes of the working plates and the reaction plate have to be scanned and the 
performed assay has to be named. Results are generated in tabular form automatically, 
after the operator has gated the raw data. 
5   Results 58 
 
 
 
Fig. 5.7  
Schematic representation of data management in high-throughput workflow. 
 
5.2.4 Results of genotyping 
In the main focus of genotyping was the novel polymorphism V771M, which has not yet 
been characterized further. The relevant polymorphisms R219K, I883M and E1172D 
were genotyped as well, when DNA material was not limited. Very little material of the 
Hungarian and Italian cohorts was available, so that not all polymorphisms could be 
investigated in these cohorts. 
A significant difference in genotype distribution was not detected in healthy blood 
donors from three different ethnical origins (Tab. 5.9). A lower prevalence of K219 
homozygotes in Italian donors (2.7%) and an increased amount of K219 homozygotes 
in Hungarians (11.9%) compared to Germans (7.4%) was found. It should also be 
stated, that Hardy Weinberg disequilibrium (pHWE=0.017*) was detected in the Italian 
donors cohort for the R219K polymorphism. The M771 allele was more abundant in 
Italians (8.9% heterozygotes) and Hungarians (9.8% heterozygotes) compared to 
Germans (5.6% heterozygotes). However, these differences are not significant 
(p=0.125 and 0.052, respectively). M771 homozygotes were not found. 
No significant differences in genotype distribution were also found in comparison of all 
German cohorts (Tab. 5.10). A slightly higher prevalence of the I883 allele in the 
diabetes cohort (79.8% homozygotes) compared to healthy blood-donors (75.6%) was 
detected (p=0.110). All genotype distributions were in Hardy Weinberg equilibrium. 
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In the Hungarian cohorts (Tab. 5.11), the V771 homozygotes were more prevalent in 
CAD patients (97.3%) compared to healthy blood donors (90.2%). The difference was 
highly significant (p=0.008**). This could indicate, that the M771 variant has a 
protective effect in the development of CAD. Homozygotes for V771 were also more 
frequent in the stroke cohort (94.3%), but this did not reach significance (p=0.133). 
In Italian centenarians (Tab. 5.12), the number of V/M771 heterozygotes was slightly 
increased (12.7%) compared to Italian blood donors (8.9%), however not significantly. 
Therefore, R/K219 heterozygotes were significantly more abundant (p=0.016*) in 
centenarians (46%) compared to the Italian control group (32.4%). In DON_I 48.7% 
were carriers of the K219 allele, in CENT 41.4%. 
Further (advanced) statistical analysis of the genotyping data was not performed, since 
in large German cohorts no association was obvious and splitting up the Italian and 
Hungarian cohorts into subgroups (age, sex) would be problematic due to the low 
number of individuals. The aim of this work was not to exhaust statistical data analysis 
methods to find weak associations, but to set up functional assays in the high-
throughput format. 
       
       
R219K N R R/K K pHWE p(χ²) 
DON 458 226 (49.3%) 198 (43.2%) 34 (7.4%) 0.364 – 
DON_H 193 97 (50.3%) 73 (37.8%) 23 (11.9%) 0.128 0.128 
DON_I 150 77 (51.3%) 69 (46.0%) 4 (2.7%) 0.017* 0.112 
V771M N V V/M M pHWE p(χ²) 
DON 478 451 (94.4%) 27 (5.6%) 0 (0.0%) 1.000 – 
DON_H 193 174 (90.2%) 19 (9.8%) 0 (0.0%) 1.000 0.052 
DON_I 191 174 (91.1%) 17 (8.9%) 0 (0.0%) 1.000 0.125 
I883M N I I/M M pHWE p(χ²) 
DON 467 353 (75.6%) 105 (22.5%) 9 (1.9%) 0.686 – 
DON_H 105 80 (76.2%) 24 (22.9%) 1 (1.0%) 1.000 0.788 
DON_I 191 140 (73.3%) 49 (25.7%) 2 (1.0%) 0.541 0.521 
E1172D N E E/D D pHWE p(χ²) 
DON 478 456 (95.4%) 22 (4.6%) 0 (0.0%) 1.000 – 
DON_I 190 177 (93.2%) 12 (6.3%) 1 (0.5%) 0.220 0.185 
          
Tab. 5.9  
Distribution of genotypes in control groups (healthy blood donors) from three different 
ethnical origins (Germans, Hungarians and Italians). M771 seems to be more prevalent 
in Hungarians and Italians. The R219K polymorphism was in Hardy Weinberg 
disequilibrium in Italian donors. N, number of individuals. 
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R219K N R R/K K pHWE p(χ²) 
DON 458 226 (49.3%) 198 (43.2%) 34 (7.4%) 0.364 – 
TTDM 375 191 (50.9%) 154 (41.1%) 30 (8.0%) 1.000 0.810 
OCT 434 224 (51.6%) 170 (39.2%) 40 (9.2%) 0.350 0.371 
CAD 613 333 (54.3%) 243 (39.6%) 37 (6.0%) 0.461 0.243 
V771M N V V/M M pHWE p(χ²) 
DON 478 451 (94.4%) 27 (5.6%) 0 (0.0%) 1.000 – 
TTDM 376 359 (95.5%) 17 (4.5%) 0 (0.0%) 1.000 0.459 
OCT 422 394 (93.4%) 27 (6.4%) 1 (0.2%) 0.392 0.505 
CAD 614 582 (94.8%) 31 (5.0%) 1 (0.2%) 0.357 0.617 
I883M N I I/M M pHWE p(χ²) 
DON 467 353 (75.6%) 105 (22.5%) 9 (1.9%) 0.686 – 
TTDM 377 301 (79.8%) 74 (19.6%) 2 (0.5%) 0.403 0.110 
OCT 434 344 (79.3%) 85 (19.6%) 5 (1.2%) 1.000 0.340 
CAD 611 452 (74.0%) 146 (23.9%) 13 (2.1%) 0.783 0.831 
E1172D N E E/D D pHWE p(χ²) 
DON 478 456 (95.4%) 22 (4.6%) 0 (0.0%) 0.781 – 
OCT 434 417 (96.1%) 17 (3.9%) 0 (0.0%) 1.000 0.609 
CAD 614 585 (95.3%) 29 (4.7%) 0 (0.0%) 1.000 0.925 
          
Tab. 5.10  
Distribution of genotypes in German cohorts. No significant differences were found. 
DON, donors; TTDM, diabetes; OCT octogenarians. 
 
 
       
       
R219K N R R/K K pHWE p(χ²) 
DON_H 193 97 50.3% 73 37.8% 23 11.9% 0.128 – 
STROKE 247 134 54.3% 84 34.0% 29 11.7% 0.008 0.679 
CAD_H 152 84 55.3% 57 37.5% 11 7.2% 0.833 0.317 
V771M N V V/M M pHWE p(χ²) 
DON_H 193 174 90.2% 19 9.8% 0 0.0% 1.000 – 
STROKE 245 231 94.3% 13 5.3% 1 0.4% 0.198 0.133 
CAD_H 150 146 97.3% 4 2.7% 0 0.0% 1.000 0.008** 
I883M N I I/M M pHWE p(χ²) 
DON_H 105 80 76.2% 24 22.9% 1 1.0% 1.000 – 
STROKE 246 178 72.4% 61 24.8% 7 2.8% 0.466 0.492 
CAD_H 153 120 78.4% 29 19.0% 4 2.6% 0.238 0.499 
          
Tab. 5.11  
Distribution of genotypes in Hungarian cohorts. V771 homozygotes were more prevalent 
in CAD patients (97.3%) compared to healthy blood donors (90.2%). The difference was 
highly significant (p=0.008**). This could indicate, that the M771 variant has a protective 
effect in the development of CAD. Homozygotes for V771 were also more frequent in the 
stroke cohort (94.3%), but this did not reach significance (p=0.133). 
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R219K N R R/K K pHWE p(χ²) 
DON_I 150 77 51.3% 69 46.0% 4 2.7% 0.017* – 
CENT 111 65 58.6% 36 32.4% 10 9.0% 0.136 0.016* 
V771M N V V/M M pHWE p(χ²) 
DON_I 191 174 91.1% 17 8.9% 0 0.0% 1.000 – 
CENT 126 110 87.3% 16 12.7% 0 0.0% 1.000 0.279 
I883M N I I/M M pHWE p(χ²) 
DON_I 191 140 73.3% 49 25.7% 2 1.0% 0.541 – 
CENT 104 72 69.2% 31 29.8% 1 1.0% 0.458 0.745 
E1172D N E E/D D pHWE p(χ²) 
DON_I 190 177 93.2% 12 6.3% 1 0.5% 0.220 – 
CENT 118 109 92.4% 9 7.6% 0 0.0% 1.000 0.667 
          
Tab. 5.12  
Distribution of genotypes in Italian cohorts. The number of V/M771 heterozygotes was 
slightly increased (12.7%) in centenarians (CENT) compared to healthy blood donors 
(8.9%), however not significantly. Therefore, R/K219 heterozygotes were significantly 
more abundant (p=0.016*) in centenarians (46%) compared to the Italian control group 
(32.4%). 
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5.3 Development of a bead-based multiplex assay 
Four SNPs resulting in amino acid exchanges in the ABCA1 protein product that have 
shown association, have been described: R219K, V771M, I883M and E1172D. In this 
part, a multiplex panel will be presented, that allows the simultaneous detection of all 
four SNPs. This panel uses the new bead-based Luminex technology described in 
chapter 2. The motivation of this work was to evaluate the Luminex platform for the 
determination of SNP risk profiles and to compare this method to other established 
technologies, especially the LightCycler and the TaqMan technology. 
Several formats of wetware have been tested to establish a functional assay panel for 
the Luminex technology, including competitive hybridization, minisequencing (SBCE) 
and allele specific primer extension (ASPE). Competitive hybridization was found to be 
less straightforward. Multiple sequences, partly very similar to each other need to be 
optimized for identical hybridization conditions and high specificity and sensitivity at the 
same time. Although it is possible to develop assays using this technique, which has 
been shown (see 2.4.3.2), intensive optimization is required. This was noticed at an 
early stage of development and the method was rejected. Instead, a set of functional 
minisequencing primers was developed, which worked well with ABI Prism Snap Shot 
(Applied Biosystems, Foster City, USA) technology using a capillary sequencer (data 
not shown). However, the primers were not adapted to bead-based analysis, since up 
to four separate reactions would have been required or a more sophisticated flow 
cytometer (capable of reading six fluorescent channels) would have been necessary 
(see 2.4.3.3). Instead, the allele specific primer extension method was used to develop 
a functional assay, which is very well suited for the Luminex platform (see 2.4.3.3 and 
Fig. 2.16). 
5.3.1 Design of primers 
PCR primers were designed using primer3 software.[99] The relevant segments of 
DNA to be amplified and the location of the sequence variation therein (green color) 
are presented in Fig. 5.8. The designed primers are marked in blue color. To obtain 
similar amplification efficiency for all amplicons, primers were designed to give product 
sizes between 150 and 200 base pairs, with at least 10 base pairs in difference to allow 
separation by agarose gel electrophoresis. Similar melting temperatures of primers 
were aimed at, between 55 and 60°C. Primer sequences, melting points and amplicon 
sizes are listed in Tab. 5.13. Primers were checked for cross-hybridization to other 
genes by blast-search [100] and to repeat regions using primer3 mispriming 
library.[101] 
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Exon 7 
  70801 cttgtctctc tttgcatgaa atgcttccag GTATTTTTGC AAGGCTACCA GTTACATTTG 
                                        >>>>>>>>>> >>>>>>>>>> 
 70861 ACAAGTCTGT GCAATGGATC AAAATCAGAA GAGATGATTC AACTTGGTGA CCAAGAAGTT 
 
 70921 TCTGAGCTTT GTGGCCTACC AAGGGAGAAA CTGGCTGCAG CAGAGCGAGT ACTTCGTTCC 
                               A                << <<<<<<<<<< <<<<<<< 
 70981 AACATGGACA TCCTGAAGCC AATCCTGgtg agtagacttg ctcactggag aaacttcaag 
 
Exon 16 
 102301 tacaagtgag tgcttgggat tgttgaggca gcacatttga tgtgtctctt ccttcccagT 
 
102361 TAGGAAACCT GCTGCCCTAC AGTGATCCCA GCGTGGTGTT TGTCTTCCTG TCCGTGTTTG 
 
102421 CTGTGGTGAC AATCCTGCAG TGCTTCCTGA TTAGCACACT CTTCTCCAGA GCCAACCTGG 
                                      > >>>>>>>>>> >>>>>>>>>> > 
102481 CAGCAGCCTG TGGGGGCATC ATCTACTTCA CGCTGTACCT GCCCTACGTC CTGTGTGTGG 
 
102541 CATGGCAGGA CTACGTGGGC TTCACACTCA AGATCTTCGC Tgtgagtacc tctggccttt 
                      A                                              <<< 
102601 cttcagtggc tgtaggcatt tgaccttcct ttggagtccc tgaataaaag cagcaagttg 
       <<<<<<<<<< <<<<<<< 
 
Exon 18 
 104941 ttgctttcag GCCAGTACGG AATTCCCAGG CCCTGGTATT TTCCTTGCAC CAAGTCCTAC 
 
105001 TGGTTTGGCG AGGAAAGTGA TGAGAAGAGC CACCCTGGTT CCAACCAGAA GAGAATATCA 
              >>> >>>>>>>>>> >>>>>>>>                               G 
105061 GAAAgtaagt gctgttgacc tcctgctctt tctttaacct agtgctgctg cctctgctaa 
 
105121 ctgttggggg caagcgatgt ctcctgcctt tctaaaagac tgtgaaacca ctccaggggc 
                                                            < <<<<<<<<<< 
105181 agagaaatca catgcagtgt ccctttccaa atcctcccat gccatttatg tccaatgctg 
       <<<<<<<< 
 
Exon 24 
 112021 ttctcacaca acagagcttc ttggaagccc tccccggcga aggtgctggt ggctctgcct 
          >>>>>>> >>>>>>>>>>> >>>> 
112081 tgctccgtcc ctgacccgtt ctcacctcct tctttgccat cagGAGGACA GTGTTTCTCA 
 
112141 GAGCAGTTCT GATGCTGGCC TGGGCAGCGA CCATGAGAGT GACACGCTGA CCATCGgtaa 
                                              C 
112201 ggactctggg gtttcttatt caggtggtgc ctgagcttcc cccagctggg cagagtggag 
         <<<<<<<< <<<<<<<<<< <<<< 
 
Fig. 5.8  
Exon 7 containing R219K (G70943A), Exon 16 containing V771M (G102555A), Exon 18 
containing I883M (A105057G), Exon 24 containing E1172D (G112177C). Primers are 
marked in blue, the SNP in green color. Codons are printed alternately in superscript and 
normal bold letters. Intronic sequence is printed in lower case letters. 
5.3.2 Multiplex-PCR 
A multiplex PCR was performed using Hot Star Kit (Qiagen, Hilden, Germany). In initial 
experiments, week bands of amplicons were improved by increasing the amount of 
used primer. Optimum primer concentration were: R219K and E1172D 0.2 µM each, 
V771M 0.3 µM each and I883 0.8 µM each. Salt concentrations were also varied in 
initial experiments and the reaction was performed with and without additiva (Q-
solution). Optimum results were gained with the reaction mix containing dNTPs 0.2 mM 
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each, 3 mM MgCl2, 2x PCR Buffer, 1x Q-solution and 0.05 U/µl Hot Star polymerase, 
as well as approximately 4 ng/µl genomic DNA. The reaction mixture was heated at 
95°C for 15 minutes, then 40 cycles of 30 seconds at 94°C, 30 seconds at 55°C and 30 
seconds at 72°C were performed. For final extension, the mixture was incubated at 
72°C for 7 minutes. A PTC-200 thermal cycler (MJ Research, Waltham, MA, USA) was 
used. For amplification of single PCR products for initial experiments in allelic 
discrimination, only one pair of primers was used with the same concentrations and 
conditions as in the multiplex PCR. Fig. 5.9 shows agarose gel electrophoresis of 
single and multiplex PCR products. 
     
     
Primer Sequence Tm Position Amplicon Size 
R219K-F GTA TTT TTG CAA GGC TAC CA 55.2°C 70,831-70,850 
R219K-R ACG AAG TAC TCG CTC TGC T 55.0°C 70,977-70,959 147 bp 
V771M-F ATT AGC ACA CTC TTC TCC AGA G 55.1°C 102,450-102,471 
V771M-R GCC TAC AGC CAC TGA AGA AA 57.8°C 102,617-102,598 168 bp 
I883M-F GCG AGG AAA GTG ATG AGA AGA 59.3°C 105,008-105,028 
I883M-R ATT TCT CTG CCC CTG GAG T 58.4°C 105,188-105,170 181 bp 
E1172D-F TCA CAC AAC AGA GCT TCT TGG A  60.8°C 112,024-112,045 
E1172D-R CCT GAA TAA GAA ACC CCA GAG T 58.4°C 112,224-112,203 201 bp 
     
Tab. 5.13  
Primers for (multiplex) PCR. 
5.3.3 Allelic discrimination 
ASPE-primer were designed manually, with melting-points of the sequence specific 3’-
residue of 55°C to 60°C. Different lengths of primers within that range of melting 
temperature and hybridizing to both, sense or antisense strand, were tested to function 
with purified single and multiplex PCR product. Always a pair of primers, targeting both 
forms of one sequence variation at the same strand, were tested. This ensures 
minimum cross-talk due to competition of ASPE-primers. Control DNAs with all 
possible alleles in homozygous and heterozygous form were selected from the 
collection of genotyped samples presented in 5.2 and confirmed by DNA sequencing. 
All possible primer combinations were tested and evaluated with respect to maximum 
signal intensity, minimum cross-talk (signal intensity of false allele) and minimum 
background (signal without PCR product). The best set of ASPE primers is presented 
in Tab. 5.14. The zip-code sequences for the primer set were selected using Tag IT 
Oligo Design Software [102] with respect to minimum cross-hybridization of zip codes 
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 and primers. The sequences of the zip codes are abbreviated by LUA (LUminex Array) 
plus the corresponding number of zip code (e.g. LUA19 refers to zip code number 19). 
The number of the zip code is identical with the number of FlexMAP Bead, carrying the 
reverse complement of the zip-code sequence. All zip codes are listed in Tab. 3.1 of 
the appendix.  
 
 
 
 
Fig. 5.9  
Single and multiplex-PCR products of 3 probands, containing polymorphic loci R219K 
(147 bp), V771M (168 bp), I883M (181 bp) and E1172D (201 bp), separated on a 3% agarose 
gel. 
 
     
 Primer Sequence 
Tm of sequence 
specific 3’-moiety  
 R219 LUA19-AGCTTTGTGGCCTACCAAG 57.7°C  
 K219 LUA08-GCTTTGTGGCCTACCAAA 56.9°C  
 V771 LUA72-AGATCTTGAGTGTGAAGCCCAC 60.5°C  
 M771 LUA07-AGATCTTGAGTGTGAAGCCCAT 59.9°C  
 I883 LUA28-TGGTTCCAACCAGAAGAGAATA 58.5°C  
 M883 LUA99-GGTTCCAACCAGAAGAGAATG 58.4°C  
 E1172 LUA17-GATGGTCAGCGTGTCACTC 57.3°C  
 D1172 LUA29-GATGGTCAGCGTGTCACTG 58.4°C  
Tab. 5.14  
ASPE primer carrying a unique zip-code at their 5’-end. The number of zip-code refers to 
Tab. 3.1. 
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The PCR product (10 µl) was treated with a mixture of shrimp alkaline phosphatase 
(SAP) and exonuclease I to remove unincorporated dNTPs and excess primers, 
respectively. The purification mix (10 µl), which consists of 2 units of SAP (Roche 
Applied Sciences, Penzberg, Germany) and 1 unit of exonuclease I (Amersham 
Biosciences, NJ, USA) in 1x phosphatase buffer (Roche Applied Sciences, Penzberg, 
Germany), was added to the PCR-product and the mixture was incubated at 37°C for 
45 minutes, then kept at 95°C for 15 minutes to inactivate the enzymes. 
Allele specific primer extension was performed using ASPE-primers (Tab. 5.14) 
carrying Luminex zip code sequences. HPSF purified oligonucleotides were purchased 
from MWG Biotech (Ebersberg, Germany). A 20 µl reaction contained 5 µl of treated 
PCR product, 1.25 mM MgCl2, 5 µM each dNTP, 5 µM biotin-dCTP (Perkin Elmer Life 
Sciences, Boston, MA, USA), 25 nM each primer and 0.075 U/µl Platinum GenoTYPE 
Tsp polymerase in 1x Tsp buffer (Invitrogen, Carlsbad, CA, USA). In a PTC-200 
thermocycler (MJ Research, Waltham, MA, USA), after two minutes initial denaturation 
at 95°C, 40 cycles of 30 seconds at 94°C, 30 seconds at 54°C and 60 seconds at 74°C 
were performed. 
Hybridization of ASPE product to FlexMap beads was carried out in Tm buffer (2x Tm 
buffer contains 0.2M NaCl, 0.1M TRIS and 0.08% Triton X-100 at pH 8.0). The ASPE 
product (5 µl) was incubated with 2,500 LUA beads of each region in in a total volume 
of 50 µl 1x Tm buffer (0.2M NaCl, 0.1M TRIS and 0.08% Triton X-100 at pH 8.0) at 
96°C for 90 seconds, then kept at 37°C for 60 minutes. The microtiter-plate was 
centrifuged at 3,000 rcf for 2 minutes, supernatant was removed and 65 µl of 
streptavidin-PE conjugate (Molecular Probes, Oregon, USA) in a concentration of 
2 µg/ml in 1x Tm buffer were added. The mixture was incubated at 37°C for 15 
minutes. 
Samples were measured on the Luminex 100 at 37°C. Acquisition of 600 beads total 
with a timeout of 60 seconds and a gating of 7,500-15,000 units were selected. Median 
fluorescence intensities were recorded. 
For data evaluation, background signals from the negative control (no template in PCR) 
were subtracted from recorded fluorescence intensities. An assay that did not produce 
a signal intensity of 200 a.u. above the background in both alleles is neglected for the 
individual sample (dropout). For better visualization and improved genotyping, 
fluorescence intensities were normalized to total fluorescence intensity of both alleles; 
the cutoff for allelic discrimination was set to 0.25 units (Fig. 5.10). 
To evaluate the developed multiplex assay, a total of 200 DNA samples were analyzed 
with the new method as described above and compared to TaqMan assays, which 
were performed in parallel. For TaqMan analysis, the set of primers and probes 
presented in 5.2 were used. 
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For evaluation, the percentage of dropouts for each method and the concordance of 
both methods were determined. In order to assess, whether the number of dropouts 
was significantly different in both methods, McNemar test (χ² test for matched pair 
data) was applied. If pMcNemar was smaller than 0.05, significantly more dropouts were 
produced in one method. Confidence intervals for concordance were calculated at a 
95% confidence level by the Clopper and Pearson method.[103] 
5.3.4 Genotyping results using the multiplex bead assay 
The results obtained by the Luminex method were plotted in discrimination plots only 
for better visualization. Genotyping was performed in Excel spreadsheets using the 
cutoffs described above. In these plots, the normalized fluorescence intensities of each 
probe are plotted against each other and cutoffs (0.25 units) are drawn in. The 
dropouts (not producing a significant signal above the background, cutoff 200 a.u.) 
were removed before assignment of genotypes. In the discrimination plots in Fig. 5.10, 
the four different populations (including no template controls) can clearly be identified. 
To assess analytical sensitivity, McNemar test was applied to compare the assays for 
both platforms with respect to dropouts and good signals only (Tab. 5.15). A significant 
difference was found in assays for R219K (p=0.002**) and E1172D (p=0.000***). 
Judging from the amount of dropouts in both assays and assuming that the remaining 
analyses produced correct results, it seems that the Luminex assay for R219K might 
be more sensitive compared to the TaqMan assay, however the Luminex assay for 
E1172D appears to be less sensitive. The assays for V771M and I883M seem to be 
comparable. 
By looking solely at data that had been assigned by both methods, concordances were 
calculated. Within a 95% confidence interval, concordances of above 95% (lower limit 
of confidence interval) were obtained for all assays (Tab. 5.16). Altogether, five SNP 
determinations showed discrepancy. These samples were further analyzed by DNA 
sequencing (Tab. 5.17) and it was found that 3 samples were falsely assigned by the 
TaqMan method and two by the Luminex method. Assuming, that concordant samples 
have been genotyped correctly, the accuracy of the newly developed Luminex assays 
in this evaluation were 100% for R219K and I883M, 99.4% for V771M and 99.2 for 
E1172D. 
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Fig. 5.10  
Discrimination plots for Luminex assays R219K, V771M, I883M and E1172D. Normalized 
fluorescence intensities of both probes are plotted against each other. The cutoff for allelic 
discrimination was set to 0.25 units. Wrongly assigned samples are marked with an arrow. 
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  TaqMan Luminex pMcNemar  
 R219K 30 (15%) 12 (6%)  0.002**  
 V771M 15 (7.5%) 21 (10.5%)  0.286  
 I883M 29 (14.5%) 23 (11.5%)  0.392  
 E1172D 30 (15%) 56 (28%)  0.000***  
 overall 104 (13%) 112 (14%)  0.554  
Tab. 5.15  
Amount of dropouts in both methods for 200 DNA samples. The Luminex assay for 
R219K seems to be more sensitive compared to the TaqMan assay, however the 
Luminex assay for E1172D appears to be less sensitive. 
 
       
  concordant discrepant concordance 95% CI  
 R219K 161 2 98.8% 0.956-0.999  
 V771M 170 1 99.4% 0.967-1.000  
 I883M 156 1 99.4% 0.965-1.000  
 E1172D 130 1 99.2% 0.958-1.000  
 overall 617 5 99.2% 0.981-0.997  
Tab. 5.16  
Concordance of genotyping-results (dropouts neglected). Within a 95% confidence 
interval, concordances of above 95% (lower limit of confidence interval) were obtained 
for all assays. 
 
      
  total discrepant 
false 
TaqMan 
false 
Luminex 
accuracy 
Luminex 
 
 R219K 2 2 0 100.0%  
 V771M 1 0 1 99.4%  
 I883M 1 1 0 100.0%  
 E1172D 1 0 1 99.2%  
 overall 6 3 2 99.5%  
Tab. 5.17  
Number of false results as confirmed by DNA sequencing of discrepant samples. 
Assuming, that concordant samples have been genotyped correctly, the accuracy of the 
newly developed Luminex assays are 99.2% and above. 
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6 Discussion 
6.1 Screening for functional sequence variations and mutations in ABCA1 
In previous studies, the ABCA1 promoter region was characterized and transcription 
factor binding sites were identified (see 2.1.5). Variable regulation of the ABCA1 
expression will ultimately lead to different levels of susceptibility to HDL levels, CVD 
and other ABCA1 related phenotypes. Therefore, the investigation of the promoter 
region is of great importance. Sequence variations in the promoter region, especially at 
transcription factor binding site might influence binding of transcription factors and 
hence the expression of the ABCA1 gene. 
The screening that has been performed of the promoter region was originally not 
intended to be an association study. The main focus was the discovery of novel 
sequence variations therefore the number of individuals investigated was low. However 
good levels of significance were obtained and that the number of individuals that have 
been sequenced is not too low compared to other high-throughput association studies 
is supported by the fact, that the results are coherent with the findings of two other 
groups. The G allele of C1176G in the promoter (Fig. 5.1) was previously associated 
with CAD [89] and it was found significantly decreased in the High-HDL cohort 
compared to DON and the Low-HDL group. The G allele of G1355C (Fig. 5.1) was 
earlier associated with decreased CAD [90], what is conclusive with the finding, that 
G1176 is significantly more prevalent in High-HDL compared to Low-HDL, DON and 
Octogenarians. The three novel polymorphisms (G1047C, C1152T and C1440T) were 
found in significantly different distribution of genotypes in some cohorts (Tab. 5.1). All 
three exchanges (especially heterozygotes) were found more frequent in probands of 
the Low-HDL cohort compared to other groups. Therefore, it can be assumed, that 
these three polymorphisms are associated with decreased HDL levels. However, 
further functional testing and haplotype analysis in larger cohorts might be required to 
fully confirm this. 
The VNTR-ZNF that was identified is part of the ZNF202 transcription factor binding-
site. ZNF202 is known to down-regulate the expression of ABCA1 and many other 
genes involved in cholesterol metabolism, therefore this variation was investigated 
further. Although there was evidence for different binding of ZNF202 in vitro, the in vivo 
assay did not display a significant effect of this promoter polymorphism. The two VNTR 
polymorphisms might be due to ethnical differences and possibly do not influence 
ABCA1 expression. The shorter form of the VNTR-ZNF polymorphism (∆ACCCC) was 
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always found in conjunction with the VNTR-SRY wild-type form, which is good 
evidence, that VNTR-ZNF (∆ACCCC) is coupled to VNTR-SRY wild-type form. The 
wild-type form of VNTR-ZNF was found with all forms of VNTR-SRY polymorphisms. 
The VNTR-ZNF wild-type and the shorter form of VNTR-SRY (∆GTTTTGTTT) seem to 
be most prevalent in European Caucasians (60% and 49%, respectively; see Tab. 5.2 
and Tab. 5.3). 
Sequencing of exons 49 and 50 revealed only one sequence variation in 249 
individuals. The fact, that there are almost no polymorphic loci in this region could 
stress the importance of the carboxyterminus of ABCA1, which is coherent with the 
phenomenon of protein-protein interaction observed in this particular region. 
Nonetheless, this region is very small (385 bp) and therefore not many sequence 
variations are expected to be found. However, the sequence variations found in patient 
E with G6PD deficiency (F2163S, V2244I) are located in exon 49 and 50, respectively 
and these mutations may account for the low HDL-cholesterol. This is supported by the 
fact that one of the enzymes that was identified in the yeast two hybrid system to 
interact with the COOH-terminus of ABCA1 is part of the succinate dehydrogenase 
complex (iron sulfur complex) [45], which is known to be involved in the pathogenesis 
of hypertrophic cardiomyopathy. The coincidence of polymorphisms within the 
carboxyterminus of the ABCA1 gene and clinical correlates of succinate 
dehydrogenase deficiency, hypertrophic cardiomyopathy and skeletal muscle 
myopathy in the father (pedigree C, Fig. 3.1) without mutations in the G6PD-gene 
indicates that the mutation in exon 50 of ABCA1 is causally related to dysfunctions of 
succinate dehydrogenase and/or G6PD, perhaps by interfering with correct protein-
protein interactions and failure of shuttling between ABCA1 and the inner mitochondrial 
membrane. 
If the introduced methionine at codon 771 is responsible for the increased HDL levels 
of patient A remains unclear. But since no sequence variation in CETP, SR-BI and the 
LDL receptor was found in this individual, and V/M771 heterozygote family members 
had lower HDL levels, it might seem conceivable that this sequence variation had an 
effect on HDL levels. In addition, methionine homozygotes seem to be extremely rare, 
which was confirmed by genotyping of 478 blood donors, in which none was found. It 
could be speculated, that the introduced methionine at codon 771 could be of 
regulatory importance for ABCA1 through the oxidation of methionine (methionine 
sulfoxide) by various reactive oxygen species (ROS). In lipoprotein metabolism 
(cholesterol efflux) it is known that methionine oxidation in apo A-I is a key regulatory 
event in LCAT activation [104], thus the amino acid exchange valine to methionine at 
codon 771 may affect functionality.[105-107] Moreover, V771M is located very close to 
a putative transmembrane region (Fig. 5.3) and it is known that mutations in the SUR1 
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gene that are localized near the transmembrane region impair the interaction of this 
ABC transporter with Kir6.2 channel.[108] Therefore, it can be speculated that the 
V711M polymorphism in ABCA1 may affect interaction with associated proteins or 
ABCA1 function. It is also possible, that the patient has an additional mutation in such 
an interacting protein. 
In the probands with HDL deficiency (patient B, C and D) three novel sequence 
variations have been identified: W840R, W590L and R1068C. It is very likely, that 
amino acid exchange W840R in the 50-year old female (patient B) is an additional 
Tangier mutation. The sequence variation was not found in a large cohort, which 
indicates, that it is not a polymorphism. It can also be assumed, that amino acid 
exchange W590L, found in patient C, is a mutation causing a defective ABCA1 protein 
product. This is supported by the fact, that a mutation in the same codon was shown to 
cause Tangier Disease (W590S) [17], but since the patient is only heterozygous for 
W590L, it remains unclear, what additional mutation in ABCA1 causes the patients 
analphalipoproteinemia. It is very likely, that the amino acid exchange R1068C, 
encountered in patient D, results in a defective or less active ABCA1 product. Although 
the mother, who is heterozygous for this sequence variation, was found to have quite 
normal HDL and apo A-I levels, the index patient who is compound heterozygous for 
R1068C and a known Tangier mutation (∆TC in exon 23), showed analpha-
lipoproteinemia. The causative effect of the mutation is supported by the fact, that the 
affected amino acid is located very close to walker B of the first ATP-binding cassette, 
which is a highly conserved region (Fig. 5.3). The father and the sister, who are 
heterozygous for the Tangier mutation and have no additional R1068C mutation, show 
typical reduced HDL levels but no analphalipoproteinemia. 
This study has revealed a number of novel sequence variations. Three SNPs in the 
promoter were associated with low HDL levels and one VNTR polymorphism indicated 
different binding of transcription factor ZNF202. Three novel mutations have been 
identified in patients with HDL deficiency. Two mutations have been found in a 
phenotype related to CVD, located in an important domain of ABCA1 (carboxy-
terminus) and a rare homozygous polymorphism (V771M) was identified in a proband 
with extremely high HDL. 
Although ABCA1 is known to play a key role in reverse cholesterol transport and 
several mutations in this gene have been identified to cause HDL deficiency 
syndromes, the regulation and activity of ABCA1 and the influence of sequence 
variations in these processes are still very limited. Further research is required in this 
area. For this reason, a webpage archive for sequence variations in ABCA1 has been 
created (http://www.abca1-mutants.all.at). The aim of this site is to store sequence 
variation relevant data and epicrisis of affected individuals. This should help to 
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elucidate important domains in ABCA1 and help in understanding function and role of 
ABCA1 in regulating plasma HDL concentration. This webpage provides a more recent 
and detailed summary of sequence variations in ABCA1 than existing databases and 
should be of interest for further research in ABCA1 and molecular diagnosis of ABCA1 
related HDL deficiency. 
6.2 High-throughput genotyping of ABCA1 polymorphisms 
The TaqMan (ABI Prism 7900HT) is very well suited for automation, since it applies 
standard microtiter plates, which can be handled routinely in roboting platforms. For the 
LightCycler a round shaped sample holder (carrousel) is required, that cannot be used 
with common robots. Although, with the MagNa Pure LC, a robot exists for the isolation 
of DNA from low volume samples that can as well handle LightCycler carrousels, the 
loading of the carrousel with fragile capillaries prior to pipeting and the capping of the 
capillaries afterwards still has to be done manually. The maximum capacity of a 
LightCycler carrousel is 32 samples, while with TaqMan 384-well plates are processed. 
In addition, reaction plates do not have to be thermally cycled in the TaqMan, additional 
standard thermal cyclers without fluorescence unit can be used to liberate bottle-neck 
capacity. Also, analytical cost can be cut. In the LightCycler, a total assay volume of 
20 µl is required, while in the TaqMan 5 µl assays can be performed. This reduces the 
required amount of expensive Taq polymerase and fluorescently labeled probes to 
about ¼ compared to the LightCycler. In addition, cheap plastic ware microtiter plates 
replace costly optical glass capillaries. While the LightCycler is best suited for analysis 
of low sample numbers, the ABI prism 7900HT is an ideal instrumentation for large-
scale association studies and high-throughput analysis. 
While genotyping of larger cohorts with LightCycler was extremely laborious and prone 
to errors since pipeting and recording of results had to be done by hand, with the new 
established workflow a huge amount of samples could be genotyped most efficiently. 
With 3 LightCyclers an amount of 960 samples could be processed per day and the 
high-throughput workflow was capable to analyze nearly 40.000 samples in 24 hours. 
The established high-throughput workflow was used in various other large-scale 
association studies, which are not part of this work, where this level of throughput was 
actually reached. Only the number of thermal cyclers (6) limited capacity, the use of 
additional cyclers could increase throughput beyond that level. 
Results obtained from genotyping of ABCA1 polymorphisms suggest, that the M771 is 
more prevalent in Italians and Hungarians compared to Germans. In Hungarians, a 
significantly decreased prevalence of V/M771 heterozygotes has been found in CAD 
patients (97.3%) compared to healthy controls (90.2%). Therefore, the introduced 
methionine at codon 771 might have a protective effect on development of coronary 
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artery disease in Hungarians. This fits well with the observation made in the M771 
homozygous patient A. She had extremely high HDL levels, which should decrease risk 
to develop CAD. 
In Italian centenarians, the K219 allele was found increased (48.7% carriers) compared 
to Italian donors (41.4% carriers). Therefore the K219 allele might represent a 
protective allele leading to longevity. It is noteworthy, that the R219K polymorphism in 
the Italian control group was in Hardy Weinberg disequilibrium. Polymorphisms should 
usually be in Hardy Weinberg equilibrium (HWE) assuming mainly that natural 
selection is not occurring and that the population is infinitely large. A marker that is not 
in HWE in case groups is a strong indication for natural selection and the importance of 
this marker. Since the control group is not in HWE, this might be an indication that 
either the assay produced false results or that the individuals do not display a 
representative cross-section of the population. The developed assay showed increased 
spreading of signals compared to other assays (Fig. 5.6) and a few falsely assigned 
results were detected during comparison of TaqMan and Luminex assay for this SNP 
(Tab. 5.17). Therefore, it seems possible, that a minor amount of samples was 
genotyped incorrectly. It is also conceivable, that this cohort did not contain enough 
individuals (N=150) or that the selected healthy blood donors are not a representative 
cross-section of the population. If the Hardy Weinberg disequilibrium is due to natural 
selection, sensitivity of the assay or constitution of the cohort remains unclear. 
However, the assumption that K219 has a protective effect in aging is in agreement 
with findings from other groups. European carriers of K219 (59% versus 50%) were 
found to have reduced severity of arteriosclerosis, a trend to increased HDL and fewer 
coronary events, which should clearly be life prolonging characteristics.[109] 
6.3 Development of a bead-based multiplex assay 
A new concept of bead-based nucleic acid testing with high multiplexing capability 
could be established in this thesis. Unlike LightCycler and TaqMan analysis, the 
Luminex method requires an initial PCR and purification step prior to allelic 
discrimination reaction. Yet its clear advantage is that a number of markers can be 
analyzed simultaneously, which could highly decrease the hands-on-time. In addition, 
analytical cost can be cut. The PCR reactions can be scaled down to 5 µl and several 
analyses can be performed in one reaction. Cheap standard (non-labeled) primers are 
required for allelic discrimination and only modified (biotinylated) dCTP is universally 
used for all discrimination reactions. 
Due to handling of beads and centrifugation steps in this assay procedure, the method 
is not fully suited for a completely automated workflow, but since standard microtiter 
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plates are used, it could be integrated in a semi-automated workflow. This could further 
decrease the hands-on-time and increase reliability of test results. 
It has been shown, that the newly developed multiplex assay is comparable to the 
firmly established TaqMan technology. Concordances of above 95.6% could be 
obtained within a 95% confidence interval (see Tab. 5.16). One Luminex assay 
(E1172D) produced a slightly increased amount of dropouts, another one (R219K) was 
more sensitive than the equivalent TaqMan assay. The two other assays are 
comparable. Two false assignments have been made by the Luminex method, which 
are due to false gating of obtained test results (see Fig. 5.10). By a more careful 
assignment, neglecting ambiguous results or further adjustment of gates, these errors 
could have been avoided. However, this experience could not be made prior to 
evaluation. Individual adjustment of gates for each assay should therefore be made in 
the future. The TaqMan technology was chosen for the evaluation of this novel assay 
system, since the newly established high-throughput workflow could readily provide 
analysis results. DNA sequencing and genotyping by sequence alignment without 
automated data processing would have been too laborious, prone to errors due to lack 
of automation and very costly. Therefore only discrepant results obtained by Luminex 
and TaqMan technology were analyzed by means of DNA sequencing. All methods are 
subject to failure due to quality of DNA and unexpected sequence variation in DNA that 
could influence correct genotyping. During the course of this work, occasionally false 
results have been obtained when genotyping V/M771 heterozygotes by DNA 
sequencing. The reason for this was that another SNP coupled with the M771 variant 
was located at a primer binding site, which caused inefficient binding of the primer and 
insufficient amplification of one allelic variant in PCR (data not shown). This illustrates, 
that all methods have their limitations and therefore, it is problematic to find a “gold 
standard“ in SNP analysis for the evaluation of a novel method. Thus it is imperative to 
apply a third method, when obtaining discrepant results. 
Altogether, it can be concluded, that the bead-based multiplexing assay in the ASPE 
and zip code format provided test results with a sensitivity and accuracy comparable to 
the well-established TaqMan technology. While the LightCycler has its clear advantage 
in the fast analysis of a low number of samples and the TaqMan (7900HT) is ideally 
suited for high-throughput genotyping, this method is appropriate for a medium amount 
of samples (96-192), of which more than two markers have to be determined. 
6.4 Final remark 
HDL cholesterol levels and disease related to HDL might genetically be determined by 
a multitude of markers and it will be difficult and laborious to determine all of these 
parameters due to weak genotype-phenotype correlation. With a number of genes 
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playing an important role in reverse cholesterol transport and additional interacting 
proteins, which all harbor numerous sequence variations, there is still a lot of research 
to be done. 
As RISCH stated: “The gene mutations studied by Mendel, and those more recently 
discovered by positional cloning, are those with large effect and strong genotype-
phenotype correlation. They are effectively the ‘low-hanging fruit’ that are easy to 
harvest. Now, however, we are left with the great majority of the fruit at the top of the 
tree, with no obvious way to reach it.” [110] 
This work did not intend to harvest a fruit from the top of this tree, but to provide 
pioneer work in identification of novel sequence variations in the ABCA1 gene and the 
development of assays for the analysis of SNPs in this gene. 
To facilitate the analysis of novel markers for large-scale association studies, a high-
throughput platform for the fast and efficient analysis of SNPs could be established. 
With the novel Luminex multiplexing method, an ideal platform for the efficient analysis 
of future multifactorial SNP profiles has been demonstrated. 
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7 Appendix 
The appendix contains useful tables, figures and sequences, which have been 
prepared during the course of this work. Most of these figures and tables and additional 
material have been made publicly available in a web-page archive. The URL is: 
www.abca1-mutants.all.at 
Tab. 7.1  
List of known sequence variations in ABCA1 coding region (page 78) 
This list contains all sequence variations in the coding region of ABCA1, reported in the 
literature so far. The numbered variations are also illustrated in Fig. 7.1. 
Fig. 7.1  
Predicted structure of the ABCA1 protein product and sequence variations 
therein (page 82) 
Illustration of location of sequence variations in the ABCA1 protein product. 
Numberings refer to Tab. 7.1. 
Tab. 7.2  
Sequence variations in non-coding region of ABCA1 (page 83) 
This list contains all sequence variations in the non-coding region of ABCA1 (promoter, 
exon 1 and 2), reported in the literature so far. The numbered variations are also 
illustrated in Fig. 7.2. 
Fig. 7.2  
Promoter region and non-coding sequence upstream of start codon (page 85) 
Illustration of location of sequence variations in the promoter and the non-coding 
regions of exon 1 and 2 in the ABCA1 protein product. Numberings refer to Tab. 7.2.  
Tab. 7.3  
Tabular summary of patients with HDL-deficiency syndrome (page 87) 
 
Tab. 7.4  
Primers for ABCA1 sequencing and fragment analysis (page 89) 
Complete set of primers for sequencing of promoter and all coding region of ABCA1. 
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List of known sequence variations in ABCA1 coding region (contd.). 
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Tab. 7.1  
List of known sequence variations in ABCA1 coding region (contd.). 
 
7   Appendix 82 
 
 
 
 
Fig. 7.1  
Predicted structure of the ABCA1 protein product and sequence variations 
therein. 
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Tab. 7.2  
Sequence variations in non-coding region of ABCA1. 
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Tab. 7.2  
Sequence variations in non-coding region of ABCA1 (contd.). 
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             SRY 
  601 GTCCTGTGTT TTTATCACAG GGAGGCTGAT CAATATAATG AAATTAAAAG GGGGCTGGTC -773 
      Sox-5                         SRY 
  661 CATATTGTTC TGTGTTTTTG TTTGTTTGTT TTGTTTGTTT CTTTTTTTGT TTTTGTGGCC -713 
                                  N1 
  721 TCCTTCCTCT CAATTTATGA AGAGAAGCAG TAAGATGTTC CTCTCGGGTC CTCTGAGGGA -662 
                     NF-kappa B 
  781 CCTGGGGAGC TCAGGCTGGG AATCTCCAAG GCAGTAGGTC GCCTATCAAA AATCAAAGTC -602 
             MZF1     SRY                                       MZF1 
  841 CAGGTTTGTG GGGGGA AAAC AAAAGCAGCC CATTACCCAG AGGACTGTCC GCCTTCCCCT -542 
    MZF1         SRY      Evi-1          N2 
  901 CACCCCAGCC TAGGCCTTTG AAAGGAAACA AA AGACAAGA CAAAATGATT GGCGTCCTGA -482 
                                                     N3       SRY 
  961 GGGAGATTCA GCCTAGAGCT CTCTCTCCCC CAATCCCTCC CTCCGGCTGA GGAAACTAAC -422 
                                                                     1021 AAAGGAAAAA AAAATTGCGG AAAGCAGGAT TTAGAGGAAG CAAATTCCAC TGGTGCCCTT -362 
                              N4 
 1081 GGCTGCCGGG AACGTGGACT AGAGAGTCTG CGGCGCAGCC CCGAGCCCAG CGCTTCCCGC -302 
                                        1141 GCGTCTTAGG CCGGCGGGCC CGGGCGGGGG AAGGGGACGC AGACCGCGGA CCCTAAGACA -242 
              N5        ZNF202/SRE-like  N6   MZF1 
 1201 CCTGCTGTAC CCTCCACCCC CACCCCACCC CACCCACC TC CCCCCAACTC CCTAGATGTG -187 
                N7          N8       Sp1/3             E-Box 
 1261 TCGTGGGCGG CTGAACGTCG CCCGTTTAAG GGGCGGGCCC CGGCTCCACG TGCTTTCTGC -127 
                                            Sp1 
 1321 TGAGTGACTG AACTACATAA ACAGAGGCCG GGAAGGGGGC GGGGAGGAGG GAGAGCACAG -67 
       DR4        DR4                  N9      TATA-Box            
 1381 GCTTTGACCG ATAGTAACCT CTGCGCTCGG TGCAGCCGAA TCTATAAAAG GAACTAGTCC -7 
        ↓                                                        N10 
 1441 CGGCAAAAAC CCCGTAATTG CGAGCGAGAG TGAGTGGGGC CGGGACCCGC AGAGCCGAGC  
                                                      N11               
 1501 CGACCCTTCT CTCCCGGGCT GCGGCAGGGC AGGGCGGGGA GCTCCGCGCA CCAACAGAGC 
                                                                    1561 CGGTTCTCAG GGCGCTTTGC TCCTTGTTTT TTCCCCGGTT CTGTTTTCTC CCCTTCTCCG 
                                                                    1621 GAAGGCTTGT CAAGGGGTAG GAGAAAGAGA CGCAAACACA AAAGTGGAAA ACAGgtaaga 
  
 1681 ggctctccag tgacttactt gggcgttatt gttttgtttc gaggccaagg aggcttcggg 
 
 1741 aagtgctcgg tttcggggac tttgatccgg agccccacat ccccaccact tgcaactcag 
 
 1801 atgggaccgg aggcggtgtt aaatggggag acgatgtcct agtacgagct ctggtgaccc 
 
[...] 
 
   sequence variations without association 
   association shown 
(intronic sequence in lower case letters) 
 
Fig. 7.2  
Promoter region and non-coding sequence upstream of start codon. 
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[...] 
 
24301  ggcatggaga  tctcatttgg  actcacagat  ttctagtcta  gcgcttggtt  ttgtatccat 
 
24361  acctcgctac  tgcattctta  gttccttctg  ctccttgttc  ctcatgccca  gtgtcccacc 
 
24421  ctacccttgc  ccctactcct  ctagaggcca  cagtgattca  ctgagccatt  tcataagcac 
 
24481  agctaggaga  gttcatggct  accaagtgcc  agcagggccg  aattttcacc  tgtgtgtcct 
 
24541  cccttccatt  tttcatcttc  tgccccctcc  ccagctttaa  ctttaatata  actacttggg 
 
24601  actattccag  cattaaataa  gggtaactgc  tggatgggtg  gctgggatac  acagaatgta 
 
24661  gtatcccttg  ttcacgagaa  gaccttcttg  ccctagcatg  gcaaacagtc  ctccaaggag 
       N12 
24721  gcacctgtga  cacccagcgg  agtagggggg  cggtgtgttc  aggtgcaggt  ggaacaaggc 
      N13 
24781  cagaagtgtg  catatgtgct  gaccgtggga  gcttgtttgt  cggtttcaca  gttgatgccc 
      N14 
24841  tgagcctgcc  atagcagact  tgtttctcca  tgggatgctg  ttttctttcc  agagacacag 
 
24901  cgctagggtt  gtcctcatta  cctgagagcc  aggtgtcggt  agcattttct  tggtgtttac 
 
24961  tcacactcat  ctaaggcacg  ttgtggtttt  ccagattagg  aaactgcttt  attgatggtg 
 
25021  cttttttttt  tttttttgag  acagagtctc  gctctgtcgc  catgctggag  tgtagtggca 
 
25081  caatcttggc  tcactgcacc  tccgcctgcc  gggttcagcg  attctcctgc  ctcagcctcc 
              N15 
25141  caagtagctg  ggactacagg  tgcctgccac  catgcccagc  taatttttgt  atttttagta 
 
25201  gagacggggt  ttcaccgtat  tggctaggat  ggtctcgatt  tcttgacctc  gtgatccgcc 
 
25261  tgcctcggcc  tcccaaagtg  ctgggattat  aggcttgagc  caccacgcct  ggccgatggt 
 
25321  gctttttatc  atttgaagga  ctcagttgta  taacccactg  aaaattagtc  tgtaaggaag 
             N16 
25381  ttcagggaat  agtataagtc  actccaggct  tgaggcaaaa  tttacaaatg  ctgctgactt 
 
25441  tgtatgtaag  gggaggcatt  ttcttagaga  agagaggtag  gtctctggga  ttccagtatg 
          N17 
25501  ccatttccat  cctcagtgtt  tttggccacc  tgagagaggt  ctattttcag  aaatgcattc 
 
25561  ttcattccca  gatgataaca  tctatagaac  taaaatgatt  aggaccataa  cacgtagctc 
 
25621  ctagcctgct  gtcggaacac  ctcccgagtc  cctctttgtg  ggtgaaccca  gaggctggga 
 
25681  gctggtgact  catgatccat  tgagaagcag  tcatgatgca  gagctgtgtg  ttggaggtct 
 
25741  cagctgagag  ggctggatta  gcagtcctca  ttggtgtatg  gctttgcagc  aataactgat 
 
25801  ggctgtttcc  cctcctgctt  tatctttcag  TTAATGACCA  GCCACGGGCG  TCCCTGCTGT 
         N18 
25861  GAGCTCTGGC  CGCTGCCTTC  CAGGGCTCCC  GAGCCACACG  CTGGGCGTGC  TGGCTGAGGG 
   START        N19 
25921  AACATG... 
 
   sequence variations without association 
   association shown 
(intronic sequence in lower case letters) 
 
Fig. 7.2  
Promoter region and non-coding sequence upstream of start codon (contd.). 
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Tab. 7.3  
Tabular summary of patients with HDL-deficiency syndrome. 
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Fig. 7.3  
Location of mutations in ABCA1 found in patients with HDL-deficiency syndrome (Tab. 
7.3) and their connection to splenomegaly and CAD. 
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Exon Primer name Primer sequence Exon size (bp) 
Size of 
amplicon (bp) 
prom1 ABCA1-pro1-f GGA GGT CTG GAG TGG CTA CAT A 
 ABCA1-pro1-r CCA GTG GAA TTT GCT TCC TCT A  554 
prom2 ABCA1-pro2-f AGC CCA TTA CCC AGA GGA CTG T 
 ABCA1-pro2-r TTC AGT CAC TCA GCA GAA AGC A  466 
prom3 ABCA1-pro3-f CCC TAA GAC ACC TGC TGT ACC C 
 ABCA1-pro3-r CTG AGA ACC GGC TCT GTT GGT  380 
prom4 ABCA1-pro4-f GGA GGT CTG GAG TGG CTA CAT 
 ABCA1-pro4-r AGA GGA CCC GAG AGG AAC AT  246 
1 ABCA1-ex1-f AGC ACA GGC TTT GAC CGA TAG T 
 ABCA1-ex1-r GGA TCA AAG TCC CCG AAA CC 221 395 
2 ABCA1-ex2-f TCC TCA TTG GTG TAT GGC TTT G 
 ABCA1-ex2-r AAG AGC CAG ATT CCA TCA ATC C 158 358 
3 ABCA1-ex3-f CCA CGA TGA ATC CTG AAG AAT G 
 ABCA1-ex3-r CTC CTG AGT TCA TGC CTT ATC A 94 540 
4 ABCA1-ex4-f ATC ACT TCT CCA ACG CTG GTA T 
 ABCA1-ex4-r TGC AGA CTC TAT CAC ACA AGC A 142 519 
5 ABCA1-ex5-f AGG CAG TTG GCC TAG CTA AAG 
 ABCA1-ex5-r CTA CTC TCT TTC CCT GGT GCA G 119 236 
6 ABCA1-ex6-f GCC TAT CAT GGT GAA ACC CTG T 
 ABCA1-ex6-r TCT TTC CAG TAG CTG CAC AAC G 122 297 
7 ABCA1-ex7-f AAA GAC TTC AAG GAC CCA GCT T 
 ABCA1-ex7-r CCT CAC ATT CCG AAA GCA TTA 177 321 
8 ABCA1-ex8-f TTT GGT TAG GAG TCG GTT TCT TG 
 ABCA1-ex8-r GGG CTG GTC TGT TAG CCA CTA 93 456 
9 ABCA1-ex9-f TCT TTC TCT TCT CAT CCC CAA C 
 ABCA1-ex9-r GCT GCT ACA GAG GGA GGA GAT 241 417 
10 ABCA1-ex10-f TCC AAA GCC CTT GTA AGT TTC T 
 ABCA1-ex10-r TAC TTA GCG CAC ACC TCT GAA G 140 305 
11 ABCA1-ex11-f CTC ATT GTC TGT GCT TCT CCT C 
 ABCA1-ex11-r GTG ACC AGA AAC TCA CCT CTC C 117 240 
12 ABCA1-ex12-f TGC TCC TCA AGA TTT AGT TGG TG 
 ABCA1-ex12-r TCA GAG AAA GAA GCC GTT AAG TC 198 306 
13 ABCA1-ex13-f GAT GAG CAA TCG TGT AGT CAG C 
 ABCA1-ex13-r ACC TTC CAG CAA GTC ATG TAC C 206 487 
14 ABCA1-ex14-f GGG CAA TAA GAG TGA AAC TCC A 
 ABCA1-ex14-r TTT CCA GAT CAT TCA CAC ATG C 177 438 
15 ABCA1-ex15-f AGA GTC TAG AGG GCC TGT CCT T 
 ABCA1-ex15-r GAA CCC TGC ACT CTC ATC CTA C 223 593 
16 ABCA1-ex16-f TAC AAG TGA GTG CTT GGG ATT G 
 ABCA1-ex16-r CCC ATT GGA AAA GAC AAT CAT C 222 391 
17 ABCA1-ex17-f TTC TGC ACC TTA TGA TTG ATC C 
 ABCA1-ex17-r AGC ACA AAG AAA GGA CAT CAG C 205 392 
18 ABCA1-ex18-f CAG AAT ACT GGG ATG ATG CTG A 
 ABCA1-ex18-r AAC AGT TAG CAG AGG CAG CAG 114 227 
19 ABCA1-ex19-f TGT CCT TAC ACT CCA CTC CTC A 
 ABCA1-ex19-r CTC TAC TGC AGA ACC CTC CTG T 172 292 
20 ABCA1-ex20-f AAG CAG ATG TGA GAA GCA CCT G 
 ABCA1-ex20-r TAA GTC CCA CTC CTC CCA TGA T 132 868 
21 ABCA1-ex21-f CGA TCT GTC ACC TTT CAC TTT G 
 ABCA1-ex21-r GCC AGG GAC AAG TTT CTG TTA C 143 490 
22 ABCA1-ex22-f CTC TGC CTT CAC TCA CTG TCT G 
 ABCA1-ex22-r TAG CCA TGA GAT ACA GCC ACA C 138 283 
23 ABCA1-ex23-f TGT GAC AAA TCA GAA CTG AGA GG 
 ABCA1-ex23-r GGT GGA GAT GGA GAA ATC ATT C 221 366 
Tab. 7.4  
Primers for ABCA1 sequencing and fragment analysis, partly published in [128]. 
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Exon Primer name Primer sequence Exon size (bp) 
Size of 
amplicon (bp) 
24 ABCA1-ex24-f CAC ACA ACA GAG CTT CTT GGA A 
 ABCA1-ex24-r TCT GCA CCT CTC CTC CTC TG 73 257 
25 ABCA1-ex25-f GGA ATG ACC TAA ACA CCT GGA A 
 ABCA1-ex25-r AGG CTA CTG GTC TGG CCT TAG 204 402 
26 ABCA1-ex26-f GGC TTC TCT CCC AGG TAA CTC T 
 ABCA1-ex26-r GCA CAA GGA AAG AAT CCC ATA C 49 404 
27 ABCA1-ex27-f TCA GTG CAC GAG TAT TGT TCC T 
 ABCA1-ex27-r TGG CTT TTA CCA TTT CCT CAC T 114 400 
28 ABCA1-ex28-f TTC AGA CAC ATG CCT TCA AGA T 
 ABCA1-ex28-r GCA AGG AAT AGA ACT GGG ATT G 149 403 
29 ABCA1-ex29-f CTC AGT CTT CAG GAG GAG GAA G 
 ABCA1-ex29-r CAT CTT TGG TCT GCT CGA ATC 125 517 
30 ABCA1-ex30-f TTG GAG TGC TCT ACG TCA CC 
 ABCA1-ex30-r GTC ACT AAT GTG GCA TGC AGT T 99 402 
31 ABCA1-ex31-f GTT TGT GGT TGT TAC GGA ATG A 
 ABCA1-ex31-r AAC AGA CCC TCC CAA CAT GAT A 190 390 
32 ABCA1-ex32-f TCT GGG ACC TGT AGT CAG GTT T 
 ABCA1-ex32-r CCT TGA AGC TGA CAA CTG AAT G 95 412 
33 ABCA1-ex33-f TGC ATC ATT AGG AAT AGG CTC A 
 ABCA1-ex33-r CCT GCA GGA GAT TTC TGA TTC T 33 401 
34 ABCA1-ex34-f GCA GAA ACC ATG GGA GTT AAG A 
 ABCA1-ex34-r TCC GTT TAA CCT GCC AAC TAC T 106 380 
35 ABCA1-ex35-f GTC CAC AGG TTC CAG ATT GAC T 
 ABCA1-ex35-r ACT ACA CCG TAC TGC CTC ACT G 75 304 
36 ABCA1-ex36-f GTT GGT GGG TAT GCA CCT G 
 ABCA1-ex36-r TCT CCA TAA CCC TCT CCC TTG 170 305 
37 ABCA1-ex37-f ACT GAT TGA GCC CTA ACT GCA T 
 ABCA1-ex37-r TGT GTT TGG TGT CAT GAA AGT G 178 408 
38 ABCA1-ex38-f GCT TGA CTG TTG GAA AGA CAG A 
 ABCA1-ex38-r CAC CAA ATG CCT TAT CCA CTG 116 402 
39 ABCA1-ex39-f ACA GTG GAT AAG GCA TTT GGT G 
 ABCA1-ex39-r AGC AAG AAA GAA AGG TGC TTT G 145 400 
40 ABCA1-ex40-f TTC TCA CTT GCC TAG TGG ATT G 
 ABCA1-ex40-r ATC CTG TGC TTA GTC ACC TGC T 124 860 
41 ABCA1-ex41-f CGA ATA CAC ATT GGC TCT GAA A 
 ABCA1-ex41-r TTG AGT TCA GTT CAA TGC AAC C 130 464 
42 ABCA1-ex42-f GGA GAC TGT GGC AAG TAG GTT T 
 ABCA1-ex42-r TGT ATT CGA GAA TGG GAA TTC AT 121 442 
43 ABCA1-ex43-f GCC TGT GTT CAA GAG GGT CTA T 
 ABCA1-ex43-r CGT TGC TTG ATT GGG TAG AGA 63 565 
44 ABCA1-ex44-f GTT TGA GGT AGT TAC GTG TTA GGG 
 ABCA1-ex44-r AAC TGG ATT GTG GTG ATG GTT G 107 516 
45 ABCA1-ex45-f GCA TGT GAA TGG TGC ATA TGA G 
 ABCA1-ex45-r GTC AGG ATG CCA AAG GAG ACA G 142 567 
46 ABCA1-ex46-f CCT CAC CAG TTG TCA GGT TAT G 
 ABCA1-ex46-r AGC CTC AAT CAC GCT AAG AAA C 135 512 
47 ABCA1-ex47-f GCT GTT TCA AAG ATG CTT CTG C 
 ABCA1-ex47-r AAA CAT CCC ACA GTG AGG AAC 104 236 
48 ABCA1-ex48-f AGT CAT GGT GAT GTT CTC ATG G 
 ABCA1-ex48-r GGA CTT CAA AGC CCT CAT TCT T 93 309 
49 ABCA1-ex49-f ACT TCA TGG GTC CAG GTG AG 
 ABCA1-ex49-r GGA ATC CAC ACC CTG AGA AGT A 244 528 
50 ABCA1-ex50-f CTT CCC TCC TTC ACA CAC AGT T 
 ABCA1-ex51-r GAC ATA GGC TAC AAA GGC ACT G 141 500 
Tab. 7.4  
Primers for ABCA1 sequencing and fragment analysis, partly published in [128] (contd.). 
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8 Abbreviations, acronyms and symbols 
A ........................ Adenine 
ABC ................... ATP-binding cassette 
APD ................... Avalanche photo diode 
apo E ................. Apolipoprotein E 
ARMS ................ Amplification refractory mutation system 
ASO .................. Allele specific oligonucleotide 
ASPE ................ Allele specific primer extension 
ATP ................... Adenosine triphosphate 
a.u. .................... Arbitrary units 
BADGE ............. Beads array for detection of gene expression 
bp ...................... Base pairs (of DNA) 
C ....................... Cytosine 
CAD .................. Coronary artery disease 
cAMP ................ Cyclic adenosine monophosphate 
Cdc42 ................ Cell division cycle 42 GTP binding protein 
CE ..................... Cholesteryl ester 
CENT ................ Cohort of Italian centenarians 
CETP ................ Cholesteryl ester transfer protein 
CFTR ................ Cystic fibrosis transmembrane conductance regulator 
contd. ................ Continued 
G ....................... Guanine 
GTP ................... Guanosine-triphosphate 
CVD .................. Cardiovascular disease 
CYP ................... Cytochrome P450 enzyme 
ddNTP ............... Dideoxynucleotide triphosphate 
Del. .................... Deletion 
dNTP ................. Deoxynucleotide triphosphate 
DON_H ............. Cohort of healthy Hungarian blood donors 
DON_I ............... Cohort of healthy Italian blood donors 
DOL ................... Dye-labeled oligonucleotide ligation assay 
DR4 ................... Direct repeat separated by four bases 
ELISA ................ Enzyme linked immunosorbent assay 
EMSA ................ Electromobility shift assay 
FEN ................... Flap endonuclease 
FI ....................... Fluorescence intensity 
Fig. .................... Figure 
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FLISA ................ Fluorescence-linked immunosorbent assays 
FRET ................. Fluorescence resonance energy transfer 
HCV .................. Hepatitis C-virus 
HDL (-C)............. High density lipoprotein (- cholesterol) 
HIV .................... Human immunodeficiency virus 
HNF1α .............. Hepatic nuclear factor 1α 
HL ..................... Hepatic lipase 
HLA ................... Human Leukocyte Antigen 
HSV ................... Herpes simplex virus 
HWE .................. Hardy-Weinberg equilibrium 
IDL .................... Intermediate density lipoprotein 
Ins. .................... Insertion 
KRAB ................ Krüppel-associated box domain (of ZNF202) 
LAT ................... Latex agglutination test 
LCAT ................. Lecithin:cholesterol acyltransferase 
LDL ................... Low density lipoprotein 
LPL .................... Lipoprotein lipase 
LXR ................... Liver X receptor 
MALDI-TOF ....... Matrix assisted laser desorption ionisation – time of flight 
MDR1 ................ Multi drug resistance gene 1 
MGB .................. Minor groove binder 
MRP1 ................. MDR-associated protein 1 
MTHFR ............. Methylene Tetrahydrofolate Reductase 
N ....................... Number of individuals of specified cohort 
NBD .................. Nucleotide binding domain 
NFQ .................. Non-fluorogenic quencher 
NSF ................... N-ethylmaleimide-sensitive fusion 
OLA ................... Oligonucleotide ligation assay 
(P) ..................... Phosphate (phosphorylation of 3’ hydroxyl group) 
PC ..................... Phosphatidylcholine 
PCR .................. Polymerase chain reaction 
PLTP ................. Phospholipid transfer protein 
PMT .................. Photo multiplier tube 
PPi .................... Pyrophosphate 
RCA .................. Rolling-circle amplification 
Ref. ................... Reference(s) 
RFLP ................. Restriction fragment length polymorphism 
RHD .................. Rhesus blood group D antigen 
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RXR .................. Retinoic X receptor 
SBCE ................ Single base chain extension 
SCAN ................ Finger associated domain in ZNF 
SM ..................... Splenomegaly 
SNAP ................ Soluble NSF attachment protein 
SNARE .............. SNAP receptor 
SNP ................... Single nucleotide polymorphism 
SPM .................. Sphingomyelin 
SR-BI ................ Scavenger receptor BI (also known as CLA1) 
SUR1 ................ Sulfonylurea receptor 1 
T ........................ Thymine 
Tab. ................... Table 
TG ..................... Trigylceride 
TD ..................... Tangier Disease 
TDI .................... Template directed dye incorporation 
Tm ...................... Melting temperature 
TMD .................. Transmembrane domain 
UC ..................... Unesterified cholesterol 
USF1/2............... Upstream stimulatory factor 1 and 2 
VLDL ................. Very low density lipoprotein 
VNTR ................ Variable number of tandem repeats 
ZNF202 ............. Zinc finger protein 202 
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Abbreviations for amino acids 
A ........ Ala ........ Alanine 
C ....... Cys ....... Cysteine 
D ....... Asp ....... Aspartic Acid 
E ........ Glu ........ Glutamic Acid 
F ........ Phe ....... Phenylalanine 
G ....... Gly ........ Glycine 
H ....... His ........ Histidine 
I ......... Ile .......... Isoleucine 
K ........ Lys ........ Lysine 
L ........ Leu ....... Leucine 
M ....... Met ....... Methionine 
N ....... Asn ....... Asparagine 
P ........ Pro ........ Proline 
Q ....... Gln ........ Glutamine 
R ....... Arg ........ Arginine 
S ........ Ser ........ Serine 
T ........ Thr ........ Threonine 
V ........ Val ........ Valine 
W ....... Trp ........ Tryptophan 
Y ........ Tyr ........ Tyrosine 
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10 Summary 
The main focus of this work was to develop high-throughput and multiplex assays for 
the fast and efficient analysis of sequence variations in the gene coding for the ATP-
binding cassette transporter 1 (ABCA1), which has recently been identified as the main 
regulator of plasma HDL cholesterol. 
Intensive literature and data base research was performed to library all known 
sequence variations in this gene. Relevant data of subjects with HDL deficiency 
syndrome were archived, which carry mutations in this gene. These data were stored in 
a web page archive (www.abca1-mutants.all.at) to provide an information resource for 
further research in ABCA1. 
A knowledge-based sequencing approach was performed to identify novel sequence 
variations in ABCA1. In the promoter region, two novel VNTR polymorphisms at a 
ZNF202 and a SRY binding-site were identified along with three novel SNPs (G1047C, 
C1152T and C1440T). While the VNTR polymorphisms might not be of functional 
relevance, the three SNPs were found in significantly different distribution of genotypes 
in some cohorts and all three nucleotide exchanges appear to be associated to low 
HDL. Six novel sequence variations affecting amino acid sequence, including the 
V771M polymorphism, were found in patients with HDL deficiency syndrome and 
probands with aberrant HDL-levels. 
LightCycler and TaqMan assays were developed for the detection of common single 
nucleotide polymorphisms of potential interest in the ABCA1 gene, including the 
V771M polymorphism. An automated high-throughput workflow with implemented 
TaqMan technology was established for fast and efficient genotyping of single 
nucleotide polymorphisms in large cohorts capable of 40,000 analyses per 24 hours. 
With the newly established workflow, several polymorphisms were genotyped and 
evaluated, including the R219K and the V771M variation. The R219K polymorphism 
was found in significantly increased prevalence in Italian centenarians compared to 
healthy Italian controls, indicating a protective effect of K219 in aging. This confirms 
findings from other groups concerning this polymorphism. The novel V771M 
polymorphism was found with significantly decreased abundance in Hungarian CAD 
patients compared to healthy Hungarian blood donors, indicating a protective effect of 
M771 on CAD. All other frequency data showed no significant difference compared to 
the control groups. 
A multiplex assay was established for the simultaneous detection of four important 
polymorphisms in the ABCA1 gene using allele specific primer extension reaction for 
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discrimination of SNP. The method uses zip- and color-coded beads for detection with 
flow cytometry (Luminex). The new assay provides a fast and cost-efficient method for 
the determination of single nucleotide polymorphisms with reliability comparable to the 
well-established TaqMan technology. 
Zusammenfassung 
Im Mittelpunkt dieser Arbeit stand die Entwicklung von Hochdurchsatz- und Multiplex- 
Assays für die schnelle und effiziente Analyse von Sequenzvariationen am 
Modellsystem des ATP-bindenden Cassetten Transporter A1 (ABCA1)-Gens, das als 
wichtigster Regulator von HDL Cholesterin im Plasma identifiziert wurde. 
Zunächst wurden in einer intensiven Literatur- und Datenbank-Recherche alle für 
dieses Gen bekannten Sequenzvariationen katalogisiert und relevante Daten von 
Patienten mit HDL Defizenz Syndrom, die Träger von bekannten Mutationen in ABCA1 
sind, archiviert. Diese Informationen, die einer weiteren Forschung mit ABCA1 dienen 
sollen, wurden auf einer Internetseite (www.abca1-mutants.all.at) zusammengestellt. 
Anschließend wurde ein wissensbasierter Sequenzierungsansatz durchgeführt, um 
gezielt neue Sequenzvariationen in ABCA1 zu finden. Hier wurden im Promotorbereich 
neben zwei neuen VNTR Polymorphismen auf einer ZNF202- und einer putativen 
SRY-Bindungsstelle, drei neue SNPs (G1047C, C1152T und C1440T) identifiziert. 
Während den beiden VNTR Polymorphismen eine eindeutige funktionelle Relevanz 
nicht nachzuweisen war, wurde bei den drei SNPs eine signifikant unterschiedliche 
Verteilung der Genotypen in mehreren Kollektiven festgestellt. Alle drei Einbasen-
austausche scheinen mit niedrigen HDL-Werten assoziiert zu sein. 
Sechs neue Sequenzvariationen die zu Aminosäureaustauschen führen (unter 
anderem V771M) wurden in Patienten mit HDL Defizienz Syndrom und Probanden mit 
anomalen HDL-Werten gefunden. Für diese und andere häufig auftretende SNPs von 
potentieller Relevanz wurden Assays für LightCycler und TaqMan entwickelt. 
Ein automatisierter Hochdurchsatz-Workflow basierend auf TaqMan Technologie 
konnte erfolgreich etabliert werden, der eine schnelle und effiziente Genotypisierung 
von großen Patientenkollektiven (bis zu 40.000 Analysen in 24 Stunden) ermöglicht. 
Mit dem etablierten Workflow wurden mehrere Polymorphismen in verschiedenen 
Kollektiven genotypisiert, unter anderem die Aminosäureaustausche R219K und 
V771M. Der Austausch R219K wurde in signifikant unterschiedlicher Verteilung in 
italienischen über einhundertjährigen Senioren im Vergleich zu italienischen 
Blutspendern gefunden, was auf einen protektiven Effekt im Alterungsprozess 
schließen läßt. Dies ist übereinstimmend mit anderen Assoziationsstudien für diesen 
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Polymorphismus. Der neue Polymorphismus V771M wurde signifikant weniger häufig 
in ungarischen CAD Patienten im Vergleich zu ungarischen Blutspendern gefunden, 
was auf einen protektiven Effekt des M771-Allels in der Entwicklung von CAD 
schließen läßt. Alle anderen Genotypisierungen zeigten keine signifikant unter-
schiedliche Verteilung zwischen den einzelnen Kohorten und den Kontrollkollektiven. 
Weiterhin wurde ein neues Verfahren zur multiplexen SNP Analytik auf der Basis der 
Luminex-Technologie etabliert. Mit Hilfe von allelspezifischer Primerextension konnten 
vier Polymorphismen von potentieller Relevanz simultan analysiert werden. Diese 
durchflusszytometrische Methode nutzt Zip-code-Technik und fluoreszenzmarkierte 
Beads. Das neue Assaysystem erlaubt die schnelle und effiziente Genotypisierung von 
SNPs mit einer Genauigkeit vergleichbar mit der anerkannten TaqMan Technologie. 
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